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 III Abstract 
 
Osteoarthritis (OA) is characterized by a progressive destruction of articular cartilage. Current treatment 
options do not enable to heal or stop the disease progression. Consequently, there is a strong need for 
disease-modifying OA drugs (DMOADs). The growth and differentiation factor 5 (GDF5) is a promising 
DMOAD candidate. It is a key regulator of cartilage development and is involved in cartilage 
maintenance during adulthood. GDF5 was shown to stimulate matrix production in chondrocytes, to 
promote chondrogenesis in mesenchymal stem cells (MSCs) and to induce cartilage formation in an OA 
model [1-3]. Moreover, it was shown to exhibit anti-catabolic properties [4]. Thus, GDF5 could enable to 
regenerate damaged OA cartilage and to prevent further cartilage worsening in vivo. However, GDF5 
was also shown to have hypertrophic and osteogenic activities [3, 5], which could result in the formation 
of inferior cartilage and unwanted bone formation. To reduce the hypertrophic/osteogenic properties of 
GDF5, different GDF5 mutants were produced and three of them (M1673, W417F, W417R) were 
selected. The aim of the present work was to evaluate these GDF5 mutants for their therapeutic potential 
in the two cells types, which can produce cartilage: chondrocytes and MSCs.  
Among the GDF5 mutants, M1673 was previously shown to have the strongest anabolic effect in 
chondrocytes from different non-human species. The first aim of this work was to confirm the anabolic 
effect of M1673 in human OA chondrocytes (hOAC). This was achieved with the use of a 3D culture 
system and modified culture conditions (slightly increased medium osmolarity). Increasing the medium 
osmolarity was shown to favor the chondrocytes phenotype and its matrix production. In addition, the 
OA characteristics (cytokine and protease production) were reduced and the expression of BMPR1a, 
BMPR1b and BMPR2 enhanced. With these culture conditions, M1673 was shown to exhibit anabolic 
and anti-catabolic effects on hOAC. Moreover, the results also suggested M1673 to be less hypertrophic 
in hOAC compared to GDF5. 
In addition, the GDF5 mutants were tested in the present work for their chondrogenic and osteogenic 
properties in MSCs. First, it was shown that the GDF5 mutants display a lower BMPR1a affinity compared 
to GDF5 but a similar BMPR1b affinity. Among the GDF5 mutants, M1673 was shown to induce the 
strongest chondrogenic differentiation while preventing hypertrophy. In addition, the osteogenic 
differentiation was delayed with M1673 compared to GDF5. Originally, it was hypothesized that 
chondrogenesis is mediated through BMPR1b, while osteogenesis is mediated through BMPR1a. 
However, in the light of the results presented here, this had to be refined: it now appears that the 
activation of BMPR1a is necessary for chondrogenesis as well as for osteogenesis. In addition, BMPs with 
a higher BMPR1a/BMPR1b ratio appear to prevent hypertrophy and delay osteogenesis.  
Taken together, the results of this work show that M1673 can stimulate cartilage production in both 
hOAC and MSCs, while having a reduced hypertrophic and osteogenic potential in comparison to GDF5. 
Therefore, it could be demonstrated that M1673 bear potential as a DMOAD.
 IV Zusammenfassung 
 
Osteoarthrose (OA) ist durch eine zunehmende Zerstörung des Gelenkknorpels charakterisiert. Zurzeit 
steht keine Behandlung zur Verfügung, die eine Heilung herbeiführt oder ein Fortschreiten der OA 
verhindert. Daher besteht ein Bedarf an krankheits-modifizierenden OA Medikamenten. In diesem 
Zusammenhang ist der Wachstums- und Differenzierungsfaktor 5 (GDF5) ein vielversprechender 
Kandidat. GDF5 spielt während der Knorpelentwicklung und bei der Knorpelerhaltung im erwachsenen 
Menschen eine Schlüsselrolle. Es wurde bereits gezeigt, dass GDF5 sowohl die Matrixproduktion im 
Chondrozyten, als auch die Chondrogenese von mesenchymalen Stammzellen (MSCs) und die 
Knorpelneubildung in einem OA Modell induziert [1-3]. Zusätzlich werden GDF5 anti-katabole 
Fähigkeiten zugeschrieben [4]. Somit könnte GDF5 in vivo die Regenerierung von OA Knorpel 
ermöglichen, wie auch ein Fortschreiten des Knorpelabbaus verhindern. Es wurde jedoch auch gezeigt, 
dass GDF5 hypertrophe/osteogene Fähigkeiten besitzt [3, 5], die den Aufbau minderwertigen Knorpels 
und eine unerwünschte Knochenbildung zur Folge haben. Zur Verringerung der Osteogenizität von 
GDF5 wurden verschiedene GDF5 Mutanten generiert, von denen M1673, W417F und W417R selektiert 
wurden. Ziel der vorliegenden Arbeit war es, diese Mutanten in Bezug auf ihr therapeutisches Potential 
hin in zwei Knorpel-produzierenden Zelltypen, den Chondrozyten und den MSCs, zu untersuchen. 
In früheren Studien zeigte die Mutante M1673 den größten anabolen Effekt in nicht-humanen 
Chondrozyten. Das erste Ziel dieser Arbeit war es, den anabolen Effekt von M1673 in humanen OA 
Chondrozyten (hOAC) zu bestätigen. Dies konnte in einem 3D Kultursystem unter modifizierten 
Bedingungen (leicht erhöhte Osmolarität) nachgewiesen werden. Dabei zeigte sich, dass eine erhöhte 
Medium-Osmolarität den Phänotyp von Chondrozyten sowie deren Matrixproduktion begünstigt. 
Zusätzlich wurden Charakteristika der OA (Zytokin und Protease Produktion) reduziert und die 
Expression von BMPR1a, BMPR1b und BMPR2 erhöht. Unter diesen Kulturbedingungen zeigte M1673 
anabole und anti-katabole Effekte in hOAC. Zudem wurde gezeigt, dass M1673 im Vergleich zu GDF5 
in hOAC weniger hypertroph sein könnte. 
Weiterhin wurden die GDF5 Mutanten auf ihr chondrogenes und osteogenes Potential in MSCs getestet. 
Zunächst wurde gezeigt, dass alle drei Mutanten im Vergleich zu GDF5 eine reduzierte BMPR1a und 
eine vergleichbare BMPR1b Affinität besitzen. Die GDF5 Mutante M1673 wies das stärkste chondrogene 
Potential auf und verhinderte gleichzeitig Hypertrophie. Zusätzlich zeigte M1673 im Vergleich zu GDF5 
eine reduzierte Osteogenizität. Die initiale Hypothese war, dass Chondrogenese über BMPR1b und 
Osteogenese über BMPR1a vermittelt wird. Versuche im Rahmen dieser Arbeit konnten allerdings 
nachweisen, dass BMPR1a sowohl für Chondrogenese als auch für Osteogenese benötigt wird und dass 
BMPs mit erhöhtem BMPR1a/BMPR1b Ratio Hypertrophie verhindern und Osteogenese verzögern. 
Zusammenfassend stimulierte M1673 die Knorpelproduktion sowohl in hOAC als auch in MSCs. M1673 
zeigte im Vergleich zu GDF5 reduzierte hypertrophe und osteogene Eigenschaften. Somit konnte gezeigt 
werden, dass M1673 Potential für ein krankheits-modifizierendes OA Medikament besitzt.
 1 Introduction 
 
Osteoarthritis (OA) is the most common joint disease. It was estimated that 250 million people 
worldwide are affected by symptomatic knee and hip OA with an increasing tendency [6]. This disease is 
characterized by a slow, progressive degradation of articular cartilage, which occurs non-linearly with 
periods of fast progression which alternate with periods of joint stability [7-8]. OA can affect any joint, 
but particularly the weight-bearing knee and hip joints. It is also recognized that OA is a multifactorial 
disease involving not only articular cartilage, but also subchondral bone, synovial membrane, 
infrapatellar fat pad, menisci, tendons, muscles and ligaments [9].  
Several risk factors for OA have been described, like age [6, 10-11], gender [12-13], race [13], obesity [12, 14], 
genetic predisposition [14], cartilage injuries [12, 14] or joint malalignments [15], which interact in complex 
ways [10]. Due to the aging society and the increased life span, there is a growing tendency for age-related 
OA [6]. The real mechanism of the correlation between an increased age and the clinical incidence of OA 
remains unclear, but it probably depends on a combination of changes in the joint structure resulting in 
a decreased capacity to adapt to mechanical loading [10]. 
The predominant symptom of OA is pain, which occurs during movement and normally decline at rest. 
However, patients with advanced stages of OA even awake from sleep because of OA-related pain at 
rest. Further symptoms are stiffness, swelling or muscle spasm [16]. All the symptoms result in a 
significant reduction of life quality because of forced inactivity and decreased mobility, which can result 
in social isolation, depression and dependency [17]. Moreover, it can result in several comorbidities like 
cardiovascular diseases or the loss for self-management in chronic diseases like diabetes or hypertension 
[6], which in turn increase the risk of premature mortality of about 23% in OA patients. Additionally to 
the burden carried by the patients, OA is combined with very high costs burdening the global health care 
systems [10].  
Presently, available medications for OA solely focus on pain relief but do not heal or stop further 
progression of the disease so that many patients are advancing towards a need for total joint 
replacement. Consequently, there exists an unmet medical need for disease-modifying OA drugs 
(DMOADs). 
 
All in all, OA is an important cause of disability for millions of patients, it is challenging the health 
system, and missing DMOADs define a clear unmet need. Based on this, the Osteoarthritis Research 
Society International (OARSI) has submitted a white paper in December 2016 to the Food and Drug 
Administration (FDA) for OA to become recognized as a serious disease. 
 
 
 
 1.1 Cartilage physiology 
 
Cartilage is a connective tissue localized in different areas in the body and can be classified into three 
different types, namely elastic cartilage, fibrocartilage and hyaline cartilage [18]. These three cartilage 
types differ in their composition and function. Elastic cartilage is localized in the larynx and the ears and 
is composed of randomly oriented elastic fibers making it elastic and flexible. Fibrocartilage is localized 
in intervertebral discs and menisci, and contains large amounts of type 1 collagen, which interact with 
type 2 collagen and together form dense collagen fibers making it very tough and strong. Finally, hyaline 
cartilage is the most predominant cartilage type and is localized in the articulations [18]. Articular 
cartilage is a typical hyaline cartilage, which covers the ends of the subchondral bones and provides a 
smooth, gliding, visco-elastic surface of 2 to 4 mm [19] to minimize friction and distribute mechanical 
stress in the joint.  
 
1.1.1 Chondrocytes 
Healthy articular cartilage is composed of one single cell type, the chondrocytes, which occupy only         
1-3% of the total tissue volume. Nevertheless, they produce, organize and maintain the extracellular 
matrix (ECM) of the cartilage [6] and are therefore responsible for cartilage metabolism. Unfortunately, 
chondrocytes have a limited cell division potential leading to a low metabolic activity which contributes 
to the limited self-healing capability of cartilage even after a minor injury [17]. Articular cartilage is an 
avascular, alymphic and aneural tissue, which forces the chondrocytes to an anaerobic metabolism [16]. 
The nutrition of articular cartilage occurs mainly by diffusion from synovial fluid (SF) nutrients, but also 
to a lesser extent from the bone marrow (BM) [20].  
 
1.1.2 Extracellular matrix of articular cartilage 
The extracellular matrix (ECM) of articular cartilage is composed of a fluid water phase, which 
represents up to 80% of the total cartilage weight, and a solid organic phase of approximately two-thirds 
of collagens, one-third of proteoglycans and of a minor amount of non-collagenous proteins like cartilage 
oligomeric matrix proteins (COMPs), fibronectin or link proteins [19]. 
Type 2 collagen is the main collagen type in healthy articular cartilage and represents 90 to 95% of the 
total collagen amount. It consists of three polypeptide chains, which are mainly composed of glycine and 
proline. The chains are wound into a triple helix via hydrogen bonds which are formed with the help of 
hydroxyproline amino acids [19]. Moreover, the type 2 collagen triple helices are associated to type 9 and 
11 collagens to form large collagen fibrils. Type 11 collagen is located inside the fibril and regulates the 
fibril size. On the contrary, type 9 collagen is located at the surface of the collagen fibril, induce the type 
2 collagen formation and enables the interaction with other ECM molecules (Figure 1). This fibril 
 network constitutes a dense network which stabilize the ECM and contribute to the cartilage rigidity [18, 
21-22].  
 
Figure 1 Structure of type 2 collagen fibrils. 
 
 
Many other collagen subtypes are present in lower quantities in articular cartilage. Nevertheless, they 
play an important role as stabilizers of the cartilage ECM and also exhibit specific biological functions. 
For instance, type 6 collagen have a high affinity to other ECM molecules and to the cell membrane and 
therefore mediates cell-matrix interactions and plays an important role as signal transducer from the 
ECM to the cartilage [21]. Type 9, 12, 14, 16 and 22 collagen are members of the fibril-associated 
collagens with interrupted triple helix (FACITs) and participate to the cartilage organization [21]. Type 4 
collagen may be responsible for maintenance of the cartilage phenotype and viability, whereas type 10 
collagen maintains the tissue stiffness and facilitates calcification processes. Type 10 collagen is not 
available in healthy articular cartilage and is mostly used as a hypertrophic marker [21]. 
Proteoglycans (PGs) can be divided into large PGs like aggrecan or versican, small leucine-rich PGs like 
decorin, biglycan, fibromodulin or lumican, basement membrane PGs like perlecan, cell surface 
associated PGs like syndecan and intracellular PGs like serglycin [23]. They are responsible for the 
lubrication function and mediate the resistance of the articular cartilage to compressive load [24]. All PGs 
consist of several core proteins, which are connected non-covalently to a hyaluronic acid (HA) molecule. 
The core protein is attached covalently to glycosaminoglycan (GAG) chains, which are long hetero 
polysaccharide chains consists of repetitive disaccharide units connected to sulfate or carboxyl residues 
[24]. According to their disaccharide units and the linkage type between the sugars, the GAGs are divided 
into hyaluronic acid (HA), keratin sulfate (KS), chondroitin sulfate (CS), dermatan sulfate (DS) and 
heparan sulfate (HS) [23]. The most dominant PG in articular cartilage is the large, 250 kDa aggrecan, 
which is composed of several core proteins comprising approximately 30 KS and 100 CS molecules 
(Figure 2). The core proteins are attached to one single HA molecule through link proteins and consisting 
three globular domains (G1, G2 and G3) and an interglobular domain, which is localized between G1 
and G2. The N-terminal G1 domain is responsible for the connection of the PG to the HA molecule via 
link proteins and is followed by the G2 domain, which is unique for aggrecan. Proximal to the G2 domain 
 is the KS binding site and distal the CS binding site, followed by the C-terminal G3 domain, which 
promotes post-translational processing and secretion of aggrecan [25].  
 
Figure 2 Structure of aggrecan aggregates. 
~
~
  
Other proteins are available in smaller amounts than collagens or proteoglycans. Nevertheless, they 
exhibit specific functions and many of these contribute to the strengthening of the complex structural 
ECM network. The glycoprotein fibronectin supports the cartilage ECM formation by interacting with 
other ECM molecules like collagens [26]. Another important glycoprotein is COMP, which strengthen the 
ECM network by binding to aggrecan, type 2 and 9 collagen and fibronectin. Moreover COMP was shown 
to contribute to lubrication properties of articular cartilage [26]. Furthermore there are many other 
functional proteins like proteases, inhibitors, degradation products, growth factors, chemokines and 
cytokines [27]. 
The articular cartilage ECM can be divided according to the distance of the matrix from chondrocytes 
into three regions: the pericellular, territorial and interterritorial matrix. The pericellular matrix (PCM) 
is a thin layer, which surrounds each chondrocyte and is together referred as the chondron. This matrix 
region may transduce load signals from the cartilage ECM to the chondrocytes [28]. The territorial matrix 
(TM) is located above the PCM and is thicker than the PCM. It contributes to both, the response to 
mechanical stress and to the elasticity of articular cartilage [19]. Thus, the PCM and TM mostly exhibit 
protective functions. On the contrary, the interterritorial matrix (ITM) is the largest matrix region and 
provides the mechanical properties of articular cartilage [19]. 
 
  
 1.1.3 Zonal architecture of articular cartilage 
The structure and composition of articular cartilage differ according to the distance from the articular 
surface. The articular cartilage can be divided in 4 different zones, which differ in their composition, cell 
density, cell shape, the cell arrangement, and exhibit different functions (Figure 3). The superficial or 
tangential zone (STZ) is the thinnest, and corresponds to 10 to 20% of the articular cartilage thickness 
and directly faces the joint cavity. It contains a high number of flattened chondrocytes that are oriented 
parallel to the articular cartilage surface. They produce lubricin, which supports the frictionless 
movement of the joint and simultaneously protect the deeper cartilage layers from shear stress. The STZ 
contains densely packed collagen fibers, mainly type 2 and 9 collagens, which are also oriented parallel 
to the articular cartilage surface. Only a low proteoglycan content is available in this zone making it 
more permeable for water flow than the other cartilage layers [18].  
 
 
Figure 3  Zonal architecture of healthy articular cartilage.
 
The middle or transitional zone corresponds to 40 to 60% of the articular cartilage thickness and is 
composed of a lower density of round shaped chondrocytes embedded in a loose-packed network of high 
amounts of proteoglycans and lower amounts of collagens, mainly type 2 collagen. The collagen fibers 
are thicker than those of the STZ and start to change their orientation from parallel to columnar [29]. 
This zone is the first responder to mechanical loading [19]. The deep zone corresponds to 30% of the total 
articular cartilage volume, contains a low chondrocyte number, the highest proteoglycan content and 
the thickest collagen fibers. The chondrocytes are still round, but they are arranged in a columnar 
fashion. The collagen fibers are located parallel to the chondrocytes and therefore perpendicular to the 
subchondral bone. Altogether, this arrangement is responsible for the resistance of articular cartilage to 
compressive forces [19]. Finally, the calcified zone contains a low number of hypertrophic chondrocytes 
and is separated from the other zones by the tide mark. The tide mark serves as an interface between 
 the soft articular cartilage and the hard subchondral bone to further reduce the mechanical shear stress 
[18]. 
 
1.1.4 Cellular microenvironment in articular cartilage 
Due to their localization in articular cartilage, chondrocytes are exposed to a specific microenvironment. 
Two specific aspects of this microenvironment are described below. 
 
1.1.4.1 Oxygen 
Chondrocytes are exposed to a hypoxic environment and adapted to it, because articular cartilage is an 
avascular tissue [30]. The calcified zone containing the tide mark represents a calcified barrier for the 
oxygen supply from blood vessels of the subchondral bone to the articular cartilage. Therefore, the main 
oxygen supply of articular cartilage occurs by diffusion from the synovial fluid, which is in contact with 
the superficial zone of the articular cartilage [20]. Therefore, the oxygen nutrition from synovial fluid 
results in an oxygen gradient from 10% oxygen in the superficial zone to 1% oxygen the deep zone [31-
32]. Hypoxia-induced factors (HIFs) are the key transcription factors to regulate cellular response to 
hypoxia. Up to now the existence of three different HIF members are described. HIF1Ƚ possesses 
protective cell effects and drives the synthesis of cartilage ECM genes and is therefore described as a 
survival factor. On the contrary, HIF2Ƚ exhibits deleterious effects by upregulating catabolic genes 
leading to ECM destruction. Next to HIF1Ƚ and HIF2Ƚ, a third member exists, HIF3Ƚ, which is a negative 
regulator of HIF1Ƚ and HIF2Ƚ [31]. It was shown that the culture of chondrocytes in vitro at hypoxia has 
a positive influence on the chondrocytes phenotype and the chondrocytes ECM production compared to 
the culture at normoxia. This positive influence was shown to be mediated by HIF1α [33-34]. Culturing 
human OA chondrocytes at hypoxia even was shown to reduce their OA characteristics compared to 
normoxia [35]. 
 
1.1.4.2 Osmolarity 
The strength of the articular cartilage and the ability to resist compressive loads is mainly determined 
by its local proteoglycan content, particularly of the GAG sidechains, which carry negative charges 
resulting in a high negative fixed-charge density (FCD) and give rise to osmolarity.  
The osmolarity of healthy articular cartilage ranges between 350 and 480 mOsm depending on the local 
proteoglycan concentration within the different cartilage zones. As the proteoglycan content increases 
with the depth of articular cartilage, the osmolarity in the superficial zone is lower (350 to 370 mOsm) 
than in the deep zone (370 to 480 mOsm) [36]. Chondrocytes are osmo-sensitive and adjust to osmolarity 
changes during short times [37]. Osmolarity changes can occur under physiological conditions for example 
during mechanical loading or under pathophysiological conditions like OA. During mechanical loading 
water efflux from articular cartilage results in a higher fixed charge density and an increased osmolarity. 
 After relaxation from mechanical loading, water moves back into the articular cartilage resulting in an 
osmolarity decrease within the cartilage which is mediated by cations (mainly sodium, but also 
potassium and calcium) neutralizing the negative charge of the GAGs [38-39]. On the other hand, under 
pathological conditions like OA, the loss of proteoglycans, particularly of the negatively charged GAG 
sidechains, is accompanied by an irreversible decrease of osmolarity down to 270 mOsm [37, 39-40]. In 
conclusion, the osmolarity within articular cartilage is very variable depending not only on the different 
proteoglycan content in respective cartilage zones, but also on mechanical loading as well as the severity 
of OA [41]. 
The osmolarity of in vitro culture media is with a range of 260 to 320 mOsm [42] too low to represent 
the specific microenvironment within healthy articular cartilage in vivo [39, 43-44]. The osmolarity of 
culture media can be varied by the addition of salts like NaCl or sucrose. It was shown that culturing 
chondrocytes at medium osmolarities which rather correspond to the microenvironment within healthy 
articular cartilage in vivo is beneficial compared to the culture at lower osmolarities of standard culture 
media. Increasing the medium osmolarity was shown to enhance the cartilage ECM production of 
chondrocytes and improved their phenotype. The expression of aggrecan, type 2 collagen and sox9, as 
a key chondrogenic transcription factor, was enhanced while the expression of type 1 collagen was 
reduced [37, 39, 41, 45-46]. The molecular mechanism behind the effect of osmolarity is only partially 
understood until now. However, the tonicity enhancer binding protein (TonEBP) is recognized as a key 
transcription factor, which is activated by hyperosmotic stress [47] and is also involved in the expression 
of cartilage ECM production markers. In combination with the observation that TonEBP knockdown in 
chondrocytes lead to a decreased expression of cartilage ECM production markers, there is evidence for 
an osmo-induced expression of ECM molecules through a TonEBP pathway [45, 48]. 
  
 1.2 Pathophysiology of OA 
 
Osteoarthritis (OA) is a multifactorial disease of the whole joint resulting in structural and functional 
failures of all connective joint tissues. Consequently, the hallmark of OA is not only the destruction of 
articular cartilage, but also bone sclerosis, osteophyte formation, synovial membrane inflammation 
(synovitis), meniscal tear and extrusion or weakening and fraying of ligaments, muscles and tendons 
(Figure 4) [9, 49].  
 
Figure 4 Joint tissues involved in OA pathogenesis.
 
All these changes interact in a complex way and contribute to OA development and progression. The 
interplay of multiple paracrine factors coming from several joint tissues lead to a very complex molecular 
pathomechanism of OA initiation and progression, which is not fully understood until now [14, 50].  
 
1.2.1 Shift in articular cartilage homeostasis 
The homeostasis of articular cartilage is maintained by a defined content of collagens and proteoglycans 
within the ECM to provide optimal conditions to ensure tensile strength and resist compressive stress 
during mobility. The articular cartilage itself is continuously remodeled as chondrocytes remove the 
existing ECM components by releasing proteolytic enzymes and replace them by synthesizing new ECM 
components. This is an exceptionally slow progress. The turnover rate of aggrecan is relatively rapid 
with an approximately lifetime of 3.5 years, whereas the collagen turnover is extremely slow with an 
 approximately lifetime of 100 years [16-17]. These extremely slow turnover rates are conditioned by the 
low metabolic activity of chondrocytes which is in turn responsible for the poor healing capacity of 
cartilage. Therefore, the cartilage is very susceptible to injuries, which can be generated by abnormal 
joint stress like excessive load bearing, orthopedic malposition’s or cartilage traumata, and is therefore 
very sensitive to degenerative processes. The abnormal joint stress first affects the chondrocytes localized 
in the superficial zone. In an early stage, the chondrocytes attempt to protect the articular cartilage by 
initiating compensatory mechanism like the increased proliferation of chondrocytes inter alia to ensure 
an increased ECM synthesis to maintain the healthy articular cartilage structure [9]. In addition, 
mesenchymal stem cell (MSC)-like progenitor cells are present in the superficial zone which could 
contribute to the replenishment of chondrocytes [29, 51]. Unfortunately, the chondrocytes cannot maintain 
the cartilage integrity for a long time and at some point, the chondrocyte death exceed the chondrocyte 
proliferation. The homeostasis in the articular cartilage is disrupted and shifted towards an elevated 
catabolism. The degradation of aggrecan is regarded as an early event during OA and is followed by the 
degradation of collagens [52-53].  
 
1.2.1.1 Cartilage-degrading enzymes 
The degradation of aggrecan during OA is mainly mediated by members of the ‘a disintegrin and 
metalloproteinase with thrombospondin motifs’ (ADAMTS) family. The most important members are 
ADAMTS4 and ADAMTS5, which are produced by chondrocytes and known to play a predominant role 
in OA. ADAMTS5 is 100-fold more active than ADAMTS4 in vitro and knockout of ADAMTS5, but not of 
ADAMTS4, in mice protect them for developing severe OA. However, there is some evidence that 
ADAMTS4 is involved in aggrecan degradation of human articular cartilage [53-55]. Additionally, several 
other ADAMTS members as well as ‘a disintegrin and metalloproteinases’ (ADAMs) are available, but 
their function within healthy and OA cartilage is largely unknown. Nevertheless, they contribute to the 
homeostasis of articular cartilage and exhibit specific functions. ADAMTS2, ADAMTS3 and ADAMTS14 
for example promote anabolism of the cartilage ECM and ADAMs are actors in several signaling pathways 
to regulate articular cartilage homeostasis. Changes of expression- or protein levels may contribute to 
catabolic events during OA and should be further investigated [56]. 
The degradation of collagens during OA is mediated by matrix metalloproteinases (MMPs). MMP13 is 
the most important collagenase during OA, because of its cleavage prevalence for type 2 collagen [44]. 
Moreover, it is also able to degrade aggrecan [53]. MMP13 is hardly detectable in healthy articular 
cartilage, but significantly over-expressed in chondrocytes within osteoarthritic cartilage [52-53, 57]. 
Additionally, it was found that the MMP13 levels within the synovial fluid correlate with the severity of 
OA [52]. Examinations with mice, which continually express MMP13, showed OA development with 
aging, whereas MMP13 knockout mice were protected from collagen and aggrecan degradation 
indicating a significant impact of MMP13 during OA [53, 57]. Next to MMP13, MMP1 and MMP8 are also 
 able to degrade type 2 collagen, but less efficient than MMP13. In contrast, MMP2 and MMP9 further 
degrade collagen fragments generated by the other MMPs [44]. Another important MMP is MMP3 which 
is able to degrade cartilage ECM components, but also upregulates the expression and activation of 
MMPs like MMP13 [58-59]. 
All in all, the most dominant proteolytic enzymes during OA are the aggrecan degrading ADAMTS5 and 
the collagen as well as aggrecan degrading MMP13.  
 
1.2.1.2 Cytokines 
Cytokines are hormone-like proteins, which are released not only by chondrocytes, but also by the 
connective tissues synovial membrane (SM), infrapatellar fat pad (IFP) and subchondral bone [60-63]. 
They regulate the intensity and duration of inflammation processes and interactions between different 
cells [64]. The articular cartilage homeostasis of modeling and remodeling in response to mechanical 
forces during joint loading is maintained by chondrocytes, which produce inter alia cytokines for 
remodeling processes. Overload and enhanced biomechanical stress increase the synthesis of pro-
inflammatory cytokines [64-65]. During OA, the balance between anti- and pro-inflammatory cytokines is 
shifted towards pro-inflammatory ones, which in turn shift the articular cartilage homeostasis towards 
catabolism by upregulating inter alia proteolytical enzymes like MMPs and ADAMTS. Simultaneously 
pro-inflammatory cytokines decrease the synthesis of articular cartilage ECM molecules [66]. 
Osteoarthritic chondrocytes produce cytokines like Il1Ⱦ, TNFȽ and Il6 [65]. Il1Ⱦ and TNFȽ are the most 
important and well-studied pro-inflammatory cytokines as they decrease the production of the main 
ECM molecules aggrecan and type 2 collagen. Additionally they stimulate their own production and the 
production of Il6, which contribute to the inflammatory status of the joint during OA [64-65, 67]. The 
production of Il1Ⱦ and TNFȽ was correlated with OA severity and pain. Pain was assessed in this study 
after intra-articular injection of hyaluronic acid in OA patients and its decrease was correlated to reduced 
synovial fluid levels of Il1Ⱦ and TNFȽ [66]. In addition, Il6 levels were also shown to be enhanced in the 
serum and the synovial fluid of OA patients [67].  
 
Taken together, the key pathophysiological mediators of articular cartilage catabolism are pro-
inflammatory cytokines like Il1Ⱦ, TNFȽ and Il6 and proteolytic enzymes like ADAMTS5 and MMP13, 
which interact in a complex way and disrupt the cartilage homeostasis leading to OA progression. 
 
  
 1.2.2 Other tissues involved in OA 
To understand the complex pathomechanism of OA, it is important to pay attention not only to changes 
within the articular cartilage, but also on changes within the other connective tissues, which contribute 
to the disease in different ways. 
The connective tissues synovial membrane (SM) and the infrapatellar fat pads (IFP) are prone to changes 
during OA. The tissue alterations enhance the joint inflammation processes by shifting the balance 
between anti- and pro-inflammatory mediators towards the latter, which finally contributes to articular 
cartilage degradation and leading to symptomatic OA [62, 68]. The SM contains two main cell types, 
macrophage-like and fibroblast-like synoviocytes. Macrophage-like synoviocytes produce and secrete 
cytokines, chemokines and other enzymes involved in tissue alterations and stimulate fibroblast-like 
synoviocytes to produce and secrete proteolytical enzymes [62]. The primary histological change of SM 
during OA is hyperplasia, which is accompanied by an increased vascularity and infiltration of immune 
cells. Both the increased vascularity and infiltration correlates with SM inflammation, which is called 
‘synovitis’, and with OA severity [9, 68]. Synovitis is an active component of OA progression and is 
mediated by complex mechanisms, which are in the following shortened and simplified. Articular 
cartilage fragments as well as any kind of tissue debris are released into the synovial fluid, which is in 
contact with the SM. Macrophage-like synoviocytes phagocytose these fragments what provokes the 
production of pro-inflammatory mediators within the SM followed by the secretion of those into the 
synovial fluid. This is the start of a vicious cycle, as the chondrocytes located in the superficial zone are 
activated leading to a production and secretion of cytokines and proteolytic enzymes by the chondrocytes 
resulting in the progression of articular cartilage destruction [9, 62]. In this way, more cartilage fragments 
are released into the synovial fluid, which in turn stimulate the SM inflammation. The IFP also produces 
inflammatory cytokines like Il6 and TNFȽ [63] and exerts its effects primarily on the SM contributing to 
an enhanced synovitis [69]. All in all, the SM and the IFP are both tissues contributing to an elevated pro-
inflammatory level within the synovial fluid of OA patients and are together with chondrocytes the main 
sources of cytokines. Besides this inflammation features, both tissues mediate OA pain, probably through 
the release of the pain neurotransmitters substance P and nerve growth factor (NGF) [62]. 
The subchondral bone is also prone to changes during OA. Already during early OA, sclerotic bone 
changes, bone cysts, bone marrow lesions (BML) and hypomineralization of the bone can appear. 
Characteristics of advanced OA are bone thickening and the formation of bony outgrowths at joint edges, 
called osteophytes, which compensate the reduced strength of the subchondral bone [70-72]. Advanced 
bone remodeling and BML are associated with increased articular cartilage damage and pain [9, 71-72] . A 
viscous circle starts as the loss of articular cartilage increases the loading and remodeling of the 
subchondral bone, which in turn progress articular cartilage damage [73]. In addition, during OA the 
articular cartilage becomes vascularized by blood vessels from the subchondral bone resulting in an 
 increased oxygen concentration within the OA cartilage as well as the presence of additional cytokines 
coming from the subchondral bone. 
 
1.2.3 Conclusion pathophysiology of OA 
Taken together, OA is a multifractional disease affecting not only the articular cartilage, but also 
connective tissues. OA leads to a disbalance of several homeostatic mediators like chemokines, inhibitors, 
growth factors, proteolytic enzymes or cytokines produced and secreted by the different joint tissues. It 
remains unknown which tissue changes are initial for OA and which are responsible for further OA 
progression. Both the trigger as well as the course of OA can vary among the different OA patients 
resulting in different OA phenotypes. Consequently, it is necessary to further evaluate the complex 
pathomechanism of OA. This knowledge will accelerate the development of new OA therapeutics. 
 
1.3 Current treatment options for OA 
 
At present OA is an incurable disease. Many treatment options are available, but they are mainly focusing 
on symptomatic relief. In a last resort a surgical intervention consisting in a total joint replacement is 
performed. There is currently no efficacious structure-modifying drug approved, which can prevent OA 
initiation, reduce or stop OA progression or even rebuilt articular cartilage. Therefore, there exist an 
unmet medical and clinical need for disease-modifying OA drugs (DMOADs).  
 
1.3.1 Existing OA medications  
Pain is increased dramatically during the course of OA what is the main reason for patients to seek for 
treatments [74]. The common OA medications mainly target the symptomatic relief of pain (Figure 5). 
The oral analgesic acetaminophen is prescribed first for mild to moderate OA. For moderate to severe 
OA, nonsteroidal anti-inflammatory drugs (NSAIDs) are prescribed as a second choice to address not 
only the pain, but also the inflammatory relief during OA. NSAIDs are more efficient but less well 
tolerated than acetaminophen [16], because adverse gastrointestinal or cardiovascular side effects are 
observed [75-76]. Consequently, the balance between efficacy and safety is questionable and it is 
recommended by the OARSI to use the minimal effective dose and only for a limited time [16]. An 
alternative medication to NSAIDs are opioid analgesics like tramadol. The use of tramadol shows 
comparable efficacy than NSAIDs but may be even more harmful combined with the risk of opioid 
dependence and abusive use. There is also no recommendation for routinely use of tramadol [16]. Besides 
the oral application of analgesics, the intra-articular injection of corticosteroids and hyaluronic acid is 
commonly used as a fourth choice to manage pain and improve joint function of moderate to serve OA 
[77]. However, the efficacy of these injections is highly controversial and varies among the patients [16, 78-
79]. As a last choice, total joint replacements (TJR) are performed, but they should not be regarded as a 
 real cure. Many people still have mobility/certain sport limitations resulting in a modification of life style 
post-surgery, there is a high infection risk, some people reported a kind of ‘phantom pain’ in the replaced 
joint [80] and the protheses have a limited lifetime of up to 15 years [16, 81]. Patients suffering from OA are 
often treated with a combination of these existing OA medications and non-pharmacological treatments 
or food supplements. Non-pharmacological treatments are for example physiotherapy to strengthening 
muscles, thermal therapy or diet [16]. Food supplements like glucosamine or chondroitin, which are both 
components of the cartilage ECM, are safe and commonly used. However, there is only limited clinical 
evidence for their efficacy, also because of quality and validity doubts of the performed clinical studies 
[81-82]. Furthermore, some surgical interventions like chondral shaving and debridement are applied, but 
mainly gaining time of less symptoms. Microfracture and drilling techniques are applied for younger and 
very active patients and aim to stimulate tissue repair, but they failed as the repaired tissue is inferior, 
less durable fibrocartilage [16, 77].  
 
 
Figure 5 Existing medications to treat mild to serve OA.
 
All these applications have strong limitations and mainly targeting symptomatic alleviations, which 
reflects and points up the unmet medical need for disease-modifying OA drugs (DMOADs). 
 
1.3.2 Disease-modifying OA drugs 
Disease-modifying OA drugs (DMOADs) should prevent OA initiation, reduce or even stop the course of 
joint destruction or promote tissue regeneration by influencing specific molecular mechanism during 
OA, leading to a reduced catabolism and/or restored anabolism. DMOADs ideally address both structural 
joint improvement combined with pain relief [77, 84-85]. In general, there exist two different approaches, 
the anti-catabolic and the anabolic approach, to reach this requirement [84-85].  
Anti-catabolic DMOADs directly or indirectly address the inhibition of cartilage-degrading proteolytic 
enzymes to prevent articular cartilage destruction during OA while anabolic DMOADs promote tissue 
 repair. Growth factors (GFs) involved in tissue development and maintenance of tissue homeostasis are 
ideal anabolic candidates.  
There is and was a great number of possible DMOADs under investigation (Figure 6), but many of these 
attempts failed in the clinic due to different reasons like sub-optimal selection of patient groups, wrong 
drug dosage, sub-optimal set of the end-point measurement or a lack of efficacy [86].  
Promising, but failed therapeutic approaches belonging to the field of anti-catabolic DMOADs are the 
unselective inhibition of MMPs, the selective inhibition of MMP13, the inhibition of inducible NO 
synthase (iNOS) which indirect inhibits the MMP activity as well as antiresorptive approaches like the 
administration of bisphosphates, calcitonin or strontium [86-87]. Anti-catabolic DMOADs which are 
currently under clinical investigation target the selective inhibition of the proteolytic enzyme cathepsin 
K [86, 88], the selective inhibition of ADAMTS5 [89], the selective inhibition of Il1Ƚ/Ⱦ [90-92] or the inhibition 
of the Wnt pathway which induce the production of proteolytic enzymes and cytokines during OA [93-95]. 
 
 
Figure 6 Different joint tissues involved in OA are targets for possible DMOAD candidates.
 
In the following, anabolic DMOADs are listed which are currently under clinical investigation. 
A potential anabolic DMOAD is TPX-100, a peptide derived from matrix extracellular phosphor-
glycoprotein, which occurs naturally in humans and is involved in the formation of cartilage and bone 
[86, 97]. In a recently published phase II study in patients with knee OA, the intra-articular application of 
TPX-100 resulted in a significant pain reduction. However, no significant improvement of articular 
cartilage thickness or volume was measurable. Further clinical studies of longer duration have been 
announced [97-98]. Platelet rich plasma (PRP), which contains a mixture of different growth factors is 
under investigation but the efficacy is still questionable. Several clinical studies demonstrated the 
potential of intra-articular injected PRP to improve joint structure and reduce pain. However, the patient 
 size was small and the clinical trial duration short. Additionally, the preparation and application is not 
standardized among the clinical studies [99-100]. Furthermore, a cell-mediated gene therapy is under 
clinical investigation (TissueGene-C/Invossa), which originally aimed to relief pain. TissueGene-C (TG-
C) is a 3:1 mixture of normal allogenic human chondrocytes and TGFȾ1-expressing allogenic human 
chondrocytes. The growth factor TGFȾ1 is important during articular cartilage formation and possess 
anti-inflammatory properties. A clinical phase II and III study demonstrated pain alleviation after one 
single intra-articular injection of TG-C lasting up to 1 year. Additionally, the phase III trial lead to the 
suggestion of structural tissue improvements [101]. TG-C was approved in 2017 for South Korea as gene 
therapy to relief pain in OA patients and is currently under investigation in a phase III trial over a longer 
duration to see possible structural changes delivered by intra-articular injections of TG-C. Another 
anabolic DMOAD candidate is the growth factor BMP7 which is involved in cartilage modeling and whose 
levels were shown to be decreased in OA cartilage explants compared to healthy explants [96, 102]. A 
clinical phase I study led to the suggestion of a possible symptomatic pain relief after intra-articular 
injection of BMP7 compared to placebo [103]. As stated on the company’s website, the clinical phase IIa 
led to promising results in an initial result analysis. The data of 78 out of 320 patients were analyzed 
and as a conclusion it was formulated that even one single intra-articular injection of BMP7 resulted in 
anabolic effects and prevented the further degradation of articular cartilage. As a conclusion, a pivotal 
phase III trial should be conducted (see company´s webpage, http://www.embertx.com/news.html). As 
a last anabolic DMOAD candidate, a recombinant and shortened version of the growth factor FGF18 
(Sprifermin/AS902330) is currently under clinical investigation. Preclinically Sprifermin was shown to 
induce the proliferation of chondrocyte resulting in an enhanced cartilage ECM production [84, 86, 104]. 
Sprifermin is injected intra-articularly and showed a dose-dependent structural cartilage improvement 
in a clinical phase I studies with OA patients [16, 104]. Two-year data out of a currently running five-year 
clinical phase II study confirmed the dose-dependent increase in total cartilage thickness. In addition, a 
50% pain alleviation was observable in all patient groups but also in the placebo group [105].  
 
Up to now, there is no DMOAD approved, but some of the DMOAD candidates have shown promising 
results. Nevertheless, there is still an unmet medical need for DMOADs. Members of the bone 
morphogenetic proteins (BMPs) could bear DMOAD potential as they are involved in the formation of 
cartilage and bone.  
 
 
 
 
 
 
 1.4 Bone morphogenetic protein (BMP) family 
 
Bone morphogenetic proteins (BMPs) were first discovered in 1965 by Marshall Urist. He implanted 
demineralized bone matrix (DBM) under the skin or within the muscle of animals and observed the 
formation of ectopic bone within the non-skeletal tissues [106]. This finding predicts the availability of 
bioactive factors within the DBM, which initiate bone formation, leading to the search for these factors 
[107-108]. These factors were named ‘bone morphogenetic proteins’ based on the observed bone 
development. Only 20 years later, a key step was done when the first BMPs, named BMP1, 2, 3 and 4, 
were characterized and cloned [109]. This enabled the biochemical investigation of individual BMPs and 
their classification to the transforming growth factor Ⱦ (TGFȾ) superfamily [110].  
Bone can be formed directly by intramembranous ossification, which is characterized by the 
differentiation of mesenchymal stem cells (MSC) into osteoid matrix producing osteoblasts [111], but most 
of the skeletal volume (~80%) is formed by endochondral ossification [112]. During the endochondral 
ossification process, the MSCs differentiate first to chondroblasts (= condensation), which begin to 
proliferate and form chondrocytes. The central chondrocytes can be further differentiated and become 
hypertrophic resulting in their apoptosis. The apoptotic chondrocyte matrix is eroded by osteoclasts 
leading to the invasion of blood vessels and osteoblasts, which ultimately initiate the bone formation. 
Thus, the chondrocytes forming a template for the formation of bone [111-113]. Based on this, the function 
of BMPs was focused on cartilage and bone formation. Later it was shown that BMPs play important 
roles during many processes of embryogenic development or during tissue homeostasis and also during 
tissue regeneration in adulthood [110, 114-115]. Not all BMPs exhibit the same osteogenicity and some BMPs 
even exhibit non-osteogenic properties depending on the expressing tissue, the molecule structure and 
the signaling events [107]. They are suggested to be attractive targets to treat different diseases, like organ 
fibrosis or skeletal disorders including OA [114]. 
 
1.4.1 BMP subgroups and synthesis  
Over 30 BMP family members were identified, of which about 15 BMP members appear in mammals 
[116]. They can be divided into four subgroups according to their structural similarity and function. The 
first group includes BMP2 and 4, the second group includes BMP5, 6, 7 and 8, the third group includes 
BMP9 and 10 and the fourth group includes BMP12, 13 and 14 [107, 110, 117]. Some BMPs are described 
with additional names. For example BMP7 and 8 are also known as osteogenic protein (OP) 1 and 2 or 
BMP12, 13 and 14 are also known as growth and differentiation factor (GDF) 7, 6 and 5 or cartilage-
derived morphogenetic protein (CDMP) 3, 2 and 1 [107, 116].  
BMPs are synthesized intracellularly as large inactive precursor molecules [118]. In contrast to other 
members of the TGFȾ superfamily, the BMPs are usually activated inside the cell before secretion [117] 
(Figure 7). The activation takes place by proteolytic cleavage through proprotein convertases at a 
 consensus RXXR region within the pro-domain to frees the mature BMP from the pro-domain. The 
mature protein consists of approximately 100 to 140 amino acids [118] and contains six highly conserved 
cysteine residues that are characteristic for members of the TGFȾ family. These cysteine residues form 
three intramolecular disulfide bonds, named cysteine knots. BMPs contain a seventh cysteine residue, 
which is located outside the cysteine knots and form intermolecular disulfide bonds allowing the 
covalent dimerization with another BMP monomer.  
 
 
Figure 7 BMPs are synthesized as precursor molecules and are activated inside the cell.
 
Usually homodimers are formed with its characteristic wrist and knuckle or banana shape structure 
(Figure 7). The biological active BMP dimers are secreted and mediate their effects by binding to BMP 
receptors to initiate intracellular signaling events [107, 110, 114, 117, 119]. 
 
1.4.2 BMP signaling 
The dimeric BMPs within the extracellular space elicit intracellular signaling by binding to two classes 
of serine/threonine kinase transmembrane receptors known as type 1 and type 2 BMP receptors 
(BMPRs). There are altogether seven type 1 and four type 2 receptors for the TGFȾ superfamily. BMPs 
can interact with three type 1 receptors, namely activin receptor-like kinase (ALK) 2, ALK3 (also known 
as BMPR1a) and ALK6 (also known as BMPR1b), and with three type 2 receptors, namely activin A 
receptor (ActR) type 2 and type 2b and BMPR2 [110, 117-118]. BMPs preferentially bind to the BMP-specific 
receptors BMPR1a, BMPR1b and BMPR2 [110]. All BMPRs consist of three parts, a short extracellular 
domain, followed by a single transmembrane domain and an intracellular domain responsible for 
 serine/threonine kinase activity [119]. For signal transmission, a heteromeric complex of two type 1 and 
two type 2 receptors is required (Figure 8).  
 
 
Figure 8 BMP signaling activates the canonical SMAD-dependent and the non-canonical MAPK pathway
 
The binding of dimeric BMPs leads to the transphosphorylation of the type 1 receptor through the 
constitutively active type 2 receptor (Figure 8). The transphosphorylation occurs at the TTSGSGSG motif 
within the conserved GS-domain, which is located between the transmembrane domain and the kinase 
domain of the type 1 receptor [118]. The type 1 receptor transduce the signal by phosphorylation of the 
receptor regulated SMAD (R-SMAD), namely SMAD1/5/8, which change its conformation to enable the 
binding of the common mediator SMAD (co-SMAD), known as SMAD4. This complex is built usually by 
a trimer of two R-SMADs and one co-SMAD and translocates to the nucleus to regulate gene expression 
[114, 118]. 
 1.4.2.1 Regulation of BMP signaling 
This signaling cascade is strictly regulated by agonists and antagonists at several checkpoints from the 
extracellular space over the transmembrane region to the intracellular space and the nucleus. 
Extracellular modulators can be divided into antagonists and agonists. Extracellular antagonists bind to 
the dimeric BMPs and regulate the extracellular BMP concentration and -bioavailability. The binding 
results in a blockade of the BMPs preventing the interaction with their receptors and leading to limited 
intracellular signaling [114, 117]. Extracellular BMP antagonists include on the one hand proteins like 
noggin, chordin, gremlin or follistatin [114]. On the other hand, ECM components like collagens or 
fibronectin can compete for BMP binding [117]. In contrast cartilage ECM components like heparan 
sulfates (HS) can act as extracellular agonists. BMPs contain a HS binding site and the binding of the 
BMP dimer to HS is thought to potentiate the BMP effects by prolonging the bioavailability/activity of 
the BMPs [120]. Furthermore, at the transmembrane region, several co-receptors and pseudo-receptors, 
which are lacking an intracellular signal domain, modify the signal transduction. Intracellular 
modulators of BMP signaling are SMAD ubiquitination regulatory factors (Smurf), inhibitory SMADs (I-
SMAD), proteins regulating phosphorylation and dephosphorylation as well as different binding 
proteins. Smurf1 and Smurf2 mark R-SMADs with ubiquitin residues at their proline, serine, threonine 
enriched domain leading to a selective proteosomal degradation of R-SMADs. SMAD6 and 7 belonging 
to the I-SMADs and prevent the interaction of R-SMADs with co-SMADs directly or indirectly [114]. 
Another kind of intracellular modulation is mediated by phosphatases, which inactivate R-SMADs by 
dephosphorylation [114, 117]. Transcriptional regulation is mediated through several co-activators and co-
repressors. BMP signaling itself also initiates the expression of several antagonists and agonists, which 
act as feedback loops. Negative feedback loops occur by expression of the extracellular antagonists, 
pseudo-receptors or I-SMADs. Positive feedback loops are induced by enhanced expression of the R-
SMADs [107].  
Another kind of BMP signaling regulation is the crosstalk with other signaling pathways such as TGFȾ, 
Wnt, Notch or hedgehog. The crosstalk is either mediated directly through protein interactions or 
indirectly through transcriptional feedback loops [117, 121]. 
 
1.4.2.2 Diversity of BMP signaling 
It is surprising that the limited number of receptors for BMP ligands can mediate such a diverse spectrum 
of cellular responses and functions. On the one hand, the crosstalk between several non-SMAD pathways 
mentioned above expands significantly the diversity of cellular responses. On the other hand, next to the 
well-described SMAD pathway, BMPs can initiate the SMAD-independent mitogen-activated protein 
kinase (MAPK) pathway including p38 MAPK, extracellular signal-regulated kinases (ERK) and c-Jun 
amino-terminal kinases (JNK) [122]. This additional SMAD-independent pathway differs from crosstalk 
pathways, because it is induced directly by BMP-receptor binding. The SMAD and MAPK pathways are 
 both crucial not only for MSC migration, proliferation and differentiation during cartilage and bone 
development, but also for the maintenance of joint integrity (including modeling and remodeling 
processes) and possible cartilage repair mechanisms during adulthood [123-124]. A differentiation factor 
for the activation of the SMAD or the MAPK pathway, is the distinct mode of receptor oligomerization 
[125]. Receptor oligomerization to build a heteromeric complex of two type 1 and type 2 receptors 
respectively, can occur in the absence of BMP ligands. Thus, the BMPs can directly bind to the preformed 
receptor complex (PFC) inducing the SMAD pathway (Figure 9). Upon BMP binding to the PFC, the 
receptor complex is internalized by clathrin-dependent endocytosis, followed by dissociation of the 
phosphorylated SMAD1/5/8 [126]. 
 
 
Figure 9 The mode of receptor oligomerization determines intracellular signaling pathways.
 
As a second way of receptor oligomerization, the BMPs can bind to their high affine type 1 receptor 
dimer complex leading to the recruitment of the type 2 receptor dimer complex (Figure 9). Thus, the 
formation of the required heteromeric receptor complex is activated after BMP binding and results in a 
BMP induced signaling complex (BISC). The BISC induces mainly the MAPK pathway resulting in the 
phosphorylation of p38, ERK and JNK, but activates also the SMAD pathway and is internalized in 
caveolae [122, 126]. The induction of the SMAD-independent pathway via BISC requires a greater stability 
of the heteromeric complex compared to the PFC, because the type 2 receptor needs a high mobility 
required for recruitment. Thus, not only the mode of oligomerization, but also the location and mobility 
of the BMPRs within the membrane contribute to broadening of cellular responses of BMPs [122]. 
Furthermore, phosphorylated MAPKs (pMAPK) can regulate the SMAD pathway and can be viewed as a 
kind of fine-tuning for the SMAD pathway. However, the specific role of the SMAD-independent pathway 
remains unclear, especially within chondrocytes. In addition to the different ways of receptor 
oligomerization, different binding affinities of the BMPs to their receptors resulting in specific functions 
which varies among the BMP ligands. 
 
 1.4.2.3 Distinct roles of BMPR1a and BMPR1b in cartilage and bone formation  
The respective roles of the BMPRs in the formation of cartilage and bone is not fully understood and 
remains controversial. However, most of the literature consider that BMPR1a and BMPR1b are the 
important receptors trigger the formation of cartilage and bone. Consequently, different binding 
affinities of the BMPs to BMPR1a or BMPR1b can determine the cell fate. As mentioned above, most of 
the skeletal volume is formed by endochondral ossification. The initial step of this developmental process 
is the chondrogenesis of stem cells resulting in the formation of articular cartilage. This step is clearly 
mediated through activation of BMPR1b [113, 115, 124, 127-128], but it remains unclear if the activation of 
BMPR1a is additionally required [129-131] or if BMPR1a and BMPR1b even have overlapping functions [113, 
115]. As a second step of endochondral ossification, the chondrocytes become hypertrophic and the 
cartilage is finally substituted by bone. This bone formation process is described as hypertrophy and 
osteogenesis and BMPR1a is the main trigger of these processes [112, 115, 124, 127, 130-131]. This is in accordance 
with expression analysis of BMPR1a and BMPR1b. BMPR1a is mainly expressed in osteolineage cells, 
bone marrow cells and pre-hypertrophic chondrocytes, whereas BMPR1b is mainly expressed in pre-
cartilaginous condensation and limb prefigures [113, 115, 124]. Amongst others, two members of the BMP 
family are considered as indispensable during bone and cartilage formation. BMP2 has a high binding 
affinity for BMPR1a and is best known for its great osteoinductive properties, is expressed in 
hypertrophic chondrocytes to trigger osteogenesis and is consequently a key regulator for endochondral 
ossification [110, 132]. In contrast GDF5 is one of the earliest markers during joint formation and is 
expressed at the sites of cartilage development as well as in adult articular cartilage making it a key 
regulator for cartilage development and cartilage maintenance [3, 131, 133]. Therefore, GDF5 could bear 
DMOAD potential. 
 
1.4.3 GDF5 as a possible DMOAD candidate 
GDF5 plays a key role during embryonic cartilage development and cartilage maintenance during 
adulthood and combines anabolic and anti-catabolic capacities. The anabolic potential of GDF5 to induce 
articular cartilage production was demonstrated in vitro and in vivo. The addition of exogenous GDF5 
promotes chondrogenesis of human mesenchymal stem cells [128, 134], induces cartilage ECM synthesis in 
human, mature healthy and OA chondrocytes cultured in alginate beads [135], aggregate cultures [134] or 
pellet cultures [1, 4] and was also shown to induce cartilage formation in a rat model of OA [3]. Recently, 
different MSC niches within the joint including the superficial zone of articular cartilage itself, the 
synovial membrane, the fat pads, the synovial fluid as well as subchondral bone were discovered. 
Probably these MSCs migrate toward the damaged OA cartilage and adhere to it to initiate tissue 
regeneration [51]. Based on the in vitro and in vivo observations mentioned above, it would be possible 
that GDF5 stimulates not only the chondrocytes itself to regenerate articular cartilage, but also to support 
the chondrogenic differentiation of MSCs. Consequently, GDF5 could enable to regenerate articular 
 cartilage. Additionally, anti-catabolic features of GDF5 were demonstrated on human OA chondrocytes 
(hOAC) by inhibition of the Wnt signaling pathway resulting in a downregulation of MMP13 and 
ADAMTS4 [4]. Based on that, GDF5 could additionally prevent further cartilage worsening/OA 
progression. Finally, single nucleotide polymorphisms (SNPs) were identified within the promotor 
sequence of the human GDF5 gene, namely rs143383 and rs143384. Both SNP variants lead to a 
substitution of the cytosine to a thymine allele which significantly reduce the expression of GDF5 within 
the whole joint [136-137]. These SNPs were associated with OA in a genome-wide association study. In 
addition, mutations within the GDF5 gene causes several joint malformations like brachydactyly type C 
(heterozygous GDF5 mutation) and chondrodysplasias like Hunter-Thompson dysplasia (homozygous 
GDF5 mutation) [3, 110, 131, 138] which are also associated with an enhanced OA risk. 
In summary, GDF5 may have therapeutic potential to treat OA. However, GDF5 was also shown to induce 
hypertrophic differentiation in MSCs [5] resulting in the production of cartilage with inferior properties 
and was shown to induce the formation of osteophytes in an OA rat model [3]. The BMPR1a affinity of 
GDF5 is believed to promote hypertrophy and osteogenesis. To reduce these hypertrophic and osteogenic 
capacities of GDF5, which are unwanted when considering GDF5 as treatment option for OA, different 
GDF5 mutants were produced and those having a lower BMPR1a affinity selected. It has been shown in 
prior investigations that these GDF5 mutants stimulate the cartilage ECM production in bovine and 
porcine chondrocytes. The goal of the work presented here was to evaluate the therapeutic potential of 
these GDF5 mutants to treat OA and to show a possible superiority over GDF5. 
 2 Objectives of the work 
 
Current treatment options for OA are limited and mainly focusing on symptomatic relief. These 
medications do not provide a real cure for OA and consequently, there is an unmet medical need for 
disease-modifying OA drugs (DMOADs), which reduce/stop OA progression or even regenerate the 
articular cartilage. Ideally, a DMOAD should provide an improvement of the articular cartilage structure 
combined with symptomatic alleviation.  
The growth and differentiation factor 5 (GDF5) could be a promising DMOAD candidate. GDF5 is a key-
regulator during embryonic cartilage development and for its maintenance during adulthood. 
Furthermore, single nucleotide polymorphisms within the GDF5 gene were associated with OA [3]. 
Previous studies demonstrated that GDF5 can induce cartilage production in chondrocytes, promote 
chondrogenesis in mesenchymal stem cells (MSCs) and induce cartilage repair in a rat model of OA [1-3]. 
Furthermore, it was shown that GDF5 downregulates the production of proteases in chondrocytes [4]. 
Therefore, GDF5 could combine anabolic and anti-catabolic features resulting in the ability to induce 
cartilage repair and simultaneously inhibit disease progression in vivo. Unfortunately, GDF5 was also 
shown to exhibit undesired hypertrophic and osteogenic features in vitro and in vivo [3, 5].  
To reduce the hypertrophic and osteogenic properties of GDF5, different GDF5 mutants were produced. 
Three of these GDF5 mutants (M1673, W417F, W417R) were selected. They display a lower BMPR1a 
affinity in comparison to GDF5 which was thought to be involved in hypertrophic differentiation and 
osteogenesis but a similar BMPR1b affinity, which was thought to be relevant for chondrogenesis. The 
present work aimed to evaluate these GDF5 mutants for their therapeutic potential in chondrocytes and 
MSCs, as both cell types can contribute to cartilage repair. 
Among the GDF5 mutants, M1673 previously showed the strongest effect on cartilage ECM molecule 
production in porcine and bovine chondrocytes. The first objective of this work was to confirm the 
anabolic effect of M1673 in human OA chondrocytes (hOAC). However, in order to do so, the culture 
conditions for the hOAC needed to be optimized. 
MSCs can differentiate into chondrocytes and participate to cartilage repair but can also differentiate 
into bone-producing cells [110]. Another objective of this work was to evaluate the GDF5 mutants for their 
abilities to stimulate chondrogenesis and osteogenesis in MSCs. It was aimed to identify the GDF5 
mutant, which combines the highest chondrogenic capacity and, in comparison to GDF5, a lower 
hypertrophic/osteogenic capacity. BMP2 was used as a positive control for hypertrophy and osteogenesis 
of MSCs. In addition, it was aimed to better understand the respective roles of BMPR1a and BMPR1b in 
chondrogenesis and osteogenesis. 
 3 Materials 
 
3.1 Consumable Material 
 
Product Supplier Cat. No. 
Adhesive Clear Seal Sheets Biozym 600208 
Biopsy cassettes VWR 87002586 
Cell sample cup Beckman-Coulter 7091168 
Cell sieve 100 µm BD Falcon 352-340 
Cell sieve 40 µm BD Falcon 352-360 
Combi TIPS Eppendorf  
613-3532 
613-3533 
ep TIPS VWR 
613-3554 
613-3555 
613-3557 
ep TIPS, dualfilter VWR 
613-3562 
613-3563 
613-3565 
Falcon tubes, 15 mL BD Bioscience 734-0451 
Falcon Tubes, 50 mL BD Bioscience 734-0448 
Falcon Tubes light sensitive, 50 ml VWR 7320438 
Flat 8-Cap Stripes Bio-Rad TCS0803 
iBlot Transfer Stacks, PVDF Thermo Scientific IB401001 
Microscope slides VWR 6302131 
Mx3000 96-well plates Agilent Technologies 401333 
NuPage 4-12% Bis-Tris Gels, 
1.5mm, 10 well 
Thermo Scientific NP0335BOX 
Osmomat measuring vessels Gonotec 30.9.0010 
PCR clean dualfilter tips 1000 µl Eppendorf 0030 077.652 
PCR clean dualfilter tips 200 µl Eppendorf 0030 077.555 
PCR clean dualfilter tips 20 µl Eppendorf 0030 077.628 
Petri dish, 10 cm VWR 7341709 
Petri dish, 15 cm VWR 7341710 
 Petri dish, 6 cm VWR 7341708 
Safe Lock tubes PCR clean 1.5 ml Eppendorf 0030 123.328 
Safe Lock tubes PCR clean 2.0 ml Eppendorf 0030 123.344 
Safe-Lock tubes 1.5 ml VWR 700-5239 
Sample cups ViCell Beckman-Coulter 383198 
Scalpel blade holder VWR 233-5202 
Scalpel blades, Size 22 Braun BB522 
Series S Sensor Chip CM5 GE Healtcare BR100668 
single use serological pipette 10 ml VWR 734-0352 
single use serological pipette 25 ml VWR 734-0347 
single use serological pipette 50 ml VWR 734-0351 
Syringe, 10 ml  VWR 10753946 
Syringe filter, 0.2 µm VWR 5140073 
T-Flask, 75 cm² VWR 734-0050 
T-Flask, primaria 75 cm² Corning 353810 
T-Flask, 175 cm² Corning 356780 
24 well plates Falcon 353226 
24 well plates, primaria Corning 353847 
24 well plates, low binding VWR 7341584 
48 multiwell plates VWR 734-0956 
48 multiwell PCR plates Bio-Rad MLL4801 
96 multiwell plates Falcon 353226 
96 multiwell plates, low binding VWR 7341585 
96 multiwell plates, black Nunc 7342018 
96 multiwell plates, white Greiner Bio-One 655083 
 
 
 3.2 Chemicals and reagents 
 
Product Supplier Cat. No. Application 
Alginic acid sodium salt Fluka 71238 
Alginate beads 
Calcium chloride Alfa Aesar L13191 
HEPES AppliChem A3268 
Hydrochloric acid, 1 M Merck 109057 
Sodium chloride Merck 106404 
Sodium citrate Merck 1064480 
Sodium hydroxide, 0.2 M Merck 109140 
Glycine Merck 104201 
ALP analysis 
Magnesium chloride 
hexahydrate 
Merck 105833 
Nonidet-P40 Calbiochem 492616 
Sodium hydroxide Merck 109141 
Phosphatase substrate Sigma N7660 
Zinc chloride Merck 108815 
4-Nitrophenol Solution, 
10 mM 
Sigma P5869 
Concentration control Beckman-Coulter 175478 Cell 
concentration 
Reagent quad pak Beckman-Coulter 383198 
Alcian blue (1% in acetic 
acid; pH 2.0) 
Morphisto 10126.01000 
Cell staining Alizarin red (0.5% in 
distilled water) 
Sigma A5533 
Paraformaldehyde Merck 818715 
Chondroitin sulfate Sigma C4384 
GAG analysis 
Dimethylmethylen blue AppliChem A1279 
Ethanol p.a  Merck 1.00983 
Formic acid  VWR 20318 
Sodium chloride Merck 106404 
 Sodium citrate Merck 106448 
Sodium formate  Merck 106443 
Acetic acid VWR 818755 
Histology 
Alizarin red Morphisto 13154 
Dewax Solution Leica AR9222 
EtOH VWR 1009843 
Fast Green FCF Sigma F7258 
Isopropanol VWR 818766 
NeoClear VWR 109843 
NeoMount VWR 109016 
Paraffin Merck 111609 
PFA VWR 818715 
Safranin O Sigma S2255 
Wash buffer (Bond-III) Leica AR9590 
Weise Buffer Merck 109468 
Acetonitrile Merck 100030 
HPro analysis 
Formic acid Merck 251364 
Hydrochloric acid Merck 100316 
4-Hydroxyproline Merck 816007 
Tween-20 Calbiochem 655204 
Multispot 
immunoassays 
(Mesoscale) 
EDTA Merck 106346 
Papain digestion 
L-cystein Merck 102838 
Na2HPO4 Merck 106346 
Papain Merck 107144 
Benchmark Prestained 
Protein Ladder 
Thermo Scientific 10748010 
SDS-PAGE 
Magic Mark XP Thermo Scientific LC5602 
 NuPage Antioxidant Thermo Scientific NP0005 
NuPage Sample Reducing 
Agent 
Thermo Scientific NP0009 
Acetate   
SPR affinity 
analysis 
HEPES Merck 1101101 
Hydrochloric acid 1 M Merck 1090571 
Protein-A Sigma P7837 
Sodium chloride Merck 106404 
Sodium hydroxide Merck 109141 
Tween20, 10% solution Calbiochem 655206 
β-glycerolphosphate Sigma 50020 
Stem cells Dexamethasone Sigma D2915 
Hydrochloric acid 1 M Merck 1090571 
Calibration standard   
300 mOsm/kg 
Gonotec 30.9.0020 
To adjust the 
medium 
osmolarity 
Calibration standard   
850 mOsm/kg 
Gonotec 30.9.0850 
Sodium chloride Merck 1.064.04 
Sucrose Calbiochem 573113 
M-Per mammalian 
protein extraction 
reagent 
Thermo Scientific 78503 
Western blot 
PMSF Thermo Scientific 36978 
 
 
3.3 Buffers 
 
Product Supplier Cat. No. 
MES SDS Running Buffer (20x) Thermo Scientific NP0002 
NuPage LDS Sample Buffer (4x) Thermo Scientific NP0007 
 
 
 
 3.4 Kits 
 
Product Supplier Cat. No. 
Amine coupling kit GE Healthcare BR100633 
Biocore maintenance kit, type 2 GE Healthcare BR100651 
Bond Polymer Refine Detection kit Leica DS9800 
EnVision+ anti-rabbit HRP kit Dako K4011 
Human MMP3 Plex Ultra-Sensitive Kit Mesoscale K150034C 
Human proinflammatory-4 tissue 
culture Kit 
Mesoscale K15025B 
Micro BCA Protein Assay Kit Thermo Scientific 23235 
Path Hunter Bioassay Detection Kit DiscoverX 93-0933 
ProC2 kit 
kindly provided by 
Nordic Bioscience 
- 
Proinflammatory Panel 1 (human) Mesoscale K15049D 
Protease Inhibitor Cocktail Kit Thermo Scientific 78410 
RNA 6000 Nano Series II Lab Chip Kit 
Agilent 
Technologies 
5067-1511 
RNeasy Mini Kit Qiagen 74106 
SuperScript III First-Strand Synthesis 
SuperMix for RT-PCR 
Invitrogen 11752050 
SYBR Green JumpStart Taq Ready Mix Sigma S5193 
Quant-iT Picogreen dsDNA Assay Kit Invitrogen P7589 
WesternBreeze Chemiluminescence Kit, 
anti-mouse 
Thermo Scientific WB7104 
WesternBreeze Chemiluminescence Kit, 
anti-rabbit 
Thermo Scientific WB7106 
 
 
 
 
 
 
 
 
 
 3.5 Enzymes & Cytokines 
 
Product Supplier Cat. No. 
Chondroitinase ABC Sigma C2905 
Collagenase NB4G Serva 17465 
DNaseI Set Qiagen/Omega 79254/E1091 
Il1β Sigma I9401 
Il6 R&D 206-IL/CF 
Proteinase K Qiagen 19131 
Proteinase K for IHC Leica AR9551 
TNFα R&D 210-TA/CF 
 
3.6 Antibodies 
 
3.6.1 Antibodies for WB  
 
Primary antibody Protein, MW, source Dilution Supplier Cat. No 
Anti-BMPR1A BMPR1A, 60 kDa, rabbit WB:1/1000 Sigma SAB2701963 
Anti-BMPR1B BMPR1B, 57 kDa, rabbit WB:1/1000 LSBio LSB12897 
 
 
3.6.2 Antibodies for IHC 
 
Primary antibody Dilution Supplier Cat. No 
Mouse anti-collagen I mab 0.55 or 5.5 µg/ml Abcam ab6308 
Rabbit anti-collgen II pab 2 µg/ml Abcam ab34712 
 
 
 
 
 
 
 3.7 Compounds 
 
Product Supplier Cat. No. 
bFGF Merck GF003AF 
BMP2 R&D 355-BM-500/CF 
BMP6 Peprotech 120-06 
TGFβ1 R&D 7754-BH/CF 
TGFβ3 R&D 243-B3-010/CF 
 
GDF5 was kindly provided by Biopharm GmbH, while M1673, W417F and W417R were produced at 
Merck KGaA. All of them were dissolved in 10 mM HCl. Accordingly, BMP2 was also dissolved in 10 mM 
HCl. The remaining compounds were dissolved as stated by the manufacturer. 
 
3.8 BMP receptors 
 
Product Supplier Cat. No. 
rhBMPR-IA/Fc Chimera R&D  315BR/CF 
rhBMPR-IB/Fc Chimera R&D  505PR 
rhmBMPR-II/Fc Chimera R&D  811BR 
 
 
3.9 Cell culture 
 
Product Supplier Cat. No. 
Accutase PAN P10-21100 
Amphotericin B PAN P06-01005 
Beaker, 100 ml VWR 2131105 
Beaker, 150 ml VWR 2131106 
BSA Merck 1120180100 
DEPC-treated water Ambion AM9922 
 FBS Biochrom S0615 
Gelatin solution, 0.1% Merck ES006B 
Geneticin Gibco 10131027 
HEPES Gibco 15630080 
Hygromycin Invitrogen 10687010 
ITS premix Sigma I2521 
L-Ascorbic acid-2-phosphate Sigma A8960 
L-Glutamine Solution, 200mM Merck TMS002C 
L-Proline Sigma P5607 
Magnetic stirring bars, micro VWR 
4420359 - 
4420368 
PBS Gibco 14190 
Pen/Strep PAN P06-07100 
RNase Away Molecular Bio Products 7002/7000 
Sodium pyruvate Gibco 11360 
 
3.10 Culture medium 
 
Product Supplier Cat. No. 
McCoy´s Invitrogen 26600 
MEMalpha+ Gibco A1049001 
DMEM high glucose Gibco 41966029 
DMEM low glucose Gibco 12320032 
 
 
 
 
 
 
 
 3.11 Cell lines 
 
Name Supplier Cat. No. Description 
C3H10T1/2 ATCC ATCC® CCL-226™ Isolated from a line of C3H embryo cells 
U2OS 
BMPR1A/BMPR2 
DiscoverX 93-1006C3 
Human osteosarcoma transfected 
with BMPR1a/BMPR2 
U2OS 
BMPR1B/BMPR2 
DiscoverX 93-1053C3 
Human osteosarcoma transfected 
with BMPR1b/BMPR2 
 
 
3.12 Devices  
 
Instrument Supplier 
Analog vortex mixer  VWR 
Analytical balance “Cubis” Satorius 
AxioCam MRc Zeiss 
Biacore 4000 GE Healtcare 
Centrifuge VWR 
Chip priming station 
Agilent 
Technologies 
CoolClamp RM Leica 
Embedding Station EG1160 Leica 
Fusion SoloS Vilber 
Glass Coverslipper CV5030 Leica 
HandyStep electronic Brand 
iBlot Dry Blotting System Invitrogen 
IHC stainer BOND-III Leica 
Incubator Forma Serie II Thermo Scientific 
Labor-pH-Meter 766 Knick 
Laminarflow KS-12 Hera-safe 
LC-MS/MS System API 4000 Sciex 
 Magnetic stirrer variomag 
multipoint 
VWR 
Meso Sector S600, model 1201 Mesoscale 
Microplate Washer BioTek 
Microscope Axio Observer.A1 Zeiss 
Multistainer ST5020 Leica 
Osmomat 030-3P Gonotec 
Paradigm detection platform Beckmann-Coulter 
PowerPac 300 Bio-Rad 
Qiavac24 Plus Manifold Qiagen 
Rotary microtome RM2255 Leica 
SallyA plate sealer Biozym 
Slide Scanner SCN400 Leica 
SpeedVac SPD131DDA Thermo Scientific 
Standard Analog Shaker VWR 
Stratagene Mx3000P 
Agilent 
Technologies 
Tabletop centrifuge CT15RE Hitachi/VWR 
Thermal Cycler C1000 Biorad 
Thermomixer comfort Eppendorf 
ThermoStat plus Eppendorf 
Tissue Processor ASP300S Leica 
Vicell XR cell and viability 
analyzer 
Beckmann-Coulter 
Vortex mixer MS 3 basic S36 
Agilent 
IKA 
Water bath HI1210 Leica 
XCell Sure Lock Mini Cell Thermo Scientific 
2100 Bioanalyzer 
Agilent 
Technologies 
 
 
 
 3.13 Software’s 
 
Software Name Supplier 
Analyst 1.62 Sciex 
Axio Vision 4.7 Zeiss 
Discovery Workbench, 4.0 Mesoscale 
GraphPad Prism 5.0.4 GraphPad Software 
ImageJ 1.49v Wayne Rasband 
MxPro qPCR Software Stratagene 
SildePath Gateway Leica 
SoftMax Pro 5.4.2 Molecular Devices 
ViCell XR Version 2.04.02 Beckmann-Coulter 
Vision Capt Vilber 
2100 Expert, B.02.08 Agilent Technologies 
 
 
 4 Methods 
 
4.1 Chondrocyte culture 
 
4.1.1 Isolation of primary chondrocytes  
Porcine chondrocytes were isolated from the cartilage of pig hips and bovine chondrocytes from 
metacarpophalangeal or knee joint cartilage of cows. The porcine and bovine joints were obtained from 
a local slaughterhouse (Odenwald Schlachthaus GmbH in Brensbach, Germany). The animals were 
slaughtered either the day of the isolation (porcine material) or the day before (bovine material) and 
were approximately one year old. 
The isolation of human OA chondrocytes was performed from human knee or hip joints of OA patients 
who underwent a total joint replacement surgery (Figure 10). These joints were provided by the clinic 
for orthopedics, traumatology and sports medicine in Agaplesion Elisabethenstift (Darmstadt, Germany) 
or by the university clinic Mannheim (Mannheim, Germany) with full, ethical, written consent (ethical 
approval No. FF24/2015 or 2013-576N-MA). 
 
 
Figure 10 Human OA material from knee (A) or hip (B) joints. 
 
Prior to the isolation of porcine and bovine chondrocytes, the whole joint was incubated in DMEM high 
glucose (DMEM-hg) + 4% Pen/Strep at least for one hour at 4°C. This step is not necessary for human 
OA chondrocyte isolation, because the joint replacement surgery is performed under sterile conditions.  
The cartilage was peeled off the bone and finely chopped with a scalpel. The small pieces were 
transferred into a pre-weighted 50 ml reaction tube filled with 20 ml DMEM-hg. The amount of cartilage 
was determined by weighing the reaction tube again. The cartilage was washed three times with 20 ml 
DMEM-hg in the 50 ml reaction tube. Afterwards remaining fat- and epithelial cells were removed by 
adding 18 ml DMEM-hg containing 0.25% collagenase solution (1/10 dilution of collagenase 2.5% NBG4 
in DMEM-hg) for 30 min at room temperature (RT) under agitation. The cartilage was washed again 
with 20 ml DMEM-hg and transferred into a beaker with 50 ml medium containing 0.1% collagenase 
solution (1/25 dilution of collagenase 2.5% NBG4 in DMEM-hg) and 1% Pen/Strep. The incubation was 
 conducted overnight (24 h +/- 5 h) at 37°C in a 5% CO2 humified incubator under agitation. On the 
following day, the resulting cell suspension was sterile filtered through a 100 µm and 40 µm cell strainer. 
Afterwards, the cell suspension was centrifuged at 1400 x g for 5 min at RT, the medium was removed 
and the cell pellet resuspended in 20 ml DMEM-hg. This step was repeated three times. Finally, the cell 
pellet was resuspended in DMEM-hg containing 10% FBS. The cell concentration was determined by a 
Vi-CELL® cell counter (see chapter 4.4.6). 5 up to 10 million chondrocytes can be extracted out of 1 g 
cartilage. 
For most of the cell cultures, the cells were first cultured one week in monolayer. 1.5x106 porcine and 
bovine chondrocytes and 8-10x106 human OA chondrocytes were seeded into PRIMARIATM tissue culture 
flasks (75 cm2) with 20 ml DMEM-hg containing 10% FBS, 50 µg/ml ascorbic acid-2-phosphate, 400 µM 
proline and 1% Pen/Strep for 5 to 7 days at 37°C in a 5% CO2 humified incubator. Afterwards, the 
primary chondrocytes were harvested by removing the medium from the culture flasks, washing the cells 
with 10 ml PBS per culture flask and incubating the cells with 3 ml accutase per culture flask at 37°C 
until the cells were detached from the bottom of the flask. To stop the reaction 7 ml DMEM-hg + 10% 
FBS was added per culture flask, the cell suspension was transferred into a 50 ml reaction tube and 
centrifuged at 1000 rpm for 5 min. The supernatant was removed and the cell pellet resuspended in 
DMEM-hg + 10% FBS. 500 µl of the cell suspension was filled in Vi-CELL® cups to determine the cell 
concentration (see chapter 4.4.6). 
 
4.1.2 Culture medium preparation and adjustment of the osmolarity 
The osmolarity in healthy articular cartilage ranges between 350 and 480 mOsm while in end-stage OA 
cartilage it decreases down to 270 mOsm [40]. The DMEM medium has an osmolarity of 340 mOsm what 
rather corresponds to conditions within OA cartilage. To reproduce the healthy cartilage condition, the 
medium osmolarity was increased by adding NaCl to the medium. In addition, the medium osmolarity 
was increased by addition of sucrose to exclude sodium and chloride specific effects. 
The culture medium used was DMEM-hg containing 10% FBS, 50 µg/ml ascorbic acid-2-phosphate and 
400 µM proline (DMEM-hg complete). In a first instance, the osmolarity was increased by adding 
different amounts of NaCl or sucrose to the medium according to the following formula: ୑Wଵ଴଴଴ × 𝛥 mOsm 
/ n= g ୒aC୪ o୰ ୱuୡ୰oୱୣ୪ ୫ୣୢiu୫  . With ‘MW’ the molecular weight (g/mol) of NaCl or sucrose, ‘Δ mOsm’ the 
difference between the desired osmolarity and the osmolarity of the medium and ‘n’ the number of 
particles in solution (n=2 for NaCl and n=1 for sucrose). After addition of the calculated quantities of 
NaCl or sucrose, the osmolarity was verified and further adjusted if needed. Osmolarity measurements 
were performed with a cryoscopic osmometer as specified by the manufacturer. 
In a second instance to simplify this procedure, NaCl was dissolved in MilliQ-water (250 mg/ml) and 
sterile filtered through a 0.2 µm strainer. Afterwards a standard curve was created by osmolarity 
measurements after adding different volumes of the 250 mg/ml NaCl solution to the DMEM-hg (Figure 
 11). The standard curve can be used to calculate the required volume of NaCl solution to adjust defined 
medium osmolarities. This approach was used instead of calculating the required volume (with the help 
of the formula above) of NaCl. This enable to take in account the non-ideality of the solution.  
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Figure 11   Standard curve to adjust medium osmolarity with a NaCl-solution.
 
A volume of 5 µl NaCl solution need to be added to 1 ml DMEM-hg to create a medium osmolarity of 
380 mOsm. 10.4 µl and 16 µl need to be added to 1 ml DMEM-hg respectively to obtain a medium 
osmolarity of 420 and 460 mOsm.  
The osmolarity was systematically verified before and after addition of the medium supplements (10% 
FBS, 50 µg/ml ascorbic acid-2- phosphate and 400 µM proline) for the five first batches of medium 
prepared. Afterwards, the osmolarity was only verified when a new NaCl solution was prepared and 
used for the first time.  
 
4.1.3 Monolayer experiments with passaged hOAC 
After a first passage (see chapter 4.1.1), the hOAC were seeded in a volume of 0.5 ml DMEM-hg complete 
(usual osmolarity of 340 or adjusted with NaCl to 380 mOsm, see chapter 4.1.2) into 24 well plates at a 
concentration of 0.4x106 cells per well. The cells were cultured at least for 2 hours at 37°C in a 5% CO2 
humified incubator to enable them to adhere to the bottom of the well plate. Afterwards, the cells were 
stimulated with 0.5 ml DMEM-hg complete containing 600 ng/ml GDF5 or M1673 or 25 µM HCl 
(control) and were cultured at 37°C in a 5% CO2 humified incubator at 21% or 1% oxygen. Every 3 to 4 
days of culture, the medium was renewed. After a total culture time of 7, 14, 21 or 28 days, 
morphological analysis was performed and medium samples were analyzed for its GAG concentration 
(see chapter 4.4.1). In addition, cell samples were analyzed for the cell concentration, viability and gene 
expression (see chapter 4.4.6 and 4.5). 
 
 
 4.1.4 Monolayer experiments with passaged hOAC in the presence of cytokines 
After a first passage (see chapter 4.1.1), the hOAC were seeded in a volume of 1 ml DMEM-hg complete 
(adjusted with NaCl to 380 mOsm, see chapter 4.1.2) into 24 well plates at a concentration of 0.4x106 
cells per well. The cells were cultured for 1 day at 37°C in a 5% CO2 humified incubator to enable them 
to adhere to the bottom of the well plate. Afterwards, the medium was removed and the cells were either 
cultured in 1 ml of serum-free DMEM-hg complete (adjusted with NaCl to 380 mOsm, see chapter 4.1.2) 
or stimulated with 10 ng/ml Il1β and TNFα or 100 ng/ml Il6 in 1 ml of serum-free DMEM complete 
(adjusted with NaCl to 380 mOsm, see chapter 4.1.2). After 2 days of culture, cell samples were 
harvested for gene expression (see chapter 4.5). 
 
4.1.5 Monolayer experiments with freshly isolated hOAC 
Freshly isolated hOAC (FIC) were used directly after collagenase digestion (see chapter 4.1.1) and 
without expansion of the cells. A part of these cells was used for total RNA extraction for gene expression 
(see chapter 4.5.1). These cells were designated ‘day 0’. The remaining cells were divided into different 
tubes and resuspended in DMEM-hg complete with different osmolarities (340, 380, 420 and 460 
mOsm). The osmolarity was adjusted either with NaCl or sucrose (see chapter 4.1.2). FIC were seeded 
in a volume of 1 ml into PRIMARIATM 24 well plates at a concentration of 0.24x106 cells per well and 
were cultured at 37°C in a 5% CO2 humified incubator. After 3 days of culture, the medium was renewed. 
After a total culture time of 6 days, morphological analysis was performed and medium samples were 
analyzed for the GAG concentration (see chapter 4.4.1) and for the presence of cytokines and MMPs 
(see chapter 4.4.5). Additionally, cell samples were analyzed for the cell concentration, viability and 
gene expression (see chapter 4.4.6 and 4.5). 
 
4.1.6 3-D culture experiments 
4.1.6.1 Cartilage tissue analogs (CTAs) 
CTAs were generated by seeding the cells in a high density of 5x106 cells per ml. One million cells/well 
were inoculated in a 96 well ultra-low attachment plate with 200 µL of DMEM-hg complete + 1% 
Pen/Strep and cultivated for one week at 37°C and 5% CO2 in a humified incubator to enable them to 
aggregate and form CTAs. Every second day a medium change was carefully performed. 
Afterwards the CTAs were transferred in a 24 well plate (1 CTA/well) containing 1 mL of DMEM-hg 
complete (usual osmolarity of 340 or adjusted with NaCl to 380 mOsm, see chapter 4.12) in the absence 
or presence of 300 ng/mL of GDF5, M1673, W417F or W417R or 12.5 µM HCl (control). The CTAs were 
cultured at 37°C in a 5% CO2 humified incubator at 21% or 1% oxygen. The medium was changed twice 
a week. On a weekly basis, medium samples were taken and analyzed for the GAG content (see chapter 
4.4.1). After 4 weeks of culture, the CTAs were collected and either lysed to analyze gene expression 
(see chapter 4.5) or fixed for histology (see chapter 4.7) or digested with papain to analyze the DNA, 
 GAG and HPro content (see chapter 4.4.7, 4.4.1 and 4.4.3). To do so, the CTAs were washed with PBS 
and incubated in 250 µL of the papain solution at 60°C overnight. The papain solution consists of 0.125 
mg/mL papain in 5 mM L-cystein, 0.1 M Na2HPO4 and 0.01 M ETDA at pH 6 with papain and L-cystein 
being freshly added to the solution. The dsDNA was measured directly to analyse cell content (see 
chapter 4.4.6). For GAG and HPro measurement (see chapter 4.4.1 and 4.4.3) the samples were stored 
at -20°C until use. 
 
4.1.6.2 Alginate beads 
After the expansion of hOAC at 340 mOsm, the cells were harvested (see chapter 4.1.1) and a cell 
suspension with 2x106 cells/ml was prepared in alginate gel. The alginate gel consists of 0.2 M HEPES, 
1.5 M NaCl and 1.25% alginate, adjusted to pH 7.4 and was autoclaved before use. With the help of a 
10 mL syringe and a 22 g needle, the cell suspension in alginate was poured drop by drop in the 
polymerization solution (120 mM CaCl2 and 10 mM HEPES, sterile) which was kept under agitation. It 
is important that the space between the needle and the polymerization solution is lesser then 10 cm to 
generate round shaped beads. During this step, the total bead number as well as the cells per bead were 
calculated. Once the complete cell suspension was poured in the polymerization solution, the beads were 
enabled to polymerize for 15 min under agitation. The formed alginate beads contained between 40.000 
to 60.000 cells. The beads were washed with a 150 mM NaCl solution 3 times and placed in petri dishes 
with 20 ml DMEM-hg complete adjusted with NaCl to 340, 380, 420 or 460 mOsm (see chapter 4.1.2) 
and cultured at 37°C and 5% CO2 in a humified incubator for 7 days. After 1 day of culture, a medium 
change was performed and after 7 days, the beads were transferred in 24 well ultra-low attachment 
plates with 5 beads /well (≈0.2-0.3x106 cells/well) in 1 mL of DMEM-hg complete (340, 380, 420 or 
460 mOsm) in the presence of 300 ng/ml GDF5 and M1673 or 12,5 µM HCl (control) with or without 4 
µg/ml heparin. Twice a week, the medium was renewed and medium samples were taken to analyze the 
GAG content in medium (see chapter 4.4.1). After 14 days, the alginate beads were dissolved and 
analyzed for their GAG content (see chapter 4.4.1), cell concentration and viability (see chapter 4.4.6) 
or cytokine concentration (see chapter 4.4.5). In addition, the cells were harvested for gene expression 
analysis (see chapter 4.5). To do so, the alginate beads were washed with PBS and incubated in 460 µL 
dissolution solution mixed with 40 µl of 2.5% collagenase (in DMEM-hg + 0.2 mM CaCl2) for a maximum 
of 1 hour at 37°C and 800 rpm. This enables the beads to depolymerize and dissolves cell clumps. The 
dissolution solution consists of 55 mM Na-citrate and 150 mM NaCl at pH 8. After dissolution of the 
beads, 500 µl PBS or DMEM-hg were added, the solution was centrifuged at 500 g for 10 min and the 
supernatant was collected. The cell concentration was measured directly to analyse cell content (see 
chapter 4.4.6). For GAG and cytokine measurement (see chapter 4.4.1 and 4.4.5) the samples were 
stored at -20°C until use. 
 4.2 Stem cell culture and differentiation 
  
The murine mesenchymal stem cell line C3H10T1/2 as well as human mesenchymal stem cells (human 
MSCs) were cultured and either differentiated into chondrocytes and osteoblasts or further cultured in 
an undifferentiated state. To enhance the compound effect on chondrogenesis of the stem cells, TGFȾ3 
was added to the cells additionally to the compounds. 
 
4.2.1 Culture of the C3H10T1/2 cell line 
C3H10T1/2 cells were obtained from the American Type Culture Collection (ATCC). The cells were 
seeded from a cryoconserved aliquot with 1x106 cells in BME basal medium + 10% FBS + 2 mM 
glutamine with 8% DMSO. To do so, the cell aliquot was thawed at 37°C in a water bath and quickly 
transferred in a tissue culture flask (75 cm2) containing 20 ml DMEM-hg + 10% FBS. The cells were 
cultured at 37°C in a 5% CO2 humified incubator. For expansion of the cells, they were routinely plated 
at a density of 4-5x106 cells in tissue culture flasks (175 cm2), maintained in DMEM-hg supplemented 
with 10% FBS and grown at 37°C in a 5% CO2 humified incubator. After reaching approximately 80% 
confluence (4-5 days), the cells were harvested: the medium was removed from the culture flasks, the 
cells were washed with 10 ml PBS per culture flask and subsequently incubated with 10 ml accutase per 
culture flask at 37°C until the cells were detached from the bottom of the flask. To stop the reaction 10 
ml DMEM-hg + 10% FBS was added, the cell suspension transferred into a 50 ml reaction tube and 
centrifuged at 1000 rpm for 5 min. The supernatant was removed and the cell pellet resuspended in 
DMEM-hg + 10% FBS. 500 µl of the cell suspension was filled in Vi-CELL® cups to determine the cell 
concentration (see chapter 4.4.6). 
 
4.2.2 Isolation, characterization and cultivation of human MSCs 
The human MSCs were provided from MilliPore Sigma (located in the United states of America). Detailed 
information concerning the origin and the processing of the human bone marrow can be found in the 
supplementary section (see supplementary, S1).  
After shipping of the cryoconserved human MSCs on dry ice to Merck KGaA Darmstadt, the cells were 
immediately kept in liquid nitrogen until use. Before cell recovery, tissue culture flasks (175 cm2) were 
coated with 15 ml gelatin for 15 min at RT. Afterwards the gelatin was removed from the flask and 40 
ml DMEM low glucose + 10% FBS + 2 mM glutamine + 8 ng/ml bFGF (DMEM-lg complete) was added 
to each flask. The gelatin-coated culture flasks with the medium were stored at 37°C and 5% CO2 in a 
humified incubator until cell seeding. For cell recovery, the cell aliquots were thawed in a water bath at 
37°C and the cells quickly transferred in a 50 ml reaction tube containing an appropriated volume of 
DMEM-lg complete. Thereafter, the cell suspension was centrifuged at 500 g for 5 min, the supernatant 
containing the remaining DMSO was removed and the cell pellet resuspended in DMEM-lg complete to 
 obtain a cell concentration of 1x106 cells per ml medium. 1x106 human MSCs were seeded per tissue 
culture flask (175 cm2) and incubated at 37°C in a 5% CO2 humified incubator. After 3 days, the medium 
was renewed with freshly added bFGF (8 ng/ml). After another 4 days, the cells normally reached 
approximately 80% confluence. They were harvested and the cell concentration was determined as 
described for C3H10T1/2 cells (see chapter 4.2.1), except that DMEM-lg complete was used. 
 
4.2.3 Osteogenic induction 
For osteogenic induction of murine and human MSCs, the cells were seeded into 24 well plates.  
For the human MSCs, the 24 well plates were coated with 400 µl gelatin for 15 min at RT. Afterwards, 
the gelatin solution was removed and 500 µl DMEM-lg complete (culture medium for human MSCs) was 
added to each well. Next, 0.2x106 human MSCs were seeded per well and cultured at 37°C in a 5% CO2 
humified incubator. 
C3H10T1/2 cells were seeded directly, without gelatin-coating, into 24 well plates at a density of 0.1x106 
cells per well in DMEM-hg + 10% FBS + 1% Pen/Strep (culture medium for C3H10T1/2 cells) and 
cultured at 37°C in a 5% CO2 humified incubator. 
Both stem cell types reached approximately 90% confluence after 2 days of culture, which was 
designated ‘day 0’. Some of the cells were lysed to harvest total RNA (see chapter 4.5.1). The medium 
of the remaining wells was changed into DMEM-hg supplemented with 10% FBS, 50 µg/ml ascorbate-
2-phosphate, 10 mM β-glycerolphosphate, 10-8 M dexamethasone and 1% Pen/Strep (osteogenic 
medium) or only renewed with the respective standard culture media without osteogenic inductors to 
determine the effect of the osteogenic medium. 
The cells were cultured in either osteogenic medium or standard culture medium in the presence of 300 
ng/ml GDF5, M1673, W417F, W417R and BMP2 or in the presence of 12.5 µM HCl (control) for 28 days 
at 37°C in a 5% CO2 humified incubator. The medium was renewed twice a week with freshly added 
compounds. Medium and cell samples were harvested on a weekly basis and analyzed for ALP activity 
(see chapter 4.4.2), alizarin red staining (see chapter 4.4.8) and gene expression (see chapter 4.5). In 
addition, pictures were taken with an invert microscope (10X objective) on a weekly basis. 
 
4.2.4 Chondrogenic induction 
For chondrogenic induction, murine as well as human MSC suspensions were divided into 6 different   
50 ml reaction tubes, spun down at 500 g for 5 min and the respective pellets were resuspended in 
DMEM-hg supplemented with 50 µg/ml ascorbate-2-phosphate, 400 µM proline, 10 mM β-
glycerolphosphate, 10-7 M dexamethasone, 1% ITS premix and 1% Pen/Strep (chondrogenic medium) 
to obtain a cell concentration of 1x106 cells per ml medium. Afterwards, 300 ng/ml GDF5, M1673, 
W417F, W417R or BMP2 were added per cell suspension individually or in combination with 10 ng/ml 
TGFȾ3. As negative controls, 12.5 µM HCl was added individually or in combination with 10 ng/ml 
 TGFȾ3 per cell suspension. Next 1 ml of each cell suspension supplemented with the different 
compounds were aliquoted in sterile 1.5 ml eppendorf tubes and spun down at 500 g for 10 min. 
Afterwards, a hole was made in each eppendorf tube with a sterile needle and the cells cultured at 37°C 
in a 5% CO2 humified incubator. The medium was renewed twice a week with freshly added compounds. 
Medium and cell samples were harvested on a weekly basis and analyzed for ALP activity (see chapter 
4.4.2), GAG concentration (see chapter 4.4.1) and gene expression (see chapter 4.5). Additionally, 
histology was performed of the 28 days old cell pellets as described in chapter 4.7. 
 
4.3 Compound analysis 
 
4.3.1 Bioactivity measurement with U2OS Assays 
The potency and efficacy of different GDF5 mutants, GDF5 and BMP2 was evaluated with U2OS 
BMPR1a/BMPR2 or BMPR1b/BMPR2 cells, obtained from DiscoverX. The U2OS cells were engineered 
by the supplier to co-express the BMPR1a or BMPR1b and the dimer partner BMPR2. The dimerization 
of BMPR1a or BMPR1b with BMPR2 induced by the binding of the ligand was analyzed via enzyme 
fragment complementation technology. The enzyme Ⱦ-galactosidase (Ⱦ-Gal) is split into a small peptide 
fragment, which acts as an enzyme donor and is fused to BMPR1a or BMPR1b, and a large protein 
fragment, which acts as an enzyme acceptor and is fused to BMPR2. These enzyme fragments have no Ⱦ-Gal activity itself. The binding of a ligand, as GDF5, to one receptor subunit induce the dimerization 
of both receptor subunits resulting in the forced complementation of the two enzyme fragments. The 
combined enzyme fragments form an active Ⱦ-Gal enzyme, which hydrolyses a substrate resulting in a 
chemiluminescence signal [139-140]. 
The cells were seeded from a cryoconserved aliquot with 1-2x106 cells (in McCoys medium + 10% FCS 
ia.dial. + 0.2 mg/ml geneticin + 0.1 mg/ml hygromycin with 8% DMSO). To do so, the cell aliquot was 
thawed at 37°C in a water bath and quickly transferred in a tissue culture flask (75 cm2) containing 20 
ml culture medium (McCoys + 10% FBS ia.dial. + 0.2 mg/ml geneticin + 0.1 mg/ml hygromycin). After 
7 days of culture, the cells were harvested as described for primary chondrocytes (see chapter 4.1.1). 
The cell pellet was resuspended and the cell suspension adjusted to a concentration of 0.2x106 cells per 
ml in seeding medium (MEMalpha + 2% ia.dial. FBS + 10 mM HEPES + 0.5% Pen/Strep). Afterwards 
20.000 cells were seeded in a volume of 100 µl into 96 well microtiter plates (white) and incubated for 
30 min at 37°C and 5% CO2 in a humified incubator. During the incubation step, the protein dilutions 
for 10-point dose response curves were prepared. As a first step, stock solutions of GDF5, GDF5 mutants 
and BMP2 (0.48 mg/ml) as well as of the reference control BMP6 (100 µg/ml) were 3-fold serial diluted 
with 10 mM HCl + 0.1% BSA to obtain concentrations ranking from 24.4 to 480000 ng/ml or from 5.1 
to 100000 ng/ml respectively. These concentrations are 400-fold higher than the final dose response 
curve concentrations. Afterwards, the prepared serial dilutions were 66.67-fold diluted in seeding 
 medium to obtain concentrations from 0.37 to 7200 ng/ml or 0.08 to 1500 ng/ml respectively, which 
are 6-fold higher than the final dose response curve concentrations. As a last step, the final 
concentrations were achieved by adding 20 µl of the prepared dilutions to the assay plate containing 
100 µl of cell suspension. The resulting concentrations ranking from 0.06 to 1200 ng/ml for the GDF5 
mutants, GDF5 and BMP2 or from 0.01 to 250 ng/ml for the reference control BMP6. In all samples the 
final concentration of HCl was 0.025 mM. Consequently, a negative control of 0.025 mM HCl was carried 
on the assay plate. The treated cells were incubated for 20-24 hours at 37°C and 5% CO2 in a humified 
incubator. 
The next day, the assay plates were analyzed by using the path hunter bioassay detection kit. Initially, 
reagent 1 + 2 were thawed and equilibrated to RT for around 1 hour. Afterwards, 12 µl of the ready to 
use reagent 1 was added to each well, the plate was shaken for 10 sec at 500 rpm and incubated for 15 
min at RT in the dark. After that incubation step, 48 µl of the ready to use reagent 2 was added to each 
well, the plate was shaken for 10 sec at 500 rpm and incubated for 1 hour at RT in the dark. 
Chemiluminescence was measured using a Paradigm MTP reader. 
The EC50 values were calculated with the GraphPad prism software 5.0.4. The concentration of the 
compounds (ng/ml) was transformed into Log(ng/ml). The data were fitted with the least squares fitting 
method by using the log(agonist) vs response – variable slope (four parameters) equation. To fit the data 
of the BMPR1b/BMPR2 dimerization assay, no constrain was used. In contrast, the upper plateau was 
not reached in the BMPR1a/BMPR2 assay and consequently a top strain was used being the EC50 value 
detected with the highest BMP2 concentration. 
 
4.3.2 Affinity measurements 
Surface plasmon resonance (SPR) is a powerful tool to investigate the functional nature of protein-
protein interactions and binding events. The SPR technique was used for affinity measurements of GDF5, 
GDF5 mutants and BMP2 to their receptors BMPR1a, BMPR1b and BMPR2. A glass sensor chip coated 
with a thin metal surface, typically a thin layer of gold was used. The metal layer consists of several 
positive charges and mobile, negative charged electrons. Incident light hits the metal layer in a defined 
angle and the electrons oscillate due to excitation of the light energy. The electron oscillation is called 
plasmon wave, propagates on the metal layer and the intensity is detected for every point on the surface 
in a defined angle by a detector. Binding events, like the interaction of a potential DMOAD to their 
receptors changes the molecule complex size, which is immobilized on the metal layer and consequently 
changes the plasmon wave and the angle of the reflected light. This signal change is described with 
resonance units (RU), where an angle shift of 10-4 degree results in a change of 1 RU [141-142].  
The affinity measurements with the SPR technology was performed in the molecular interaction 
laboratory by Andreas Schoenemann. For SPR analysis, a Biacore4000 was used, which contains 4 
independent flow cells with 5 detection spots each, which enable to analyze 20 binding events 
 simultaneously. The detection spots 1+5 were immobilized with two different concentrations of    
protein A and an equal concentration of the BMP receptor or Erbitux as negative control (1 µg/ml for 
BMPR1a, BMPR2 and Erbitux or 1.75 µg/ml for BMPR1b). The detection spot 2+4 were immobilized 
only with the two different concentrations of protein A and were used as reference surfaces. Detection 
spot 3 was activated and deactivated but neither immobilized with protein A nor with a BMP receptor 
or Erbitux to exclude unspecific sensor chip binding events. The flow cells 1, 2, 3 and 4 were used to 
detect binding affinities to BMPR1a, BMPR1b, BMPR2 or Erbitux respectively. 
In general, a Biacore Maintenance Kit was used for cleaning, normalization of RU signals and 
performance testing of the Biacore4000. At the start of the SPR experiments, the immobilization buffer 
(10 mM Acetate, pH 4.0), the running buffer for immobilization (10 mM HEPES + 150 mM NaCl, pH 
7.4) and the running buffer for kinetic evaluation (10 mM HEPES + 500 mM NaCl + 0.05% Tween20, 
pH 7.4) were prepared. In addition, all reagents, solutions and remaining buffers were prepared, added 
in 96 well plates and placed into the Biacore4000. The BMPR were solved in PBS to reach a concentration 
of 1 µg/ml for BMPR1a, BMPR2 and Erbitux (negative control to exclude unspecific binding) and of  
1.75 µg/ml for BMPR1b. Ligand samples (GDF5, M1673, W417F, W417R and BMP2) were adjusted to 
a start concentration of 200 nM in running buffer for kinetic evaluation and 2-fold serial diluted to reach 
concentrations of 100, 50, 25, 12.5, 6.25, 3.13, 1.56, 0.78, 0.39 nM. Additionally, two non-ligand control 
samples were prepared (= running buffer for kinetic evaluation) which were injected before and after 
the different ligand concentrations respectively. 
The CM5 sensor chip was first activated, protein A was coupled and remaining activated groups 
deactivated. Therefore, 0.4 M EDC and 0.1 M NHS were mixed by the device and were injected (10 min 
@ 10 µl/min) to ensure the amine coupling of protein A on the sensor chip surface. Protein A (52 mg/ml) 
was diluted 2000-fold in immobilization buffer and injected for 90 sec for detection spot 1+2 and         
180 sec for detection spot 4+5 at a flow rate of 10 µl/min in running buffer for immobilization. 
Deactivation of remaining active groups on the surface was performed using 1 M ethanolamine-HCl 
(7min @ 10µl/min). The receptor capture was performed at the beginning of each cycle at a flow rate 
of 10 µl/min for 60 sec in running buffer for kinetic evaluation. Protein A interacts specifically with the 
Fc portion of antibodies (Ab) and therefore mediates the correct aligned immobilization of the different 
Fc-tagged BMP receptors on the sensor chip surface [143]. Before the binding studies were performed, the 
CM5 sensor chip immobilized with the BMP receptors was equilibrated with running buffer for kinetic 
evaluation. One ligand or non-ligand control was injected per cycle at a flow rate of 30 µl/min for 300 
sec followed by a dissociation phase of 900 sec in running buffer for kinetic evaluation respectively. 
Between the different ligand concentrations, an ‘extra wash’ was performed with 50 mM NaOH to clean 
the flow system and the injection needle followed by a stabilization time of 60 sec. At the end of each 
cycle, the running buffer for kinetic evaluation was injected, the sensor chip surface was regenerated 
with 50 mM HCl for 30 sec and the running buffer for kinetic evaluation was injected again before 
 starting a new cycle. The regeneration step removes all molecules bound to the protein A surface but 
without affecting the protein A surface. Data were collected with 10 Hz corresponding to 10 points/sec 
and fitted to a 1:1 Langmuir binding model. 
 
4.4 Cell and medium analysis 
 
4.4.1 Glycosaminoglycan analysis  
Glycosaminoglycan (GAG) concentration was quantified in medium or in alginate beads and CTAs. A 
spectrophotometric assay based on metachromasia was used. In the presence of sulfated GAGs, which 
are negatively charged and located in the cartilage ECM, the absorption maximum of the cationic 
dimethylmethylene blue (DMMB) shifts and the blue dye changes his color to purple [144]. 
The DMMB solution was prepared by solving 8 mg DMMB in 2.5 ml ethanol. After the dissolution of 
DMMB, 1 g sodium formate and 1 ml formic acid was added. The solution was completed to 500 ml with 
MilliQ-water.  
To generate a standard curve, a chondroitin stock solution (1 mg/ml) was prepared in appropriate 
medium or buffer. The stock solution was diluted 1/20 to obtain a concentration of 50 µg/ml. To 
generate the subsequent concentrations, serial 1/2 dilutions were performed down to 0.78 µg/ml. As a 
blank control only medium or buffer was used. 50 µl of the respective standard solutions were transferred 
in a 96 well microtiter plate in a 3-fold determination. 
 
GAG concentration in medium 
To determine the GAG concentration in medium, the supernatant was collected, 50 µl of the undiluted 
samples were transferred in the 96 well microtiter plate containing the standards. Samples and standards 
were mixed with 200 µl DMMB solution. The absorbance at 540/595 nm was read using a Paradigm 
MTP reader and compared to that of chondroitin sulfate standards. 
 
GAG concentration in alginate beads and CTAs 
For GAG quantification in alginate beads and CTAs, they were firstly dissolved (see chapter 4.1.6.1 and 
4.1.6.2). To quantify the GAG concentration, the alginate bead samples were diluted at least 1/10 to 
avoid interference from remaining alginate. 50 µl of the samples were transferred in the 96 well 
microtiter plate containing the standards. Samples and standards were mixed with 200 µl DMMB 
solution. The absorbance at 540/595 nm was read using a Paradigm MTP reader and compared to that 
of chondroitin sulfate standards. 
 
 4.4.2 Alkaline phosphatase (ALP) activity  
Alkaline phosphatase (ALP) is considered as a marker of hypertrophic chondrocytes and osteogenesis 
[145-146]. ALP catalyzes the hydrolysis of p-nitrophenylphosphatase to p-nitrophenol and phosphatase.       
P-nitrophenol has a strong yellow color and an absorbance at 405 nm, which directly correlates with the 
enzyme activity.  
First, the ALP-buffer was prepared by solving 3.754 g glycine, 101.65 mg MgCl2x6H2O and 68.15 mg 
ZnCl2 in 500 ml MilliQ-water. Afterwards, the pH value was set to 9.6, the solution was sterile filtered 
and stored at 4°C.  
To generate a standard curve, p-nitrophenol solution (10 mM) was diluted in ALP-buffer to obtain a 
concentration of 200 µg/ml. Afterwards, 100 µl of the p-nitrophenol solution was diluted in 100 µl of 
corresponding medium and was 2-fold serial diluted directly in the 96 well microtiter plate to obtain 
concentrations ranking from 1.56 to 100 µg/ml. Additionally, a blank value of the used medium was 
carried on the assay plate. The standard curve was performed in a 3-fold determination. 
The ALP substrate solution was prepared freshly by dissolving one capsule containing 100 mg p-
nitrophenylphosphatase in 10 ml ALP buffer at 37°C in the water bath. For ALP activity analysis, 100 µl 
of the samples were transferred in the 96 well microtiter plate with the prepared standard samples. 100 
µl of the ALP substrate solution was added to each well and incubated for 1 hour at RT. Afterwards the 
absorption was measured at 405/490 nm using a Paradigm MTP reader and compared to that of p-
nitrophenol standards. 
 
4.4.3 Hydroxyproline measurement 
The quantitative determination of 4-Hydroxyproline was realized in the quantitative bioanalytics 
laboratory and was performed by using an HPLC-MS/MS assay. 4-Hydroxyproline [2H3] was used as an 
internal standard. A stock solution of 4-Hydroxyproline was prepared with a concentration of 30 mg/mL 
in MilliQ-water. The working solution of the internal standard was prepared by diluting the stock 
solution to a concentration of 1.2 µg/mL in MilliQ-water. Calibration standards from 0.1 to 200 µg/mL 
of 4-Hydroxyproline were prepared in the cell culture medium.  
5 µL of the samples were mixed with 10 µL of internal standard solution and 200 µL of 25% HCl and 
hydrolysed overnight at 110°C. After centrifugation for 1 min at RT and 1200 rpm the samples were 
evaporated to dryness at 55°C/10 Torr. Samples were then resuspended in 1 ml MilliQ-water and an 
aliquot of 100 µl was mixed 1/5 in acetonitrile for injection in a HPLC-MS/MS system. HPLC separation 
was achieved on a HILIC column (Sequant ZIC-HILIC, 50-2.1mm, 3.5µm, 200Å column, Merck KGaA) 
using a mobile phase gradient (eluent A: 0.1% formic acid, eluent B: acetonitrile). Detection was 
performed on a Tandem MS with a turbo ion spray interface operating in the positive ion mode. 
Selectivity of the method was achieved using multiple reaction monitoring (MRM) for MS/MS detection 
of the compounds. The concentrations of 4-Hydroxyproline in unknown samples and calibration 
 standards were calculated by interpolation of the peak area ratio of analytes/internal standard versus 
the ratio of their nominal concentrations into the regression line obtained from the calibration standards 
using the program Analyst 1.62. 
 
4.4.4 ProC2 measurement 
ProC2 is a marker for type 2 collagen production developed by Nordic Bioscience [147] and was measured 
in the dissolved alginate beads (see chapter 4.1.6.2). All incubations were performed at RT with shaking. 
A standard curve was obtained by a 2-fold serial dilution of the provided standard in the provided assay 
buffer and was carried on the plate in a double determination. The provided streptavidin-coated 96 well 
plates were additionally coated with 100 µl biotin-peptide per well (diluted 1/100 in provided assay 
buffer) for 30 min and were washed 5 times with the provided washing buffer (diluted 1/50 in ddH2O). 
20 µL of the standards, samples or controls were added together with 100 µL of the primary antibody 
(1/100 in provided assay buffer). After an incubation time of 3 hours the wells were washed 5 times 
with the provided washing buffer (diluted 1/50 in ddH2O) and 100 µL of the secondary antibody (1/100 
in provided assay buffer) was added per well. After 1 hour of incubation, the wells were washed 5 times 
with the provided washing buffer (diluted 1/50 in ddH2O) and 100 µL of the ready to use TMB was 
added and incubated 15 min in the dark. The reaction was stopped with 100 µL of the ready to use 
stopping solution. Absorbance was read at 450 nm and the absorbance at 650 nm was used as reference. 
Absorbance of the samples were compared to the absorbance of the standard curve. The two controls 
provided should give a concentration of 6.75 ng/mL (±20%) for the low control and 18.2 ng/mL for the 
high control (±20%). 
 
4.4.5 Cytokine and matrix metalloproteinase (MMP) measurements 
Cytokine and matrix metalloproteinase (MMP) measurements from cell supernatants were performed 
using sandwich multi-spot immunoassays from Mesoscale Discovery. For this purpose, a specific 
microtiter plate was used with a working electrode surface pre-coated with capture antibodies. After 
adding the sample, the capture antibodies bind specific cytokines present in the sample. Detection of the 
captured cytokines is achieved by subsequent binding of the detection antibodies which are labeled with 
a sulfo-tag™ and able to emit light after applying voltage on the plate [148]. 
For cytokine measurements, two different multi-spot arrays were used. The 4-spot proinflammatory 
tissue culture array and the 10-spot proinflammatory panel. Both arrays are designed for the detection 
of human cytokines and were used to detect Il1Ⱦ, Il6 and TNFȽ. The 10-spot arrays were used 
additionally because of a higher sensitivity compared to the 4-spot assay. For MMP measurements, the 
human MMP3 Plex Ultra-Sensitive Kit were used. 
As an initial step, all reagents were equilibrated to RT before starting the multisport arrays. Afterwards 
the calibrator solutions were prepared. 
 In the case of the 4-spot array a ready to use calibrator solution (10000 pg/ml) was diluted 4-fold in the 
corresponding sample medium to obtain concentrations of 2500, 625, 156.25, 39.06, 9.77 and 2.44 
pg/ml. In addition, a medium blank was used (0 pg/ml). Afterwards, 25 µl of the calibrator or blank 
solutions were added in a double determination and 25 µl of the undiluted samples were added to the 
pre-coated plate and incubated with vigorous shaking for 2 hours at RT. During the incubation time, the 
detection antibody was prepared by gently mixing 2.94 ml of diluent 100 with 60 µl of the antibody, 
which has been previously diluted 1/50. Next, 25 µl of the prepared detection antibody was added on 
the plate containing the pre-coated antibody and the calibrator/sample and incubated with vigorous 
shaking for another 2 hours at RT. During this incubation time, the washing buffer was prepared by 
diluting the 10-fold concentrate down to a 1-fold solution in MilliQ-water. Afterwards the plate was 
washed 3 times with the washing buffer consists of PBS + 0.05% Tween-20 by using a microplate 
washer. An appropriate chemical environment for the detection of electrochemiluminescence was 
created by diluting the 4-fold concentrated read buffer down to a 2-fold dilution and dispensing 150 µl 
to each well. 
In the case of the 10-spot array the lyophilized calibrator was reconstituted by adding 1000 µl of the 
sample medium. This solution was inverted 3 times, equilibrated to RT for 30 min and vortexed with 
short impulses. Afterwards the calibrator solution was diluted 4-fold in the same medium to generate 
seven calibrators. The medium was used as a zero control. Il1Ⱦ has a starting concentration of 599, Il6 
of 799 and TNFȽ of 371 pg/ml. The plates were washed 3 times with the washing buffer (preparation 
see above) using a microplate washer. Next, 50 µl of calibrator solutions/samples were added to the pre-
coated plate and incubated with vigorous shaking over night at 4°C. This step was performed overnight 
at 4°C to further improve the sensitivity of the array. The next day, the detection antibody was prepared 
by diluting the 50-fold stock solutions of Il1Ⱦ, Il6 and TNFȽ down to a 1-fold working solution in diluent 
3. The plates were washed 3 times with the washing buffer using a microplate washer and 25 µl of the 
detection antibody was added to each well and incubated with vigorous shaking for 2 hours at RT. 
Afterwards the plates were washed 3 times again and 150 µl reading buffer (preparation see above) was 
added to each well. 
In the case of the MMP3 plex array, the ready to use calibrator solution was diluted 10-fold in the 
corresponding sample medium to prepare the highest calibrator solution of the 8-point standard curve 
(MMP1 and MMP3 1x106, MMP9 5x106 pg/ml). Afterwards the calibrator solution was diluted 4-fold in 
the same medium to generate the required calibrators. The medium was used as a zero control. As a first 
step, 25 µl diluent 2 were added to the pre-coated plate and incubated with vigorous shaking for 30 min 
at RT. All the next steps were performed as described for the 4-spot proinflammatory tissue culture array. 
The plates were read on the SECTOR instrument and analyzed with the Software Discovery Workbench 
according to the manufacturer protocol.  
 
 4.4.6 Cell counting 
Cell suspensions were analyzed for their cell concentration and viability by using the automated trypan 
blue dye exclusion method with a Vi-CELL® Counter. A minimum of 500 µl cell suspension had to be 
transferred into Vi-CELL® sample cups and placed into the Vi-CELL® Counter. The cell suspension is 
mixed with a trypan blue solution (provided by the manufacturer), aspirated in a capillary and is 
delivered to a flow cell system containing a camera. For imaging up to 100 images per sample are 
captured and analyzed with digital image analysis. During analysis, the dead cells were differentiated 
from the viable cells. Dead cells have a higher permeability for trypan blue and consequently appear 
darker than viable cells, which are not penetrable by this dye. Therefore, the concentration of viable cells 
per ml cell suspension as well as the viability of the cell suspension can be determined. 
 
4.4.7 dsDNA measurement 
Papain digestion of the CTAs disrupt the cells making it impossible to assess the cell content. 
Alternatively, the dsDNA content was measured in the lysed CTAs to estimate their primary cell content. 
An ultrasensitive dye, named Quant-iT PicroGreen-dsDNA reagent, was used for dsDNA quantification. 
Before usage, the Quant-iT PicroGreen-dsDNA reagent was equilibrated at RT without light exposure. 
Afterwards a 1xTE buffer was prepared by diluting the 20xTE (200 mM Tris-HCl, 20 mM ETDA, pH 7.5) 
buffer in MilliQ-water. The Quant-iT PicroGreen-dsDNA reagent was diluted 200-fold in 1xTE buffer to 
obtain the working picogreen solution. The lambda DNA standard (100 µg/ml) provided in the kit was 
diluted with 1xTE buffer to obtain concentrations of 1000, 750, 500, 250, 125, 62.5 and 31.25 ng/ml. 
As a last calibrator to complete the 8-point calibration curve, a 1xTE buffer blank was used (0 pg/ml). 
The papain digested samples were centrifuged at 3000 g for 5 min to remove any particles and 
subsequently diluted 100-fold in 1xTE buffer. 80 µl of the 1xTE buffer was pipetted into a 96 well 
microtiter plate (black) and 20 µl of the samples, standards and blanks were added respectively. 
Afterwards 100 µl of the picogreen solution was added to each well and incubated for 5 min at RT in 
the dark. The fluorescence at 485/535 nm was measured using a Paradigm MTP reader and compared 
to that of lambda DNA standards. 
 
4.4.8 Alizarin red staining 
To determine the cell type in vitro or test the capability of cells to differentiate into osteoblasts, the 
Alizarin red staining can be used to identify calcium depositions. Alizarin Red is a small hydrophilic 
anionic dye, which chelates several cationic metals such as calcium and form a dye-metal covalent bond. 
As 99% of the calcium in the body is localized in the bone, Alizarin red selectively interacts with bone 
or calcium deposits in mineralized extracellular matrix.  
To stain cells, which were grown in monolayer cultures, as a first step the medium was carefully 
aspirated. Afterwards, the cells were washed with PBS and fixed with 0.5 ml PFA (4% in PBS) for 1 hour. 
 After fixation, the cells were washed with 1 ml MilliQ-water for 2 times. For cell staining, 400 µl of the 
staining solution was added to the fixed cells and incubated for 20 min at RT. Subsequently the cells 
were washed with 1 ml MilliQ-water for 4 to 5 times. For documentation and storage, the cells were 
covered with 1 ml PBS. 
 
4.5 Gene expression analysis 
 
Gene expression analysis is an important tool to analyze different properties of potential DMOADs. As a 
first step, RNA was extracted, analyzed and transformed into cDNA by reverse transcription. Afterwards 
the gene expression was analyzed by quantitative real time PCR (qRT-PCR) to investigate, which genes 
were up- or downregulated at different conditions or after compound treatments. Therefore, the cDNA 
is first denatured, followed by primer annealing and elongation to create a double-stranded DNA 
(dsDNA). A fluorescence dye, which incorporates in dsDNA, is used to determine the amount of the 
amplified product in real-time. 
The extraction of RNA is a crucial step, which works very well for chondrocyte monolayer cultures, while 
the extraction from 3D cultures, like CTAs or human MSC pellets, is very difficult because of the ECM 
which surrounds the chondrocytes. Therefore, different methods, like the extraction by using several 
freeze-thaw cycles, pestles or ultra-turrax as well as combined methods were evaluated for their ability 
to extract RNA. The method with the most robust results was the lysis of the samples with the RLT buffer 
provided in the RNeasy Mini Kit from Qiagen, followed by proteinase K treatment, homogenization with 
absolute ethanol and purification using RNeasy spin columns. 
All steps were performed by using PCR clean dual filter tips. 
 
4.5.1 RNA extraction 
Total RNA was extracted from all samples by using the Qiagen RNeasy Mini Kit as specified by the 
manufacturer. As a first step, the biological samples were lysed with a highly denaturing guanidine-
thiocyanate-containing buffer (RLT Buffer) and were subsequently homogenized. 
For monolayer cultures of primary chondrocytes, cell disruption was performed by adding 350 µl RLT 
buffer to each well and scraping the cell layer with the pipette tip. The lysate was collected in a 
QIAshredder spine column placed in a 2 ml collection tube and spun down at full speed for 2 min to 
remove insoluble materials and reduce lysate viscosity. The lysate can be stored at -20°C or directly 
processed. In both cases 1 volume of 70% EtOH was added and gently mixed to homogenize the mixture 
and to provide conditions which facilitate the specific binding of RNA to the column.  
3D cultures as well as monolayer cultures of stem cells were lysed with 300 µl RLT buffer. After cell lysis, 
an additional step of proteinase K treatment was performed to remove the ECM as well as endogenous 
proteases such as RNases. To do so, the lysate was mixed with 590 µl DEPC-water and 10 µl proteinase 
 K, incubated for 10 min at 55°C and centrifuged at 10000 g for 5 min. The supernatant was collected in 
a 2 ml collection tube and either stored at -20°C or directly processed. In both cases RNA isolation started 
by gently homogenizing the lysate with 0.5 volumes of absolute EtOH. 
For the RNA extraction, RNeasy spin columns (up to 24) were inserted in the VacConnector manifold, 
which was connected to the house vacuum. Homogenized lysates were transferred to the columns 
containing a silica-membrane, which binds RNA. Subsequently the house vacuum was turned on to draw 
the lysates efficiently through the columns. Afterwards 350 µl RW1 buffer was added to each column to 
remove contaminants and was vacuumed. A DNA digestion was performed directly on the column by 
adding 80 µl of the DNase I incubation mix on the silica-membrane. The incubation was performed at 
least for 15 min. 350 µl RW1 buffer was added on top and was vacuumed. After this wash step 500 µl 
of the EtOH containing RPE Buffer (4 volumes of absolute EtOH were added to the concentrate to obtain 
a working solution) was added to the columns and was vacuumed. This step was repeated once. Next 
the empty RNeasy spin columns were removed from the manifold and placed in the provided collection 
tubes and centrifuged for 1 min at full speed to remove the residual RPE buffer from the silica-membrane. 
Elution of the total RNA was performed by carefully placing the spin columns in 1.5 ml collection tubes 
respectively, adding 30 µl DEPC-water directly to the silica-membrane and spun down in a centrifuge 
for 1 min at 8000 g. The final RNA concentration was increased by adding the obtained eluate on the 
silica-membrane again and spun it down as described previously.  
The collection tubes were labelled and the samples were either immediately analyzed for their RNA 
concentration and purity or stored at -20°C. 
 
4.5.2 RNA Analysis 
RNA concentration and purity of samples were analyzed by capillary gel electrophoresis using the “lab-
on-a-chip” technology with an Agilent 2100 Bioanalyzer. The chip contains several interconnected 
microchannels. Once the chip is filled with a sieving polymer, a fluorescence dye and the RNA sample, 
an electrical voltage is applied. The RNA, as a charged molecule, is size separated by the sieving polymer. 
The intercalation of the fluorescence dye enables the detection of the RNA molecules by laser-induced 
fluorescence which enables for instance to determine the RNA concentration and integrity. 
As an initial step, the RNA ladder was prepared. The ladder was thawed, spun down, heat denatured for 
2 min at 70°C and immediately cooled down on ice. Afterwards, the denatured ladder was aliquoted at 
1.2 µl in 0.5 ml RNase-free collection tubes and stored at -80°C. 
All reagents were equilibrated to RT for approximately 30 min before preparing the assay. Afterwards 
550 µl of the RNA nano gel matrix (sieving polymer) was transferred into a spin filter and centrifuged 
for 10 min at 1500 g. The gel matrix was stored at 4°C and can be used within 1 month. In order to 
prepare the gel-dye mix, 65 µl of the filtered gel was transferred into a 1.5 ml RNAse-free collection tube 
and the RNA dye concentrate was mixed and spun down for 10 sec. Afterwards 1 µl of the dye was added 
 to the gel aliquot, mixed by vortexing and centrifuged for 10 min at 13000 g. The gel-dye mix can be 
used for two chips within 1 day.  
Before starting the experiment, one cleaning electrode was filled with 350 µl of RNeasy away solution 
and another one with 350 µl of RNase-free water. The electrode cleaner with RNeasy away solution was 
placed in the Bioanalyzer. A new RNA nano chip was inserted in the chip priming station and 9 µl of the 
gel-dye mix was pipetted into the appropriately marked well. It is very important to pipette all substances 
on the bottom of the RNA chip to avoid bubbles. Once it was verified that the plunger is positioned at     
1 ml, it was pushed down until it was hold by the chip priming station. After waiting for exactly 30 sec, 
the plunger was released with the chip release mechanism, it was waited about 5 sec and subsequently 
the plunger was slowly and carefully pulled back at the 1 ml position to finish the ‘pressurize procedure’. 
The chip priming station was opened and another 9 µl of the gel-dye mix was pipetted into the remaining 
appropriately marked two wells, respectively. As a next step, 5 µl of the nano marker was loaded into 
the well which is marked with the ladder symbol as well as in each of the sample wells. Further 1 µl of 
the nano ladder and of each sample, which were thawed and kept on ice, were loaded into the ladder 
and sample wells respectively. Unused wells were filled with a total of 6 µl of the nano marker to 
guarantee the same volume in all wells of the chip. 
The chip was vortexed for exactly 1 min at 2200 rpm by the IKA vortex mixer. At the same time, the 
electrode cleaner filled with RNase-free water was inserted into the bioanalyzer. Once the 1 min shacking 
was finished, the chip was inserted into the Bioanalyzer and the software was started within 5 min. After 
starting the analyzing procedure, the sample and chip information were entered. The analyzed data are 
translated into a gel-like image or an electropherogram by the bioanalyzer. In addition, the RNA 
concentration and integrity number (RIN) are displayed.  
 
4.5.3 cDNA synthesis 
Complementary DNA (cDNA) was generated by reverse transcription of RNA samples using the 
SuperScript III First-Strand Synthesis Supermix Kit. The kit contains a 2xRT reaction mix, which includes 
oligo (dT)20, random hexamers, MgCl2 and dNTPs, and an enzyme reaction mix. The enzyme reaction 
mix includes the reverse transcriptase and RNase OUT which inhibit RNases. 
First the 2xRT reaction mix was thawed and 12 µl were pipetted in each well of the 48 well PCR plate. 
Afterwards 2 µl of the enzyme reaction mix was added. The RNA samples were thawed on ice to inhibit 
degradation processes. The same RNA concentration in the range of 20 ng up to 1 µg was used for all 
RNA samples of 1 experiment to synthesize cDNA. A maximum of 8 µl RNA sample was added to each 
well. RNA samples with a higher RNA concentration were diluted in DEPC-treated water to reach a 
volume of 8 µl. Afterwards the 48 well PCR plate was sealed, centrifuged and placed in the thermal 
cycler. The samples were first incubated at 25°C for 10 min to enable primer annealing, followed by a 
30 min incubation at 50°C for cDNA synthesis and terminated by a 5 min incubation at 85°C. Afterwards, 
 the samples were cooled down to 4°C and 1 µl RNase H was added to each well and incubated at 37°C 
for 20 min to remove the RNA template from the synthesized cDNA. The plate was stored at -20°C. 
 
4.5.4 Quantitative real time PCR 
Quantitative real time PCR (qRT-PCR) was performed using SYBR Green as a fluorescence dye, which 
exhibits only a little fluorescence signal in unbound state, but emits a strong fluorescence signal upon 
incorporation in double-stranded DNA (dsDNA). The fluorescence signal was measured in the 
exponential phase of the qRT-PCR after each cycle and is directly proportional to the amplified DNA. 
This allows the detection of product accumulation in real-time. Additionally, the reference dye ROX was 
used to compensate non-PCR related fluorescence changes and to stabilize the baseline, which is used 
for sample normalization [149-150].  
As a first step, sequence specific primers were designed, ordered (from Eurofins MWG Operon, see Table 
1) and the delivered lyophilizates were solved with DEPC-water to a 100 pmol/µl stock solution. Primer 
working solutions of 10 pmol/µl were prepared by diluting the stock solution with DEPC-water. For 
primer validation, cDNA (containing the target gene) was serial diluted and a standard curve was created 
by qRT-PCR. The standard curve should have a coefficient of correlation (R2) over 0.985 indicating a 
good data point fit and an efficiency of 90-110% [151].  
Table 1 Primers used for qRT-PCR reactions. 
Gene Primers 
Bovine EF1 Forward: 5’- AGCTGAAGGAGAAGATTGATC -3’ 
Reverse: 5’- GGCAGACTTGGTGACCTTG -3’ 
Bovine Aggrecan Forward: 5’- GAAACCTCTGGACTCTTTGGTGTC -3’ 
Reverse: 5’- GCCAGATATTTCTCCATAAAACCCTGA -3’ 
Bovine Collagen 2 Forward: 5’- GAACCCAGAACCAACACAATCC -3’ 
Reverse: 5’- TCTGCCCAGTTCAGGTCTCTTAGAGA -3’ 
Human EF1 Forward: 5’- CCTTGTGGAAATTTGAGACC -3’ 
Reverse: 5’- CCATTTTGTTAACACCGACA -3’ 
Human ADAMTS5 Forward: 5’- TCAAAGCCAAAGACCAGACT -3’ 
Reverse: 5’- ATTTCCTTCGTGGCAGAGTA -3’ 
Human Aggrecan Forward: 5’- GAAAGGCATCGTGTTCCATT -3’ 
Reverse: 5’- ACGTCCTCACACCAGGAAAC -3’ 
Human BMPR1a Forward: 5’- CAGGTTCCTGGACTCAGCTC -3’ 
Reverse: 5’- CTTTCCTTGGGTGCCATAAA -3’ 
Human BMPR1b Forward: 5’- AAAGGTCGCTATGGGGAAGT -3’ 
Reverse: 5’- GCAGCAATGAAACCCAAAAT -3’ 
Human BMPR2 Forward: 5’- GCTAAAATTTGGCAGCAAGC -3’ 
Reverse: 5’- CTTGGGCCCTATGTGTCACT -3’ 
Human Collagen2 Forward: 5’- TCCATAGCTGAAATGGAAGC -3’ 
Reverse: 5’- CCTGAGTGGAAGAGTGGAGA -3’ 
 Human Collagen 10 Forward: 5’- AGGGTTACCAGGTCCAAAAG -3’ 
Reverse: 5’- TGAGGCCCTTAGTTGCTATG -3’ 
Human MMP13 Forward: 5’- CCAACCCTAAACATCCAAAAAC -3’ 
Reverse: 5’- AAAAACAGCTCCGCATCAAC -3’ 
Human Osteocalcin Forward: 5’- GTGCAGAGTCCAGCAAAGGT -3’ 
Reverse: 5’- TCAGCCAACTCGTCACAGTC -3’ 
Human Osteopontin Forward: 5’- TGAAACGAGTCAGCTGGATG -3’ 
Reverse: 5’- TGAAATTCATGGCTGTGGAA -3’ 
Murine EF1 Forward: 5’- ACAGGCGCAGAGGTAAAAAT -3’ 
Reverse: 5’- TATATGGCACAGCCTCCTCA -3’ 
Murine Aggrecan Forward: 5’- TGGCTTCTGGAGACAGGACT -3’ 
Reverse: 5’- GGGACATGGTTGTTTCTGCT -3’ 
Murine BMPR1a Forward: 5’- CTTCTCCAGCTGCTTTTGCT -3’ 
Reverse: 5’- ATAGCGGCCTTTACCAACCT -3’ 
Murine BMPR1b Forward: 5’- AGCTGGTTCCGAGAGACTGA -3’ 
Reverse: 5’- CAGCATGGACTTTGCGTCTA -3’ 
Murine BMPR2 Forward: 5’- TGGCAGTGAGGTCACTCAAG -3’ 
Reverse: 5’- TTGCGTTCATTCTGCATAGC -3’ 
Murine Collagen 2 Forward: 5’- AGGTGTTCGAGGAGACAGTG -3’ 
Reverse: 5’- CAACAATGCCCCTTTGACCA -3’ 
Murine Collagen 10 Forward: 5’- TTCTCCTACCACGTGCATGT -3’ 
Reverse: 5’- GAGGCCGTTTGATTCTGCAT -3’ 
Murine Osteocalcin Forward: 5’- ATGAGGACCATCTTTCTGCTCA -3’ 
Reverse: 5’- GTAGCGCCGGAGTCTGTT -3’ 
Porcine RPL13A Forward: 5’- TCAAGGTGGTGCGTCTGAAG -3’ 
Reverse: 5’- TACGTTCTTTTCCGCCTGCT -3’ 
Porcine Aggrecan Forward: 5’- GCTTATGCCTTCCCAGCTAC -3’ 
Reverse: 5’- GATGCTGCTCAGGTGTGACT -3’ 
Porcine Collagen 2 Forward: 5’- GGATGGGCAGAGGTATAATG -3’ 
Reverse: 5’- TCTCCAGGTTCTCCTTTCTG -3’ 
 
During qRT-PCR each cDNA sample was analyzed in duplicates against the selected gene of interest and 
against EF1Ƚ or RPL13A as housekeeping genes. Additionally, a non-template control (NTC) was run for 
each primer-pair used in the qRT-PCR to evaluate the absence of contamination of the master mix.  
The components listed in Table 2 were mixed to generate a master mix. One master mix per primer pair 
was prepared. The reference dye was diluted 1/10 in DEPC-water before mixing it with the other 
components. 
 
 
 
 
 Table 2 Master mix preparation per cDNA sample and analyzed gene for qRT-PCR reaction. 
Component Volume (µl) per sample 
SYBR Green 12.5 
diluted reference dye 0.25 
Forward primer 0.5 
Reverse primer 0.5 
MgCl2 3.0 
DEPC-H2O 3.25 
 
20 µl of the master mix was transferred into each well of a Mx3000 96 well plate. Afterwards 5 µl of the 
cDNA sample (1/5 diluted with DEPC-water) or 5 µl of DEPC-water (NTC) was pipetted into the 
appropriate wells. The plate was sealed, centrifuged and checked for disturbing air bubbles. Immediately 
the plate was run in the thermocycler Mx3000P using the thermal profile of Table 3. 
 
Table 3 Thermal profile used for qRT-PCR reactions. 
Temperature [°C] Time Reason  
 ]cycle repetition 40x 
94 4 min Initial denaturation of DNA 
94 30 sec Denaturation of DNA 
60 30 sec Annealing of primer 
72 1 min Elongation 
95 1 min  
Melt curve analysis 
(fluorescence is read at each 
degree) 
55 30 sec 
95 30 sec 
 
For each sample and each gene, the cycle threshold (Ct) was determined in the amplification plot, which 
reflects the fluorescence change during cycling. This change is inversely proportional to the product. The 
more product, the lower is the Ct value, because lesser cycles are necessary to reach a fluorescence signal 
above the background. The relative abundance of target mRNA is calculated according to the following 
formula [152]: 
ctGOI
ctHKG
ctGOIctHKGabundancerelative
2
22_ )(     
The dsDNA of the PCR product has a higher melting point compared to unspecific dsDNA fragments or 
primer dimers. Thus, a melt curve analysis was performed following qRT-PCR to determine the specificity 
of the qRT-PCR. 
 
 4.6 Western blot analysis 
 
The Western blot (WB) is an important tool for the identification and characterization of specific proteins 
from cell samples. The cell samples were lysed, separated by a discontinuously SDS-PAGE and 
transferred to a PVDF membrane. Afterwards the immobilized proteins were incubated with specific 
antibodies against the protein of interest and the antibody signal was developed with 
chemiluminescence. 
 
4.6.1 Sample preparation 
First, the lysis buffer was freshly prepared by mixing 5 ml M-PER extraction reagent with 1 mM PMSF 
(1/100 dilution of 100 mM PMSF solved in isopropanol) as well as with 5 mM EDTA and 1% protease 
inhibitor (provided in the Protease Inhibitor Cocktail Kit). 
To evaluate the presence of BMP receptors by western blot analysis, a cell concentration of 0.2x106 
C3H10T1/2 cells and human MSCs were transferred in a 1.5 ml eppendorf tube and centrifuged for      
10 min at 500 g. The cell pellets were lysed with 100 µl of the freshly prepared lysis buffer and stored 
at -80°C until further processing. 
 
4.6.2 SDS PAGE 
The lysed samples were thawed and prepared for SDS PAGE by mixing 39 µl of each sample with 6 µl 
NuPage Sample Reducing agent (10x), 15 µl NuPage LDS Sample Buffer (4x) to reach a total volume of 
60 µl. One sample were used for the detection of both BMPR1a and BMPR1b, to allow their comparison. 
Afterwards, the prepared samples were mixed, briefly centrifuged and heated for 10 min at 70°C. During 
this step, the 1x running buffer was prepared by mixing 40 ml of MES SDS Running Buffer (20x) with 
760 ml MilliQ-water. Additionally, 200 ml of the 1x running buffer was mixed with 0.5 ml NuPage 
antioxidant. The XCell Sure Lock Mini cell was constructed according to the manufacturers manual and 
the required number of NuPage 4-12% Bis-Tris Protein Gels were unpacked and rinsed with water. The 
tapes covering the slot on the back on the pre-cast gels and the combs were carefully removed and the 
lanes were rinsed with 1x running buffer several times. Afterwards the gels were placed in the 
electrophoresis apparatus, the 1x running buffer containing antioxidant was filled in the upper buffer 
chamber to completely cover the sample lanes and the 1x running buffer was filled in the lower buffer 
chamber to dissipate heat during the run. Afterwards 5 µl of the Bench Mark Prestained Protein Ladder 
as well as 5 µl of the Magic Mark were loaded together in 1 lane, the remaining lanes were loaded with 
25 µl of the prepared samples respectively. The gels were run at 150 volts for approximately 1-1.5 hours 
with the PowerPac 300 until the pre-stained ladder was separated and the dye of the sample buffer was 
run out the separation gel. Afterwards, the gel cassettes were opened, the stacking gel were cut off the 
 gels, the gels were removed from the cassette plates and put in a petri dish containing 20 ml MilliQ-
water respectively. 
 
4.6.3 Immunoblotting & detection 
The protein transfer from the gels to a PVDF membrane was performed using a dry blotting system with 
the iBlot Gel Transfer device. For the transfer the iBlot Transfer Stacks kit was used, it contains the PVDF 
membrane and the filters and sponge, ready to use. First the anode stack, then the gels and finally the 
cathode stack were placed in the transfer devise according to the manufacturer instructions. Two gels, 
out of 1 XCell Sure Lock Mini cell, could be transferred simultaneously. The transfer ran for 7 min at 20 
volts. For immunodetection of the transferred proteins, the WesternBreeze Chemiluminescent Kit was 
used. During the protein transfer, the blocking solution was prepared by mixing 5 ml MilliQ-water, 2 ml 
Diluent A (concentrated buffered saline solution with detergent) and 3 ml Diluent B (concentrated 
hammarsten casein solution) per membrane. All incubation steps were performed under agitation on a 
shaker. As a first step, the PVDF membrane with the immobilized proteins was incubated in 10 ml of 
blocking solution for 1 hour. Afterwards the membranes were washed with 20 ml MilliQ-water for 5 
min. This washing step was repeated once and during the incubation time the primary antibody solution 
was prepared by mixing 7 ml MilliQ-water, 2 ml Diluent A, 1 ml Diluent B and the necessary volume of 
primary antibody (dilutions see chapter 3.6.1). The primary antibody solution was incubated overnight 
at 4°C. The next day, a sufficient volume of 16x antibody wash solution was diluted to 1x antibody 
solution with MilliQ-water. The membranes were washed three times with 20 ml of 1x antibody wash 
solution for 5 min. Next the membranes were incubated with secondary antibody solution (ready to use, 
anti-rabbit or anti-mouse) for 1 hour. The membranes were washed three time with the 1x antibody 
wash solution and rinsed twice with 20 ml MilliQ-water for 2 min. Afterwards they were placed on a 
clean, transparent plastic sheet and incubated with 2 ml chemiluminescence substrate (ready to use) for 
5 min. Next, the membranes were covered with another clean, transparent plastic sheet to prepare a 
membrane sandwich for imaging with the Fusion SoloS using the Vision Capt Software. 
 
4.7 Histology 
 
Histology was realized in the exploratory osteoarthritis laboratory by Thomas Schnellbaecher and was 
performed for bovine and porcine CTAs as well as for human MSC pellets at the end of the culture 
(cultivation conditions see chapter 4.1.6.1 and 4.2.4). CTAs and pellets were prepared for histology by 
fixing the cell samples with a 4% phosphate buffered PFA solution for 30 min at RT. Afterwards the cell 
samples were washed with PBS for 15 min. This washing step was repeated 3 times and the cell samples 
were transferred in biopsy cassettes and handed over in PBS to the histology laboratory. As a first step, 
the cell samples were dehydrated with an increasing alcohol series and infiltrated with paraffin. To do 
 so, the cell samples were incubated with 30% EtOH for 2 hours and followed by 50% EtOH for 2 hours. 
Afterwards the cell samples were transferred into a fully enclosed tissue processor, which further 
dehydrated the cell samples with 70, 80, 90 and 96% EtOH as well as with isopropanol and NeoClear 
(Xylol derivate) and infiltrated them with paraffin as described in Table 4. 
 
Table 4 Process for cell dehydration and paraffin infiltration using a tissue processor. 
Station Reagent Time 
1 70% EtOH 15 min 
2 80% EtOH 15 min 
3 90% EtOH 1 h 
4 96% EtOH 1 h 
5 96% EtOH 1 h 
6 Isopropanol 1 h 
7 Isopropanol 1:15 h 
8 Neoclear 1:30 h 
9 Neoclear 1:30 h 
10 Neoclear 1:30 h 
11 Paraffin 2 h 
12 Paraffin 12 h 
  
Cell samples were subsequently embedded with paraffin (60°C) in paraffin blocks on an embedding 
station and were cooled down on a cold plate (-4°C) until paraffin solidification. The paraffin embedded 
samples can be stored at RT until further processing. 
As a next step, the cell preparations were cut with a rotary microtome (5 µm) under the use of a 
CoolClamp to ensure a continuous cooling. The slices were applied on microscope slides and transferred 
into a water bath (40°C) for straightening. Afterwards the slices were dried on a heat plate overnight. 
The slices could be analysed for different extracellular matrix components via histochemical or 
immunohistochemical stainings.  
For histochemistry a combined auto- and multistrainer was used. The slices were de-paraffinized in 
NeoClear and rehydrated in decreasing concentrations of EtOH. Next, the slices were stained with 
Fastgreen (counterstaining) and Safranin O (stains proteoglycans) or Alizarin Red (stains calcium 
deposit indicating mineralization) and finally dehydrated in absolute EtOH and NeoClear as described 
in Table 5. At the end of the process, slides were mounted with Neomount with a Glass Coverslipper. 
 
 
 
 Table 5 Process for Safranin O staining (left) and Alizarin Red staining (right) with an auto- and multistainer. 
 
Step Reagent Time [min]  Step Reagent Time [min] 
1 NeoClear 5  1 NeoClear 5 
2 NeoClear 7  2 NeoClear 7 
3 96% EtOH 5  3 96% EtOH 5 
4 80% EtOH 5  4 80% EtOH 5 
5 70% EtOH 5  5 70% EtOH 5 
6 60% EtOH 5  6 60% EtOH 5 
7 Water 3  7 Water 3 
8 Fastgreen 5  8 0.5% Alizarin Red 5 
9 1% acetic acid 0.75  9 Weise Buffer 0.5 
10 0.01% Safranin O  10  10 0.04% Fastgreen 0.25 
11 100% EtOH  1  11 Glacial acetic acid 0.33 
12 100% EtOH 2  12 96% EtOH 2 
13 100% EtOH 5  13 100% EtOH 5 
14 NeoClear 5  14 NeoClear 5 
15 NeoClear   15 NeoClear  
 
The immunohistochemical detection of type 2 and type 10 collagen was performed using a fully 
automated immunohistochemistry stainer (Leica Bond III). First the samples were baked on the slides 
for 30 min at 60°C and de-paraffinized with dewax solution for 30 sec followed by 2 washing steps with 
dewax solution at 72°C. Afterwards, the slices were cooled down to RT, rehydrated with 96% EtOH for 
3 times and washed with a washing buffer. The washing step was repeated 3 times and next an antigen 
retrieval step was performed. This step was performed with chondroitinase for 15 min (type 2 collagen: 
0.5 U/ml) or with proteinase K for 10 min (type 10 collagen: 97.1 µg/ml) at 37 °C. Following antigen 
retrieval, the sections were rinsed 3 times using the bond wash solution. The following steps were 
performed by using different detection kits (type 2 collagen: EnVision+ anti-rabbit HRP kit K4011 from 
DAKO; type 10 collagen: Polymer refine detection kit DS9800 from Leica). Endogenous peroxidase 
activity was quenched for type 2 and 10 collagen using a peroxidase block (provided in the kits) for 10 
min at RT, followed by 3 bond wash solution steps. A saturation of binding sites was performed for type 
2 collagen using the antibody dilution buffer for 10 min at RT. Afterwards primary antibodies diluted in 
the antibody diluent were applied to all sections for 30 min at RT, followed by 4 wash steps. To detect 
type 2 collagen, a rabbit anti-Collagen 2 antibody was used at 2 µg/ml. Type 10 collagen was detected 
by using a mouse anti-Collagen 10 antibody diluted 1/20. The secondary antibody was incubated for 20 
min (type 2 collagen: goat anti-rabbit HRP labeled, Kit K4011 from DAKO) or 15 min (type 10 collagen: 
 rabbit anti-mouse HRP labelled, Kit DS9800 from Leica) at RT. Next 3 washing steps were performed 
with the bond washing solution. For the detection of type 10 collagen, the polymer solutions provided 
in the kits were added to the slices to enhance the signal and incubated for 10 min followed by 3 washing 
steps with bond washing solution. An additional washing step with MilliQ-water was performed for both 
collagens. Next the slices were treated with the substrate solutions of the kits. A DAB solution was added 
for 12 min to detect type 2 collagen and for 10 min to detect type 10 collagen. Following 3 washing 
steps were performed with MilliQ-water and a counterstaining with hematoxylin was performed for 30 
sec (type 2 collagen) or 15 sec (type 10 collagen). The slices were digitalized by scanning them using 
the Leica Scanner SCN400 (40x magnification), the recordings were imported and examined with the 
software Leica Slidepath Gateway. Finally, the sections were dehydrated in increasing concentrations of 
EtOH and subsequently in NeoClear with the combined Auto- and Multistainer. At the end of the process 
slides were mounted with Neomount with a Glass Coverslipper. 
 
4.8 Statistics 
 
Statistical analysis was performed with the GraphPad Prism Software 5.0.4.  
Stimulated samples were compared to the control or between each other using a 1-way ANOVA followed 
by a Bonferroni or Dunnett test to correct for multiple comparisons.  
Correlations between the osmolarity and the effect size of the analyzed parameters were performed with 
a Pearson correlation test.  
Regarding the MSC trials the samples were compared to each other using a 2-way ANOVA and a 
Bonferroni´s multiple comparison test. The compound was defined as the column factor and the time as 
the row factor. 
  
5 Results 
 
GDF5 was shown to induce matrix synthesis in chondrocytes, to stimulate chondrogenesis in 
mesenchymal stem cells and to promote cartilage repair in a rat model of osteoarthritis (OA). These 
results indicate that GDF5 might be a promising therapeutic agent for OA. However, GDF5 was also 
demonstrated to increase hypertrophy in mesenchymal stem cells and osteophyte formation in vivo. To 
design an improved GDF5 version, single point mutations were performed in the receptor binding site 
leading to different receptor binding profiles. For the present work three of these mutants (M1673, 
W417F and W417R) were selected, all having a reduced affinity for BMPR1a and a similar affinity for 
BMPR1b in comparison to GDF5. These GDF5 mutants were characterized for their ability to stimulate 
cartilage ECM production in the two only cell types which can produce cartilage: chondrocytes and 
mesenchymal stem cells (MSCs).  
Of the three GDF5 mutants M1673 was previously shown to have the strongest anabolic effect in porcine 
and bovine chondrocytes. In a first instance, the present work aimed at confirming the anabolic effect of 
M1673 in human OA chondrocytes (hOAC). However, to be able to do so the hOAC culture needed to 
be optimized. In another part of this work, the chondrogenic/hypertrophic and osteogenic properties of 
the three GDF5 mutants were evaluated on MSCs and compared to GDF5 and BMP2. From these results, 
it could be determined which of the GDF5 mutants can promote chondrogenesis but simultaneously 
show a low ossification potential. In addition, the respective roles of the BMPR1a and BMPR1b in 
chondrogenesis and osteogenesis could be further elucidated.  
 
5.1 Establishment of an in vitro model to analyze the anabolic effect of 
M1673 in hOAC 
 
To evaluate the anabolic effect of M1673 on hOAC and compare it to GDF5, the monolayer culture was 
first used. Next, the culture conditions were optimized to develop a system that is better mimicking the 
physiology of articular cartilage and enabled a more robust response to M1673. 
 
5.1.1 Effect of M1673 on hOAC in monolayer  
As a first step, the anabolic effect of GDF5 and M1673 was investigated in hOAC monolayer cultures 
over 7 days. Previous experiments showed that with a compound concentration of 300 ng/ml a 
significant effect was achieved and that increasing the concentration did not result in an enhanced effect. 
Consequently, a compound concentration of 300 ng/ml was chosen for the present work. Ten cultures 
were realized with cells isolated from ten different donors. At the end of the cultures three cartilage ECM 
production markers, namely the GAG concentration in medium, type 2 collagen and aggrecan 
expression, were analyzed. In the presence of GDF5 or M1673 only four out of ten monolayer cultures 
  
showed a significant upregulation of at least one of the three tested ECM production markers compared 
to untreated cells. Not a single monolayer experiment showed a significant upregulation of all three 
analyzed ECM production markers with GDF5 or M1673 compared to control cells (Table 6). Overall, 
the effect of GDF5 and M1673 in hOAC monolayer cultures was weak or inexistent.  
 
Table 6 Effect of GDF5 and M1673 on ECM production of hOAC in monolayer cultures over 7 days.
 Cell 
content 
GAG  
content 
Collagen 2 
expression 
Aggrecan 
expression 
Donor 1 
GDF5 1.06 1.03 1.50 1.14 
M1673 0.77 0.97 0.50 0.43 
Donor 2 
GDF5 0.92 1.00 1.80 4.00 
M1673 0.94 0.82 1.00 3.80 
Donor 3 
GDF5 0.92 1.00 1.20 1.50 
M1673 0.87 0.95 0.67 1.75 
Donor 4 
GDF5 0.98 0.96 1.50 1.80 
M1673 0.98 0.92 0.83 1.00 
Donor 5 
GDF5 1.08 0.96 1.30 1.67 
M1673 0.97 0.94 1.70 2.33 
Donor 6 
GDF5 1.05 1.05 1.32 1.00 
M1673 0.92 1.03 1.18 1.20 
Donor 7 
GDF5 0.90 0.92 2.00 2.00 
M1673 0.88 0.83 1.50 1.39 
Donor 8 
GDF5 0.97 1.00 0.74 1.00 
M1673 0.91 1.00 0.63 0.98 
Donor 9 
GDF5 0.98 1.17 2.16 1.08 
M1673 0.97 1.00 1.00 1.04 
Donor 10 
GDF5 1.14 1.07 1.79 1.17 
M1673 1.00 1.21 0.79 1.25 
 
  
It was first hypothesized that GDF5 and M1673 might need a longer time to exert their effects. 
Consequently, a 28-day long monolayer culture was realized. Two independent experiments were 
performed with cells from two different donors. On a weekly basis, medium samples were analyzed for 
the GAG concentration. The first experiment showed an enhanced GAG concentration in medium after 
GDF5 treatment, but not after M1673 treatment for all analyzed time points from 7 up to 28 days 
compared to untreated cells (Figure 12 A). Similarly, the second experiment showed an enhanced GAG 
concentration in medium after GDF5 treatment for all analyzed time points from 7 up to 28 days 
compared to untreated cells. However, M1673 treatment enhanced the GAG concentration in medium 
after 7 and 21 days, but not after 14 and 28 days compared to untreated cells (Figure 12 B). These 
results show that there is no advantage for a long-term monolayer culture. Indeed, when there was an 
effect of the compounds it was already visible after 7 days of culture.  
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Figure 12   Effect of GDF5 and M1673 on GAG concentration in hOAC monolayer cultures over 28 days. 
±
 
Overall, in hOAC cultured in monolayer GDF5 and M1673 showed only an inconsistent and weak 
anabolic effect.  
 
5.1.2 Optimization of hOAC culture conditions 
As a first instance to optimize the hOAC culture conditions, two different 3D culture systems were tested. 
Generally, 3D culture systems better mimic the physiological environment of chondrocytes and are 
known to better preserve their phenotype in comparison to monolayer cultures. The hOAC were either 
seeded into low attachment plates without scaffold and pre-cultured for one week to allow the cells to 
aggregate and form cartilage tissue analogs (CTAs) or encapsulated in alginate beads. For both 3D 
cultures, the hOAC were treated with 300 ng/ml GDF5 or M1673 or remained untreated. At the end of 
the culture the GAG concentration was analyzed within the CTAs or the alginate beads and compared to 
  
untreated cells. No significant effect of GDF5 or M1673 on GAG concentration in neither CTAs nor 
alginate beads was detectable compared to untreated cells (Figure 13). These results were confirmed 
with two more CTA and alginate experiments respectively (data not shown).  
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Figure 13 Effect of GDF5 and M1673 on GAG concentration in hOAC cultured as CTAs or encapsulated in alginate beads. 
±
 
In summary, hOAC in monolayer as well as in 3D cultures (CTAs or alginate beads) showed only a weak, 
non-reproducible effect on ECM production after GDF5 or M1673 treatment.  
These results are not in accordance with previous results showing a strong anabolic effect of M1673 in 
porcine and bovine chondrocytes cultured in 3D as CTAs. It was then hypothesized that the difference 
between the response observed with animal and human chondrocytes resides in the disease status of the 
cells. Animal chondrocytes were isolated from healthy cartilage while the human chondrocytes were 
extracted from late-stage OA cartilage. Indeed, in contrast to healthy chondrocytes, the environment of 
late-stage OA chondrocytes is profoundly altered. The joint is usually inflamed, the cartilage is degraded 
and shows altered physicochemical properties: for instance, it has a decreased osmolarity and increased 
oxygen tension in comparison to healthy cartilage. These parameters - among others - lead to an aberrant 
behavior of the cells and possibly unresponsiveness to anabolic factors that persists in culture after cell 
isolation. In the following experiments, the end-stage disease hOAC were cultured at conditions imitating 
a ‘healthier’ cartilage environment to possibly improve their responsiveness to GDF5 and M1673. The 
conditions chosen to mimic a ‘healthier’ cartilage environment were the cultivation of hOAC at low 
oxygen (1% instead of the usual 21%) and higher osmolarity (380 mOsm instead of 340 mOsm, the 
usual osmolarity of DMEM medium). In a first attempt, the culture of hOAC was performed in monolayer 
over 7 days with a hypoxic (1%) or normoxic (21%) oxygen tension combined with a medium osmolarity 
of 340 mOsm (osmolarity of the medium was unchanged) or 380 mOsm. 340 mOsm rather corresponds 
to conditions within OA cartilage and 380 mOsm to the osmolarity within healthy cartilage. The 
monolayer culture of hOAC at 1% or 21% oxygen combined with the standard medium osmolarity of 
340 mOsm showed nearly the same GAG concentrations in medium. Consequently, a low oxygen tension 
  
of 1% had no beneficial effect over a standard cultivation at 21% oxygen on the GAG concentration in 
hOAC at 340 mOsm. Moreover, it was shown that at 380 mOsm using 21% instead of 1% oxygen was 
beneficial regarding the GAG concentration (Figure 14). Additionally, it was observed that the 
monolayer culture of hOAC at 380 mOsm significantly enhanced the GAG concentration in medium at 
both oxygen tensions of 1% and 21% compared to the respective oxygen tensions at 340 mOsm (Figure 
14).  
To summarize, reducing the oxygen tension had no or even a negative influence while a moderate 
osmolarity increase had a positive influence on the GAG concentration of hOAC cultured in monolayer 
over 7 days. 
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Figure 14   Effect of oxygen and osmolarity on GAG concentration in hOAC cultured in monolayer over 7 days
±
 
The negative effect of a reduced oxygen tension on the GAG concentration in hOAC was confirmed in a 
CTA culture system over 28 days (Figure 15). The GAG concentration in medium was significantly higher 
after 7, 14, 21 and 28 days at 21% oxygen compared to 1% oxygen (Figure 15 A). Similarly, the GAG 
concentration in CTAs was significantly increased after cultivation at 21% oxygen compared to 1% 
oxygen for 28 days (Figure 15 B). Additionally, the cell concentration per CTA was significantly higher 
after cultivation at 21% compared to 1% oxygen for 28 days (Figure 15 C). Thus, a low oxygen tension 
of 1% is accompanied with an increased cell loss and lesser ECM accumulation in the CTAs compared to 
21% oxygen. These results were confirmed in one additional CTA experiment (data not shown). Taken 
together, these results indicate that the exposure of hOAC to an oxygen tension of 1% is not beneficial. 
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Figure 15   Effect of oxygen in hOAC cultured as CTAs over 28 days
±
 
In contrast increasing the medium osmolarity to 380 mOsm already showed an increased GAG 
concentration in medium after culturing hOAC over 7 days in monolayer compared to the standard 
medium osmolarity of 340 mOsm (Figure 14). As a consequence, the effect of 380 mOsm osmolarity was 
next tested in hOAC cultured as CTAs or in alginate in the presence of 300 ng/ml GDF5 or M1673 over 
28 days. Neither the GAG accumulation in medium over 28 days, nor the GAG concentration within the 
CTAs at day 28 were increased after GDF5 or M1673 treatment at 380 mOsm compared to untreated 
cells at the same osmolarity (Figure 16 A+B). In contrast, hOAC encapsulated in alginate beads showed 
a significant increase of GAG accumulation in medium over 14 days in the presence of GDF5 and M1673 
at 380 mOsm compared to untreated cells at the same osmolarity. Similarly, the GAG concentration 
within the alginate beads at day 14 was significantly enhanced after GDF5 and M1673 treatment 
compared to untreated cells at 380 mOsm (Figure 16 C+D).  
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Figure 16 Effect of GDF5 and M1673 on GAG accumulation in hOAC cultured as CTAs or in alginate beads at 380 mOsm
±
 
Based on these results it can be concluded that an increased medium osmolarity of 380 mOsm together 
with the 3D culture in alginate results in an improved responsiveness of hOAC to GDF5 and M1673. 
Therefore, this culture system seems to be more appropriate to investigate the effect of M1673 in hOAC.  
Besides the role of osmolarity and oxygen on the response of hOAC to GDF5 and M1673, the effect of 
heparin was also analyzed. BMPs like GDF5 and M1673 contain a heparin/heparan sulfate binding site, 
which is believed to potentiate the BMP effect upon binding of heparin/heparan sulfate. Healthy 
chondrocytes produce an abundant ECM containing inter alia heparan sulfates. However, hOAC have a 
reduced capacity to produce ECM molecules and the lack of heparan sulfate could also explain their low 
responsiveness to GDF5 or M1673. Therefore, the effect of heparin on the GDF5 and M1673 response 
was analyzed in the alginate system with hOAC over 14 days. In presence of GDF5 combined with 
heparin the GAG concentration was unchanged, whereas in presence of M1673 combined with heparin 
a small, not significant reduction of the GAG concentration was observed within the alginate beads at 
day 14 compared to the treatment with solely GDF5 or M1673 respectively (Figure 17). These results 
were confirmed in two additional experiments (data not shown). Overall, the addition of heparin did 
not increase the effect of neither GDF5 nor M1673 in hOAC cultured in alginate beads over 14 days.  
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Figure 17  Heparin effect on the GDF5 and M1673 response in hOAC cultured in alginate beads over 14 days
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Taken together these results show that hOAC are responsive to GDF5 and M1373 in alginate culture at 
380 mOsm. Therefore, these culture conditions were selected to further investigate the effects of these 
two compounds on hOAC. However, before doing so, it was aimed at better characterizing the effect of 
osmolarity on hOAC and better understand the physiological relevance of this parameter.  
 
5.1.3 Characterization of the osmolarity effect on hOAC 
To evaluate the effect of osmolarity on hOAC, several monolayer and alginate cultures were realized 
with a triple objective: 1. Better understand the effect of osmolarity on hOAC phenotype and 
inflammatory status and 2. Evaluate if higher osmolarities than 380 mOsm could bring an additional 
benefit and 3. Understand how osmolarity influence the responsiveness of hOAC to M1673 and GDF5. 
 
5.1.3.1 Effect of osmolarity adjusted with NaCl on hOAC in monolayer cultures 
To investigate the effect of an increased medium osmolarity on hOAC, cells were used directly after cell 
isolation to preserve as much as possible their OA characteristics which tends to get lost in culture. These 
cells were cultured over 6 days at the standard medium osmolarity of 340 mOsm what rather 
corresponds to the osmolarity within OA cartilage and at increased medium osmolarities of 380, 420 
and 460 mOsm what covers the range of osmolarities that have been reported for healthy cartilage. At 
the end of the culture the cell concentration and viability, ECM synthesis, cytokines and proteases 
production as well as BMPR expression were evaluated. In addition, freshly isolated chondrocytes (FIC) 
were sampled before starting the culture and analyzed for determining initial gene expression. For all 
parameters, the correlation between the osmolarity and the effect size was evaluated with a Pearson 
correlation test. In addition, the single osmolarities 380, 420 and 480 mOsm were compared to 340 
mOsm for statistical difference.  
  
The cell concentration increased at all medium osmolarities over 6 days of culture compared to the 
seeding concentration. However, the increase in cell concentration became lower with increasing 
osmolarities from 340 to 460 mOsm indicating a reduced cell proliferation at increased osmolarities. 
This effect reached statistical significance (Figure 18 A). In contrast, the viability of the cells remained 
unchanged and stayed between 90 and 95% at all osmolarities (Figure 18 B). The GAG production 
(µg/million cells) was increased and significantly correlated to increasing osmolarities. Furthermore, the 
GAG production at 380, 420 or 460 mOsm was also significantly higher than at 340 mOsm (Figure 18 
C). 
Regarding gene expression, the expression of type 2 collagen and aggrecan was increased from 340 to 
460 mOsm and significantly correlated to increasing osmolarities. However, when looking at single 
osmolarities, a significant difference to 340 mOsm was only achieved at 460 mOsm (Figure 18 E+F). 
On the contrary, type 1 collagen expression negatively correlated with increasing osmolarities (Figure 
18 D). 
For the gene expression, the expression was also analyzed in cells sampled just after isolation (FIC, 
freshly isolated chondrocytes) and before starting the cell culture to evaluate how the phenotype evolves 
during the culture. An enhanced type 1 collagen and a decreased type 2 collagen expression was 
detectable after culturing hOAC for 6 days at 340 mOsm compared to the FIC (Figure 18 D+E). That 
indicates a dedifferentiation and therefore a phenotype loss of hOAC in monolayer cultures. Increasing 
the medium osmolarity from 380 to 460 mOsm prevented this phenomenon and resulted in type 1 and 
2 collagen expressions approaching the values obtained with the FIC (Figure 18 D+E). That indicates a 
better phenotype maintenance of hOAC at increased medium osmolarities. These results were confirmed 
in four additional experiments (see supplementary, S2).  
Overall, the medium osmolarity seems to play an important role for the cultivation of hOAC. Increasing 
the medium osmolarity in monolayer cultures improved the phenotype of hOAC and enhanced the ECM 
production but also resulted in a decreased proliferation of the cells. 
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Figure 18  ECM production and phenotype analysis of hOAC in monolayer culture at different osmolarities adjusted with 
NaCl.
<0.01) ±
 
To further characterize the osmolarity effect on hOAC, the production of ECM-degrading enzymes and 
inflammatory cytokines was analyzed in the same culture. The expression of the two major proteolytic 
enzymes, MMP13 and ADAMTS5, which are responsible for degradation of the two main cartilage ECM 
components, type 2 collagen and aggrecan, was significantly decreased after 6 days of monolayer culture 
at 340 mOsm in comparison to FIC. The expression of MMP13 was further significantly decreased at 
380, 420 and 460 mOsm in comparison to 340 mOsm, whereas the ADAMTS5 expression was nearly the 
same at all osmolarities after 6 days of culture (Figure 19 A+B). Additionally, the production of MMP1, 
MMP3 and MMP9 (pg/million cells) were evaluated. A negative correlation between MMP1 production 
and osmolarity could be found. Although the MMP1 production decreased with increasing the medium 
osmolarity, it was only significant different at 460 mOsm compared to 340 mOsm (Figure 19 C). A 
negative correlation between MMP3 and osmolarity was also observed. Furthermore, the MMP3 
production at 380, 420 or 460 mOsm was significantly reduced compared to that at 340 mOsm (Figure 
19 D). On the contrary, a correlation between the MMP9 production and osmolarity was not observed. 
However, the MMP9 concentration was significantly decreased at 380 mOsm compared to 340 mOsm, 
but was not further reduced at higher osmolarities (Figure 19 E). Moreover, the production of the 
  
inflammatory cytokines TNFȽ, Il1Ⱦ and Il6 was measured. A negative correlation was only found 
between TNFα and osmolarity. However, when looking at single osmolarities, the production of all tested 
cytokines was significantly decreased with increasing medium osmolarities from 380 to 460 mOsm 
compared to 340 mOsm (Figure 19 F+G+H). The results of protease expression and cytokine production 
were confirmed in four additional experiments (see supplementary, S3). 
Overall these results show that using osmolarities corresponding to healthy cartilage tends to decrease 
the OA phenotype of the hOAC: they produce less cytokines and less proteases. This effect was already 
significant at 380 mOsm.  
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Figure 19 Proteases and cytokines production of hOAC in monolayer culture at different osmolarities adjusted with NaCl.
α β
  
Finally, to understand why hOAC are unresponsive to M1673 and GDF5 at 340 mOsm but become 
responsive at 380 mOsm, the influence of the osmolarity on BMPR expression was investigated. The 
BMPR expression of hOAC was analyzed in freshly isolated chondrocytes (FIC) or after 6 days of 
monolayer culture at different osmolarities of 340, 380, 420 and 460 mOsm. The expression of BMPR1a, 
BMPR1b and BMPR2 was significantly decreased after 6 days of culture at 340 mOsm compared to the 
initial BMPR expression profile in FIC (Figure 20) but were increased with increasing osmolarities. A 
positive correlation was only observed between BMPR1a and BMPR1b expression and osmolarity (Figure 
20 A+B). Although, the BMPR2 expression seems to increase with increasing osmolarities, it showed 
neither a correlation to the osmolarity nor a significant difference by comparing the single osmolarities 
(Figure 20 C). These results were confirmed in four additional experiments for BMPR1a and BMPR2 and 
in three additional experiments for BMPR1b (see supplementary, S4). 
Thus, culturing hOAC at higher osmolarities than 340 mOsm seems to enhance the expression of 
BMPR1a and BMPR1b, which are necessary for signal transmission of M1673.  
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Figure 20  BMPR expression of hOAC in monolayer culture at different osmolarities adjusted with NaCl.
 
In summary, increasing the medium osmolarity positively influenced hOAC in monolayer cultures. The 
cartilage ECM production was enhanced and the chondrocytes phenotype was improved at 380, 420 and 
460 mOsm compared to 340 mOsm. Moreover, the production of inflammatory cytokines and proteases 
(OA phenotype) was reduced with increasing osmolarities. The OA phenotype was already significantly 
attenuated at 380 compared to 340 mOsm. In addition, the BMPR expression tended to increase at 380, 
420 and 460 mOsm in comparison to 340 mOsm. 
 
 
  
5.1.3.2 Effect of osmolarity adjusted with sucrose on hOAC in monolayer cultures 
To confirm that the observed results are ‘real’ osmolarity effects and not a NaCl effect, the experiment 
was repeated by using sucrose to increase the medium osmolarity. After 6 days of hOAC monolayer 
culture at 340, 380, 420 and 460 mOsm, cell concentration and viability, ECM synthesis, cytokines and 
proteases production as well as BMPR expression were evaluated. In addition, freshly isolated 
chondrocytes (FIC) were sampled before starting the culture and analyzed for determining initial gene 
expression levels. For all parameters, the correlation between the osmolarity and the effect size was 
evaluated with a Pearson correlation test. In addition, the single osmolarities 380, 420 and 460 mOsm 
were compared to 340 mOsm for statistical difference. 
As seen before, the cell concentration increased at all medium osmolarities over 6 days of cultivation 
compared to the seeding concentration. The cell concentration was significantly reduced at 460 mOsm 
compared to 340 mOsm, but a statistically significant negative correlation between the cell concentration 
and an increased osmolarity was not observed (Figure 21 A). Similarly to the NaCl experiment, the 
viability of the cells remained nearly unchanged and stayed around 80% at the different medium 
osmolarities (Figure 21 B). As seen before with NaCl, the GAG production (µg/million cells) was 
increased and significantly correlated to increasing osmolarities. Furthermore, the GAG production at 
380, 420 and 460 mOsm was also significantly enhanced in comparison to 340 mOsm (Figure 21 C).  
Gene expression analysis was also in accordance to the data obtained with NaCl. The type 2 collagen 
and aggrecan expressions were both positively correlated to increasing osmolarities. However, when 
looking at the single osmolarities, a significant difference between 380, 420 and 460 mOsm compared 
to 340 mOsm was only achieved for the expression of aggrecan, but not for the expression of type 2 
collagen (Figure 21 E+F). In contrast, type 1 collagen expression negatively correlated to increasing 
osmolarities. In addition, the type 1 collagen expression was significantly reduced at 380, 420 and 460 
mOsm compared to 340 mOsm (Figure 21 D).  
For the gene expression, freshly isolated chondrocytes (FIC) were also sampled before starting the cell 
culture to evaluate the chondrocytes phenotype development during cell culture. The type 1 collagen 
expression was enhanced while the type 2 collagen expression was reduced after culturing hOAC for 6 
days at 340 mOsm compared to FIC (Figure 21 D+E). That confirmed the dedifferentiation and 
phenotype loss of hOAC during monolayer cultures observed previously in the NaCl experiment. 
Increasing the medium osmolarity from 380 to 460 mOsm also prevented this phenomenon and resulted 
in type 1 and 2 collagen expressions approaching the values obtained with the FIC (Figure 21 D+E). 
These results were confirmed in one additional experiment (data not shown). 
Overall, increasing the medium osmolarity with sucrose instead of NaCl resulted in comparable 
observations on the hOAC phenotype. Increasing the medium osmolarity enhanced the ECM synthesis, 
improved the hOAC phenotype and led in trend to lower proliferation of the cells. 
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Figure 21  ECM production and phenotype analysis of hOAC in monolayer culture at different osmolarities adjusted with 
sucrose.
. 
 
The influences of increasing the medium osmolarity with sucrose was further evaluated by analyzing the 
production of proteolytic enzymes and inflammatory cytokines in the same culture.  
As seen before with NaCl, the expression of MMP13 decreased significantly after 6 days of monolayer 
culture at 340 mOsm in comparison to FIC. Furthermore, a negative correlation between the MMP13 
expression and increasing osmolarities was found (Figure 22 A). In contrast, the expression of ADAMTS5 
was not correlated with increasing osmolarities while its expression was significantly reduced after 6 
days of culture at 380 or 420 mOsm compared to 340 mOsm (Figure 22 B). Additionally, the production 
of MMP1, MMP3 and MMP9 (pg/million cells) was analyzed. In contrast to the NaCl experiment, a 
negative correlation was only observed for the MMP3 production, but not for the MMP1 production, and 
increasing osmolarities (Figure 22 C+D). Although, the MMP3 production decreased with increasing 
osmolarities, it was only significantly reduced at 460 mOsm compared to 340 mOsm (Figure 22 D). The 
MMP1 and MMP9 production was nearly the same at all osmolarities (Figure 22 C+E). Moreover, the 
production of the inflammatory cytokines TNFȽ, Il1Ⱦ and Il6 was evaluated. A negative correlation was 
not only found for TNFȽ, but also for Il1Ⱦ and increasing osmolarities. However, when looking at single 
osmolarities, the production of all analyzed inflammatory cytokines was significantly decreased with 
  
increasing medium osmolarities from 380 to 460 mOsm compared to 340 mOsm as seen before with 
NaCl (Figure 22 F+G+H). By comparing the NaCl and the sucrose monolayer cultures with each other, 
some differences can be noticed. Contrary to the NaCl experiment, the MMP13 concentration in the 
sucrose experiment showed a negative correlation, but did only decrease in trend, but not statistically 
significant from 380 to 460 mOsm compared to 340 mOsm (Figure 19+22 A). The other way around, a 
significantly decreased ADAMTS5 expression was detectable at 380 and 420 mOsm compared to 340 
mOsm in the sucrose experiment, whereas the ADAMTS5 expression of the NaCl experiment was 
comparable at all osmolarities (Figure 19+22 B). Furthermore, the decrease of MMP concentrations in 
medium was more pronounced in the NaCl compared to the sucrose experiment (Figure 19+22 C,D,E). 
These results were confirmed in one additional experiment (data not shown). 
Overall, using NaCl or sucrose to increase the medium osmolarity resulted nearly in the same effects on 
the production of proteolytic enzymes and inflammatory cytokines; observed differences were small. 
Increasing the medium osmolarity to match the osmolarity of healthy articular cartilage led to a reduced 
production of proteases and cytokines and consequently decreased the OA phenotype of the cells. This 
effect was already significant at 380 mOsm. 
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Figure 22  Proteases and cytokines production of hOAC in monolayer culture at different osmolarities adjusted with 
sucrose.
α β
Lastly, the expression profile of the different BMPRs, BMPR1a, BMPR1b and BMPR2, was measured in 
hOAC cultured for 6 days in monolayer at the different osmolarities of 340, 380, 420 and 460 mOsm 
adjusted with sucrose. The expression of BMPR1a and BMPR1b was significantly decreased after 6 days 
of culture compared to that of FIC (Figure 23 A+B), whereas the BMPR2 expression was not altered 
(Figure 23 C). A positive correlation between the expression of BMPR1a and increasing osmolarities was 
observed. Similarly, a significant difference of BMPR1a expression with increasing medium osmolarities 
from 380 to 460 mOsm compared to 340 mOsm was detectable (Figure 23 A). Although, the BMPR1b 
expression was not correlated with increasing osmolarities, it was significant different at 380 and 460 
mOsm in comparison to 340 mOsm (Figure 23 B). The expression of BMPR2 positively correlated with 
  
increasing osmolarities, but was only significant different at 420 and 460 mOsm compared to 340 mOsm 
(Figure 23 C). These results were confirmed in one additional experiment (data not shown). 
As seen before with NaCl, increasing the medium osmolarity from 380 to 460 mOsm increased the 
expression of BMPRs. This effect was even more pronounced when the osmolarity was adjusted with 
sucrose instead of NaCl (Figure 20+23). 
 
re
la
tiv
e 
m
RN
A 
co
n
te
n
t
FIC
34
0 m
Os
m
38
0 m
Os
m
42
0 m
Os
m
46
0 m
Os
m
0.0000
0.0005
0.0010
0.0015
0.0020
0.0025
BMPR1a expression
**
***
osmolarity effect: **
*
*
re
la
tiv
e 
m
RN
A 
co
n
te
n
t
FIC
34
0 m
Os
m
38
0 m
Os
m
42
0 m
Os
m
46
0 m
Os
m
0.00000
0.00005
0.00010
0.00015
0.00020
BMPR1b expression
* **
***
osmolarity effect: ns
re
la
tiv
e 
m
RN
A 
co
n
te
n
t
FIC
34
0 m
Os
m
38
0 m
Os
m
42
0 m
Os
m
46
0 m
Os
m
0.000
0.002
0.004
0.006
0.008
0.010
BMPR2 expression
**
osmolarity effect: **
*
A B C
 
Figure 23 BMPR expression of hOAC in monolayer culture at different osmolarities adjusted with sucrose.
 
From these results, it can be concluded that the observed effects can be really attributed to osmolarity 
changes and not to an effect of NaCl or sucrose itself. Consequently, for further experiments it was 
decided to use NaCl to increase the medium osmolarity. 
In summary, the monolayer experiments with hOAC at different osmolarities indicate that increasing the 
medium osmolarity has a positive impact on hOAC in monolayer cultures. The ECM production was 
enhanced and the chondrocytes phenotype was improved at 380, 420 and 460 mOsm in comparison to 
340 mOsm. Furthermore, the production of proteolytic enzymes and inflammatory cytokines was 
significantly reduced – already at 380 compared to 340 mOsm - indicating a decreased OA phenotype of 
the cells at increased medium osmolarities. The expression of BMPRs increased with increasing 
osmolarities from 340 to 460 mOsm. It was, however, unclear if the osmolarity has a direct effect on the 
BMPR expression or if this effect is indirectly driven by other factors as for instance the inflammatory 
status of the chondrocytes. 
 
5.1.3.3 Influence of inflammatory cytokines on BMP receptor expression 
To analyze the impact of an inflammatory environment on BMPR expressions, the effect of various 
cytokines known to be produced by hOAC was evaluated on the expression of BMPR1a, BMPR1b and 
BMPR2. The hOAC were cultured in monolayer, treated with 10 ng/ml TNFȽ and Il1Ⱦ or 100 ng/ml Il6 
  
over two days and analyzed for the BMPR expression. The presence of TNFȽ and Il6 resulted in a 
significant downregulation of BMPR1a and BMPR1b compared to unstimulated cells. In addition, the 
presence of Il6 also reduced significantly the BMPR2 expression compared to unstimulated cells. On the 
contrary, the addition of Il1Ⱦ enhanced significantly the expressions of BMPR1a, BMPR1b and BMPR2 
compared to unstimulated cells (Figure 24) These results are representative of three experiments (see 
supplementary, S5). 
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Figure 24  Expression of BMP receptors in hOAC cultured in monolayer after stimulation with TNFȽ, Il1Ⱦ or Il6.Ƚ Ⱦ
 
From these results, it can be hypothesized that the enhanced BMPR expression of hOAC cultured at 
higher osmolarities indirectly could be driven by the reduced inflammatory status of hOAC. Here a clear 
link was established between the presence of specific cytokines and BMPR expression. However, it cannot 
be excluded that osmolarity could also influence directly BMPR expression, or that other indirect effects 
are at play. 
 
5.1.3.4 Effect of osmolarity on hOAC in 3D culture 
As a next step, the osmolarity effect observed in monolayer cultures was evaluated in the alginate system, 
which was found to be a favorable 3D culture system to investigate the anabolic effects of M1673 
(Chapter 5.1). The hOAC were encapsulated in alginate and cultured over 14 days at the usual medium 
osmolarity of 340 mOsm or at higher medium osmolarities of 380, 420 and 460 mOsm which were 
adjusted with NaCl. At the end of the culture cell concentration and viability, ECM synthesis, cytokines 
and protease production as well as BMPR expression were evaluated. In addition, freshly isolated 
chondrocytes (FIC) were sampled before starting the culture to analyze the initial gene expression levels. 
For all parameters, the correlation between the osmolarity and the effect size was evaluated with a 
Pearson correlation test. In addition, the difference between the single osmolarities 380, 420 and 460 
mOsm were compared to 340 mOsm for statistical analysis. 
As seen before in the monolayer system, the cell concentration negatively correlated with increasing 
osmolarities from 340 to 460 mOsm indicating a reduced cell proliferation at higher osmolarities. The 
  
cell concentration was significantly reduced with 420 and 460 mOsm, but not with 380 mOsm, compared 
to 340 mOsm (Figure 25 A). On the contrary, the cell viability remained unchanged and stayed between 
90 and 95% at all osmolarities (Figure 25 B). The GAG production (µg/million cells) in alginate beads 
did not correlate to increasing osmolarities. However, when looking at the single osmolarities, the GAG 
production at 380, 420 and 460 mOsm was significantly higher in comparison to 340 mOsm (Figure 25 
C).  
Regarding gene expression, the expression of type 2 collagen and aggrecan was increased from 340 to 
460 mOsm and significantly correlated to increasing osmolarities (Figure 25 E+F). Similarly, the type 2 
collagen expression increased at 380, 420 and 460 mOsm compared to 340 mOsm osmolarities, whereas 
the expression of aggrecan was only significantly enhanced at 420 and 460 mOsm in comparison to 340 
mOsm (Figure 25 E+F). Although, no statistically significant negative correlation between type 1 
collagen expression and increasing osmolarities was detectable, it was significantly reduced at 380, 420 
and 460 mOsm compared to 340 mOsm (Figure 25 D). 
In addition, freshly isolated chondrocytes (FIC) were sampled before starting the cell culture and 
analyzed for gene expression to evaluate the chondrocytes phenotype change during cell culture. In 
contrast to the monolayer experiments, the type 2 collagen expression increased significantly while type 
1 collagen expression decreased significantly after 14 days of alginate culture at 340 mOsm in 
comparison to FIC. That indicates a preserved chondrocytes phenotype in 3D culture (Figure 25 D+E).  
Overall, the positive impact of increasing osmolarities on hOAC was confirmed in the 3D culture system 
using alginate beads. Increasing the medium osmolarity further improved the hOAC phenotype, 
enhanced the ECM production but also resulted in a reduced proliferation of the cells.  
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Figure 25  ECM production and phenotype analysis of hOAC in alginate beads at different medium osmolarities.
±
 
As done in the previous section, the osmolarity effect was further characterized on hOAC in alginate 
culture by analyzing the expression of proteolytic enzymes and the production of inflammatory cytokines 
in the same culture. The expressions of MMP13 and ADAMTS5, two key proteolytic enzymes able to 
degrade collagens and aggrecans, were significantly decreased after 14 days of alginate culture at 340 
mOsm in comparison to FIC (Figure 26 A+B). The expression of MMP13 was further significantly 
decreased at 380, 420 and 460 mOsm in comparison to 340 mOsm. In contrast, the ADAMTS5 expression 
was only significantly decreased at 460 mOsm compared to 340 mOsm (Figure 26 A+B). Regarding 
cytokine production, the production of TNFα, Il1Ⱦ and Il6 was decreased with increasing osmolarities, 
but a significant negative correlation between the effect size and osmolarity was only found for TNFα 
and Il1Ⱦ. However, when looking at the single osmolarities, the production of all of them was 
significantly decreased with increasing medium osmolarities from 380 to 460 mOsm compared to 340 
mOsm (Figure 26 C+D+E). 
Overall, it was confirmed that increasing the medium osmolarity in alginate culture reduced the OA 
phenotype of the cells by decreasing cytokines production and the expression of proteolytic enzymes. 
This effect of higher osmolarities was already significant at 380 mOsm.  
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Figure 26  Proteases and cytokines production of hOAC in alginate beads at different osmolarities.
α β
±
 
Finally, the influence of osmolarity on BMPR expression in alginate culture was evaluated. The BMPR 
expression was analyzed in freshly isolated chondrocytes (FIC) as well as after 14 days of alginate culture 
at the different osmolarities of 340, 380, 420 and 460 mOsm. The expression of BMPR1a and BMPR2 
was significantly increased, whereas the BMPR1b expression was significantly decreased after 14 days 
of culture at 340 mOsm compared to FIC (Figure 27). A positive correlation was detectable between 
BMPR1a and BMPR2 expression and increasing osmolarities. In addition, a significant difference to 340 
mOsm was achieved at 420 and 460 mOsm (Figure 27 A+C). In contrast, the expression of BMPR1b 
could not be correlated to increasing osmolarities, but was significantly enhanced at 460 mOsm 
compared to 340 mOsm (Figure 27 B). 
Overall, it was confirmed in alginate culture that increasing the medium osmolarity enhances the 
expression of BMPRs. 
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Figure 27 BMPR expression of hOAC in alginate beads at different osmolarities.
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Taken together, increasing the osmolarity positively influenced hOAC in monolayer and in alginate 
cultures. The ECM production was enhanced and the phenotype of chondrocytes improved at 380, 420 
and 460 mOsm in comparison to 340 mOsm in both cultures. In addition, increasing the medium 
osmolarity reduced the OA phenotype by decreasing inflammatory cytokines and proteolytic enzymes. 
This effect was already significant at 380 mOsm. Moreover, the expression of BMPRs were enhanced by 
increasing the medium osmolarity in both culture systems. 
 
5.1.3.5 Conclusion: Effect of osmolarity on hOAC 
To summarize, increasing the osmolarity of the culture medium towards the osmolarity of healthy 
articular cartilage favors the chondrocytes phenotype and ECM production as well as reduced the 
inflammatory status of the cells. In addition, it also resulted in an increased BMPR expression what could 
possibly restore the responsiveness of the hOAC to M1673 (Figure 28).  
 
Figure 28  A new paradigm for culturing hOAC and analyzing effects of anabolic factors in hOAC.
 
This hypothesis was investigated in the next section. 
  
5.1.3.6 Responsiveness of hOAC to M1673 at 380 mOsm 
From the previous results it was hypothesized that a reduction of cytokine production, which already 
occurred at 380 mOsm can decrease the cellular stress, enhance the BMPR expression and enable hOAC 
to respond to M1673. This hypothesis was first tested with only one ECM production marker; the GAG 
production. Therefore, seven different hOAC donors were investigated for their responsiveness to GDF5 
and M1673 by analyzing the GAG production in alginate beads after 14 days at 380 mOsm compared to 
340 mOsm (Figure 29). GDF5 and M1673 showed no significant effect on GAG accumulation at 340 
mOsm (Figure 29 A). In contrast, GDF5 and M1673 enhanced significantly the GAG concentration within 
the alginate beads in these hOAC when culturing them at 380 mOsm (Figure 29 B). Thus, a medium 
osmolarity of 380 mOsm enabled to obtain a more robust and an enhanced effect of GDF5 and M1673 
on GAG accumulation of hOAC cultured in alginate beads. 
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Figure 29  Effect of GDF5 and M1673 on GAG accumulation in hOAC from seven donors at 380 mOsm compared to 340 
mOsm.
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To characterize the effect of M1673 on hOAC, it was chosen to culture the cells at 380 mOsm.  
Indeed, the target cells of a DMOAD like M1673 are OA chondrocytes located in middle-stage OA 
cartilage. However, the chondrocytes used in the present work were isolated mostly from end-stage 
cartilage. These end-stage chondrocytes cultured at 380 mOsm instead of 340 mOsm showed reduced 
OA characteristics corresponding possibly to a shift from end-stage chondrocytes toward middle-stage 
chondrocytes. On the other hand, using higher osmolarities exacerbate this shift and leads possibly to 
almost healthy chondrocytes exhibiting low protease and cytokine production. Consequently, it was 
estimated that 380 mOsm would be the condition enabling to obtain chondrocytes that are the closest 
to the target cells in comparison to the other tested osmolarities.  
 
 
  
5.2 Effect of M1673 on hOAC 
 
Previously, the anabolic effect of the GDF5 mutants M1673, W417F and W417R had been investigated 
in healthy porcine and bovine chondrocytes. The highest cartilage ECM production was observable after 
addition of 300 ng/ml M1673, whereas the addition of 300 ng/ml W417F and W417R only led to a 
weak effect on cartilage production (see supplementary, S6+7). Therefore, only the effect of M1673 
was evaluated in hOAC. It was also compared to GDF5. The anabolic effect of 300 ng/ml GDF5 and 
M1673 on hOAC was analyzed in alginate culture at 380 mOsm as previously defined (Chapter 5.1). 
After 14 days of culture the proteoglycan synthesis (GAG production and aggrecan expression) and 
collagen synthesis (hydroxyproline and pro-peptid of collagen 2 content as well as type 2 collagen 
expression) were evaluated respectively as the two main protein components of the cartilage ECM.  
Both, GDF5 and M1673, exerted a strong increase on proteoglycan synthesis in hOAC. On the one hand, 
the GAG accumulation in alginate beads was enhanced significantly after treatment with GDF5 or M1673 
compared to untreated cells. GDF5 treatment led to a 3.8-fold increase, whereas M1673 led to a 2.0-fold 
increase in GAG concentration over untreated cells (Figure 30 A). On the other hand, the aggrecan 
expression in alginate beads was significantly increased after treatment with GDF5 by 4.4-fold or M1673 
by 2.7-fold over untreated cells (Figure 30 B). The GAG results were confirmed with fourteen other 
hOAC donors and the results of aggrecan expression with six other hOAC donors (see supplementary, 
S8).  
Moreover, GDF5 and M1673 exerted a strong beneficial effect on collagen synthesis in hOAC. First, the 
hydroxyproline (HPro) accumulation in alginate beads was significantly increased after GDF5 and 
M1673 treatment compared to untreated cells, although the fold-increase over control cells was only 
about 1.2 for both compounds (Figure 30 C). Second, the accumulation of the pro-peptide of collagen 2 
(ProC2) was enhanced significantly after treatment with GDF5 or M1673 compared to untreated cells. 
Similarly, to HPro, the fold-increase over control was only about 1.1 to 1.2 (Figure 30 D). The same 
trend was confirmed for HPro and ProC2 production with two additional hOAC donors (see 
supplementary, S9). Third, the type 2 collagen expression in alginate beads increased significantly with 
GDF5 or M1673 compared to untreated cells. The increase of type 2 collagen expression after GDF5 and 
M1673 treatment was the strongest of all analyzed cartilage production markers. GDF5 treatment led to 
a 9.8-fold increase and M1673 treatment to a 4.7-fold increase of type 2 collagen expression over 
untreated cells (Figure 30 E). Similar results regarding type 2 collagen expression were confirmed with 
six other hOAC donors (see supplementary, S9). 
In summary, the anabolic effect of M1673 was confirmed in hOAC and was similar to the effect observed 
in bovine and porcine chondrocytes. M1673 showed a strong and significant effect on cartilage ECM 
production in hOAC, which was similar or slightly lesser than that of GDF5.  
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Figure 30  Anabolic effect of GDF5 and M1673 on ECM synthesis in hOAC at 380 mOsm.
±
 
There are some indications in the literature that GDF5 also exhibit anti-catabolic characteristics. To 
investigate if M1673 shows a similar effect, MMP13 and ADAMTS5 expressions were evaluated. The 
expression of MMP13 and ADAMTS5 was significantly reduced in hOAC after treatment with 300 ng/ml 
GDF5 and M1673 compared to untreated hOAC. However, M1673 showed a less pronounced reduction 
of MMP13 and ADAMTS5 expression in comparison to GDF5 (Figure 31 A+B). The results for MMP13 
were confirmed with 5 other hOAC donors (see supplementary, S10). Additionally, the expression of the 
hypertrophic marker type 10 collagen and the dedifferentiation marker type 1 collagen were analyzed, 
but only in one donor. The expression of type 10 collagen was significantly enhanced with GDF5, but 
not with M1673 compared to untreated cells. In addition, a significantly reduced type 10 collagen 
expression was observable with M1673 compared to GDF5 indicating a reduced hypertrophic capacity 
of M1673 compared to GDF5 in this donor (Figure 31 C). Similarly, the expression of type 1 collagen 
was significantly enhanced after GDF5 and to a lesser extent after M1673 treatment compared to 
untreated cells. In addition, a significantly reduced type 1 collagen expression was detected with M1673 
compared to GDF5 indicating a reduced dedifferentiation capacity of M1673 compared to GDF5 in this 
donor (Figure 31 D). 
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Figure 31  Effect of GDF5 and M1673 on catabolic, hypertrophic and dedifferentiation markers in hOAC at 380 mOsm.
±
 
In conclusion, it was shown that M1673 exerts an anabolic as well as an anti-catabolic effect on hOAC 
cultured in alginate beads at 380 mOsm. In addition, it can be suggested that M1673 might have a less 
hypertrophic capacity than GDF5 in hOAC. These results confirm the therapeutic potential of M1673 as 
a DMOAD. 
 
 
 
 
  
  
5.3 Differentiation capacities of GDF5 mutants in mesenchymal stem cells 
 
Bone morphogenetic proteins (BMPs) induce the formation of cartilage and bone during embryonic 
development by binding to the BMP receptors BMPR1a or BMPR1b (both type 1 receptors) which 
dimerize with BMPR2. After binding of BMPs to the BMPR complex, the type 1 receptors initiate the 
intracellular signal transmission. It is believed that the affinities of the different BMPs towards BMPR1a 
and BMPR1b influence the differentiation of mesenchymal stem cells (MSCs) into bone or cartilage 
during skeletal development. However, the distinct roles of BMPR1a and BMPR1b are not completely 
understood. It is known that BMPR1a is mainly expressed in osteolineage cells and pre-hypertrophic 
chondrocytes while BMPR1b is mainly expressed at sites were cartilage will be developed. In addition, 
GDF5 which exhibits a higher affinity for BMPR1b compared to BMPR1a is known to be involved in 
cartilage formation while BMP2 which exhibit similar affinities for BMPR1b and BMPR1a is involved in 
bone formation. Thus, the initial hypothesis of this work was that BMPs with a higher binding selectivity 
to BMPR1b induce chondrogenesis resulting in cartilage formation, while BMPs with a higher binding 
selectivity to BMPR1a induce chondrocytes hypertrophy and osteogenesis resulting in bone formation. 
GDF5 mutants were designed by single point mutations in the type 1 receptor binding site of GDF5 to 
modify the binding affinities to BMPR1a and BMPR1b. Three GDF5 mutants (M1673, W417F, W417R) 
with a similar affinity to BMPR1b and a lower affinity to BMPR1a were selected for further evaluations. 
It was hypothesized that these mutants will have a maintained chondrogenic but a reduced hypertrophic 
and osteogenic capacities in comparison to GDF5. The aim of the following experiments was to verify 
this hypothesis. BMP2 was used as control for osteogenesis and chondrocyte hypertrophy. In addition, it 
was aimed to better understand the respective roles of BMPR1a and BMPR1b. 
 
5.3.1 Receptor affinity and bioactivity of GDF5 mutants  
As a first step, all GDF5 mutants as well as GDF5 and BMP2 were characterized regarding their receptor 
affinities and their bioactivity in vitro. The aim of the receptor affinity measurement was to confirm 
former measurements showing the impact of the mutations on BMPR1a and BMPR1b affinities. In 
addition, it was evaluated if the binding to BMPR2 was also affected.  
The affinity measurements were performed in the molecular interaction laboratory by Andreas 
Schoenemann. The smaller the KD value, the greater is the binding affinity of the analyzed BMPs for its 
target receptor. For BMPR2 the lowest binding affinity was detected for BMP2 with a KD of 104 nM. 
GDF5, M1673 and W417F exhibit similar BMPR2 affinities with KD values of 26.5 nM, 23 nM and 15 
nM. For W417R no binding was observed to BMPR2 (Table 7). The highest binding affinity to BMPR1a 
was obtained for BMP2 with a KD of 119 pM, followed by GDF5 with a KD of 2.1 nM. Among the GDF5 
mutants, M1673 showed the highest BMPR1a affinity with a KD value of 12.4 nM followed by W417F 
with a KD value of 85.9 nM. For W417R no binding was observed to BMPR1a. These results confirm that 
  
the BMPR1a binding affinity was reduced in the GDF5 mutants compared to GDF5 (Table 7). Regarding 
BMPR1b, the highest binding affinity was obtained for GDF5 (42 pM), followed by BMP2 (72 pM) and 
the GDF5 mutants. Among the GDF5 mutants, M1673 and W417F exhibit similar affinities for BMPR1b 
with KD values of 110 and 115 pM, whereas W417R with a KD of 273 pM has a slightly lower BMPR1b 
affinity (Table 7). By comparing the affinities of the tested compounds for BMPR1a and BMPR1b, it can 
be noticed that there are large differences among KDs for BMPR1a, whereas the BMPR1b affinities 
showed smaller variations. To compare the binding affinities of the respective compounds towards 
BMPR1a compared to BMPR1b, the KD ratio of BMPR1a/BMPR1b was calculated. A high ratio indicates 
a higher ability of the compound to bind BMPR1b compared to BMPR1a. The GDF5 mutants obtained a 
higher KD ratio of BMPR1a/BMPR1b compared to GDF5 and showed therefore a higher binding 
selectivity towards BMPR1b than towards BMPR1a. In detail, W417F has the highest ratio (747), 
followed by M1673 (113) and GDF5 (50). The KDBMPR1a/BMPR1b ratio for W417R could not be determined, 
because of the absence of binding to BMPR1a in our experimental setting but this ratio can virtually be 
considered as being +∞. With 1.7, BMP2 showed the lowest KDBMPR1a/BMPR1b ratio of all tested compounds 
(Table 7). The calculated KD ratio of BMPR1a/BMPR1b results in a ranking of 
(W417R)>W417F>M1673>GDF5>BMP2. 
 
Table 7 Affinity measurements of BMP2, GDF5 and GDF5 mutants for BMPR2, BMPR1a and BMPR1b. 
 
 
 
In addition to the affinity measurements, the ability of BMP2, GDF5 and GDF5 mutants to bind to their 
BMP receptors and trigger their dimerization was tested in two dimerization assays. The cells used co-
express BMPR2 together with BMPR1a or BMPR1b and were stimulated with different concentrations of 
BMP2, GDF5 and GDF5 mutants. In these cells, receptor dimerization upon ligand binding results in a 
luminescent signal.  
In each dimerization assay, a dose response curve was performed and the half maximal effective 
concentration (EC50) was calculated for each compound. Each dose-response curve was done twice. The 
smaller the EC50 value, the greater is the potency of the compound for receptor dimerization. All 
compounds increased the dimerization of BMPR1a with BMPR2 in a dose-dependent manner. M1673 
  
and BMP2 behave similarly in both experiments with EC50s of 17.61 and 25.34 ng/ml for M1673 and 
19.48 and 16.08 ng/ml for BMP2. GDF5 was less potent with an EC50 of 74.32 ng/ml in the first 
experiment and 73.38 ng/ml in the second experiment, followed by W417F with an EC50 of 155.7 ng/ml 
in the first experiment and 207.40 ng/ml in the second experiment. The weakest potency was observed 
for W417R with EC50s of 1048 and 1434 ng/ml (Figure 32). This results in a ranking for the 
BMPR1a/BMPR2 receptor dimerization potency of BMP2=M1673>GDF5>W417F>W417R. 
Interestingly, W417R for which no affinity could be measured with BMPR2 and BMPR1a by SPR, was 
able to stimulate dimerization of BMPR2 and BMPR1a at high concentrations. It indicates that W417R 
is still able to interact with BMPR1a and BMPR2. The BMPR1b/BMPR2 dimerization assay showed also 
a dose-dependent receptor dimerization for all analyzed compounds. M1673 was the most potent 
molecule with an EC50 value of 6.33 ng/ml obtained in the first experiment and 17.82 ng/ml in the 
second experiment, followed by BMP2, GDF5, W417F and W417R which all behaved similarly: BMP2 
obtained an EC50 of 41.68 and 64.35 ng/ml, GDF5 of 54.32 and 91.11 ng/ml, W417F of 50.21 and 
126.7 and W417R of 78.88 and 81.47 ng/ml (Figure 32). This results in a ranking for the 
BMPR1b/BMPR2 receptor dimerization potency of M1673>BMP2=GDF5=W417F=W417R.  
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Figure 32   Ability of BMP2, GDF5 and GDF5 mutants to bind to their receptors and activate dimerization of type 1 and 
type 2 BMPRs in a cell assay. 
  
In both cell assays, the potencies obtained result to a ranking that is different than the ranking obtained 
for the affinities for BMPR1a and BMPR1b by SPR. This discrepancy can be due to the difference between 
the assay systems.  
The average of each EC50 from the two experiments and the ratio EC50BMPR1a/BMPR2/EC50BMPR1b/BMPR2 
(referred as EC50 ratio later in the text) were calculated (Table 8). A higher ratio indicates a higher 
ability to dimerize BMPR2 with BMPR1b than with BMPR1a. With an EC50 ratio of 0.3, BMP2 was the 
only compound with a ratio lower than one indicating a higher ability to dimerize BMPR2 with BMPR1a 
than BMPR1b. GDF5 had a ratio of 1 indicating the comparable ability to dimerize BMPR1a and BMPR1b 
with BMPR2. Finally, the GDF5 mutants had all ratios higher than 1: M1673 had a ratio of 1.8 followed 
by W417F with 2 and W417R with 15 indicating that they all have a higher ability to dimerize BMPR2 
with BMPR1b than with BMPR1a. 
 
Table 8 EC50s of BMP2, GDF5 and GDF5 mutants for BMPR1a/BMPR2 and BMPR1b/BMPR2. 
 
 
 
When comparing the potencies obtained with the various compounds, it can be noticed that there are 
large differences in the EC50s for BMPR1a/BMPR2, whereas the EC50s for BMPR1b/BMPR2 varied less 
between the tested compounds (Table 8). These observation is in accordance to the results of the affinity 
measurements (Table 7). 
Despite some discrepancies regarding single KDs and EC50s, the ratio of EC50s resulted in the same 
ranking than the ratio of KDs with (W417R)>W417F>M1673>GDF5>BMP2. This ranking indicates a 
higher specificity of the GDF5 mutants to BMPR1b than to BMPR1a followed by GDF5 and BMP2. 
Therefore, the mutations performed on the GDF5 molecule successfully increased the selectivity towards 
BMPR1b binding in comparison to GDF5. Based on the initial hypothesis that BMPs with a higher binding 
selectivity to BMPR1b induce chondrogenesis, while BMPs with a higher binding selectivity to BMPR1a 
induce hypertrophy and osteogenesis, the GDF5 mutants should exhibit a similar chondrogenic but 
reduced hypertrophic and osteogenic capacities than GDF5. In this regard W417R should be the GDF5 
mutant showing the most reduced hypertrophic and osteogenic properties. On the other hand, BMP2 
should exert a strong hypertrophic and osteogenic effect in addition to its chondrogenic effect.  
 
  
5.3.2 Effect of GDF5 mutants on chondrogenesis and osteogenesis in murine MSCs 
The chondrogenic and osteogenic capacities of the GDF5 mutants were analyzed in the murine stem cell 
line C3H10T1/2 and compared to GDF5 and BMP2. As a first step, the murine stem cell line was tested 
for the presence of BMPRs at the gene expression and protein level by qRT-PCR and western blot 
analysis. BMPR1a and BMPR2 showing comparable expression levels while the expression of BMPR1b 
was significantly lower compared to BMPR1a and BMPR2 (Figure 33 A). At the protein level, both 
BMPR1a and BMPR1b were detectable in C3H10T1/2 cells. In accordance to the gene expression 
analysis, the protein level of BMPR1b appeared lower than that of BMPR1a (Figure 33 B). 
 
 
Figure 33   BMPR analysis in the murine stem cell line C3H10T1/2 at the gene expression and protein level. 
±
 
In summary, the presence of the BMPRs responsible for signal transmission of BMPs were confirmed in 
C3H10T1/2 cells. Next, the GDF5 mutants were tested for their chondrogenic/hypertrophic and 
osteogenic properties in C3H10T1/2 cells and compared to GDF5 and BMP2. 
 
5.3.2.1 Ability of GDF5 mutants to stimulate chondrogenesis and hypertrophy in murine MSCs 
Chondrogenic induction of the murine stem cell line C3H10T1/2 was performed in a pellet culture 
system with one million cells/pellet. The cells were cultivated in a chondrogenic medium including 
several essential substances for chondrogenic induction of MSCs (see methods, chapter 4.2.4) and were 
stimulated with 300 ng/ml BMP2, GDF5 and GDF5 mutants or remained unstimulated over 28 days. On 
a weekly basis, cell and medium samples were analyzed for several differentiation markers. Type 2 
collagen and aggrecan expression are chondrogenic differentiation markers, while type 10 collagen 
expression and ALP concentration are hypertrophic differentiation markers. In addition, for gene 
expression analysis cell samples were taken before starting the culture to analyze the initial expression 
profile of the murine MSCs (defined as day 0). 
The stimulation of murine MSCs with BMP2 and GDF5 resulted in an enhanced gene expression of type 
2 collagen at 14 and 21 days for GDF5 and at 7 days for BMP2 compared to day 0. Unfortunately, for 
  
GDF5 no RNA could be isolated at day 7 and the gene expression data are missing for this time point. 
M1673 stimulated the type 2 collagen expression at day 7 and day 14 compared to day 0. Type 2 collagen 
expression was significantly lesser pronounced with M1673 than with GDF5 at day 14 and day 21. On 
the contrary to BMP2, GDF5 and M1673, the stimulation of murine MSCs with W417F only led to a 
slightly enhanced type 2 collagen expression, while no effect was observed on type 2 collagen expression 
after W417R stimulation compared to day 0 (Figure 34 A). Similarly, the aggrecan expression was 
enhanced after stimulation with BMP2 and GDF5 for 14, 21 and 28 days compared to the initial 
expression at day 0. The treatment with M1673 led to a strong upregulation of aggrecan expression at 
all analyzed time points compared to day 0, but to a significantly lesser extent than observed with GDF5 
stimulation. The stimulation with W417F resulted in a significantly reduced aggrecan expression 
compared to M1673. No effect was observable after W417R stimulation on aggrecan expression 
compared to day 0 (Figure 34 B).  
In summary, GDF5 showed the highest chondrogenic capacity followed by M1673, BMP2 and W417F. 
BMP2 was ranked after M1673 because of its lower type 2 collagen expression. W417R showed no 
chondrogenic effect in C3H10T1/2 cells. 
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Figure 34  Analysis of chondrogenic markers in murine MSCs cultured in chondrogenic medium in the absence or presence 
of BMP2, GDF5 and GDF5 mutants over 28 days.
± 
  
While BMP2, GDF5 and M1673 all strongly activated chondrogenesis in murine MSCs, only BMP2 
strongly upregulated the expression of the hypertrophic marker type 10 collagen. The expression of type 
10 collagen increased after 7 days in the presence of BMP2 compared to day 0 and subsequently 
decreased with time over 28 days. GDF5 and M1673 also upregulated the type 10 collagen expression, 
but in a lesser extend in comparison to BMP2. In addition, the expression of type 10 collagen was 
significantly lower with M1673 compared to GDF5. W417F and W417R showed hardly any type 10 
collagen expression (Figure 35 A). Similarly, only the treatment with BMP2 strongly enhanced the ALP 
concentration in medium in a time-dependent manner over 28 days, but not the treatment with GDF5, 
M1673, W417F or W417R (Figure 35 B).  
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Figure 35  Analysis of hypertrophic markers in murine MSCs cultured in chondrogenic medium in the absence or presence 
of BMP2, GDF5 and GDF5 mutants over 28 days.
± 
 
Taken together, GDF5, M1673 and BMP2 induced chondrogenesis but only BMP2 strongly induced 
hypertrophy. Both GDF5 and M1673 showed only a weak effect on type 10 collage expression with 
M1673 showing the smallest stimulation. W417F had a reduced ability to stimulate chondrogenesis in 
comparison to GDF5 or M1673 and had no effect on hypertrophy. W417R showed no effect at all.  
  
In the light of those results, the initial hypothesis that BMPs, with a higher binding selectivity towards 
BMPR1b induce chondrogenesis, while BMPs with a higher binding selectivity to BMPR1a promote 
hypertrophy and osteogenesis had to be refined. BMPR1b signaling alone is not sufficient to stimulate 
chondrogenesis. Indeed, W417F and W417R, both having a BMPR1b affinity comparable to M1673, but 
a strongly reduced BMPR1a affinity, showed a diminished or even no chondrogenic capacity. This 
indicates that BMPR1a activation is necessary for the induction of chondrogenesis. On the other hand, 
compounds with a higher BMPR1a/BMPR1b ratio seems to prevent hypertrophic differentiation. 
To better illustrate this, the ratio of collagen 2/10 (chosen as respective markers for chondrogenesis and 
hypertrophy) was plotted against the EC50 ratio of BMPR1a/BMPR1b. A lower EC50 ratio corresponds 
to a lower ratio of collagen 2/10 expression. For instance, BMP2 with a very low EC50 ratio of 
BMPR1a/BMPR1b showed an increased hypertrophic differentiation but only a moderate 
chondrogenesis compared to GDF5 and M1673. On the contrary, M1673 with a higher EC50 ratio of 
BMPR1a/BMPR1b was more chondrogenic than hypertrophic. W417F and W417R with a high EC50 
ratio of BMPR1a/BMPR1b but a strongly reduced BMPR1a affinity showed a diminished or even lost its 
chondrogenic capacity (Figure 36).  
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Figure 36  Correlation between the expression ratio of collagen 2/10 and the EC50 ratio of BMPR1a/BMPR1b after 
treatment with BMP2, GDF5 and GDF5 mutants in murine MSCs cultured for 21 days in chondrogenic medium.
 
5.3.2.2 Ability of GDF5 mutants to stimulate osteogenesis in murine MSCs 
In addition to the chondrogenic and hypertrophic capacities of the GDF5 mutants, their ability to 
stimulate osteogenesis was compared to GDF5 and BMP2. Osteogenesis of the murine stem cell line 
C3H10T1/2 was performed in monolayer cultures. After reaching confluence, the cells were cultured 
and treated with 300 ng/ml BMP2, GDF5 and GDF5 mutants or remained untreated over 28 days. To 
analyze the osteogenic properties of the compounds, they were cultured in a standard culture medium. 
On a weekly basis, cell and medium samples were analyzed for the presence of osteogenic markers. The 
  
concentration of ALP was used as an early osteogenic marker, whereas the expression of osteocalcin was 
used as a late-stage osteogenic marker. In addition, alizarin red staining of the cells was analyzed as a 
marker for calcium deposition occurring at later stages of osteogenesis. Regarding gene expression 
analysis, cell samples were also taken before starting the culture to analyze the initial expression profile 
of the murine MSCs (defined as day 0). 
Only the stimulation with BMP2 resulted in an upregulation of ALP concentration in medium at all time 
points (Figure 37 B). Simultaneously the expression of osteocalcin was enhanced at all time points after 
stimulation with BMP2 compared to day 0, but not with GDF5, GDF5 mutants or in unstimulated cells 
(Figure 37 A). In contrast, the alizarin red staining was negative with all compounds at all tested time 
points (Figure 37 C). 
Taken together these results indicate that, as expected, GDF5 and GDF5 mutants showed no osteogenic 
induction potential in murine MSCs cultivated in the standard culture medium. In contrast, the 
stimulation with BMP2 resulted in the upregulation of some osteogenic markers. However, a complete 
osteogenesis was not achieved as no alizarin red staining was detectable.  
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Figure 37 Analysis of osteogenic markers in murine MSCs cultured in standard culture medium in the absence or presence 
of BMP2, GDF5 and GDF5 mutant over 28 days.
± 
 
  
To further analyze the impact of GDF5 mutants compared to GDF5 and BMP2 on osteogenesis in murine 
MSCs, the cells were cultured as described before, but in an osteogenic medium containing several 
essential substances for osteogenic induction of MSCs in vitro (see methods, chapter 4.2.3). On a weekly 
basis, cell and medium samples were analyzed for the presence of osteogenic markers. As in the previous 
experiment, ALP concentration, osteocalcin expression and alizarin red staining were measured as 
osteogenic markers. In addition, microscopic images of the cells were recorded. Regarding gene 
expression analysis, cell samples were also taken before starting the culture to analyze the initial 
expression profile of the murine MSCs (defined as day 0). 
Osteogenesis of murine MSCs was the strongest with BMP2 treatment (Figure 38). The expression of 
osteocalcin was strongly upregulated after BMP2 treatment compared to day 0 and unstimulated cells. 
The stimulation with GDF5 resulted in a less pronounced upregulation of osteocalcin expression 
compared to BMP2 and no effect on osteocalcin expression was detectable with M1673, W417F and 
W417R (Figure 38 A). The concentration of ALP in medium was only detectable with BMP2, but not 
with GDF5 or GDF5 mutants (Figure 38 B). In addition, the alizarin red staining was analyzed. An 
alizarin red staining of murine MSCs cultured in osteogenic medium was not detectable at the beginning 
of the experiment (day 0) and after 7 days of culture (data not shown). However, an alizarin red staining 
could be detected after 14 days in presence of BMP2, after 21 days in presence of GDF5 and only after 
28 days in the presence of M1673 and W417F (Figure 38 C). The delayed apparition of the alizarin red 
staining with GDF5 compared to BMP2 and with M1673 and W417F compared to GDF5 indicate a 
delayed mineralization of the cells. No alizarin red staining could be seen in the presence of W417R and 
in control cells cultured in osteogenic medium without stimulation (Figure 38 C).  
The ranking of the tested compounds for their capacity to induce osteogenesis in murine MSCs is in 
accordance with their BMPR1a/BMPR1b ratios: BMP2<GDF5<M1673<W417F<W417R. A higher 
BMPR1a/BMPR1b ratio indicating a higher specificity towards BMPR1b compared to BMPR1a resulted 
in a reduced osteogenicity of the compounds.  
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Figure 38  Analysis of osteogenic markers in murine MSCs cultured in osteogenic medium in the absence or presence of 
BMP2, GDF5 and GDF5 mutants over 28 days.
± 
 
The delayed mineralization of the murine MSCs in presence of GDF5 mutants compared to GDF5 was 
also observable by looking at the cell morphology. In general, the cells were already over-confluent at 
day 21 and 28 resulting on the one hand in a changed cell morphology from a fibroblastic to a polygonal 
cell shape and on the other hand in a cell grew on the top. It was striking that the cells formed black 
aggregates at day 21 and 28 indicating mineralization of the cells. The mineralization was observable 
after 21 days of BMP2 treatment and to a lesser extent after 21 days of GDF5 treatment, but not in the 
presence of M1673, W417F, W417R or in untreated cells at day 21 (Figure 39). After 28 days, a strong 
mineralization was observable with BMP2 and GDF5 and to a lesser extent in the presence of M1673 
and W417F, but not in W417R stimulated cells or in control cells cultured in osteogenic medium without 
stimulation (Figure 39).  
These observations are in accordance with the alizarin red staining and confirmed a delayed 
mineralization with the GDF5 mutants compared to GDF5 and BMP2. Thus, an earlier mineralization 
and induced osteogenesis could be confirmed for the compounds having a lower BMPR1a/BMPR1b ratio. 
  
 
Figure 39  Representative microscopic images of murine MSCs cultured in osteogenic medium in the absence or presence 
of BMP2, GDF5 and GDF5 mutants for 21 and 28 days.
 
Overall, it was shown that BMP2 exhibits strong osteoinductive properties in murine MSCs even in the 
absence of osteogenic inductors in the culture medium. Osteogenesis of murine MSCs cultured in 
osteogenic medium was also the strongest in the presence of BMP2, followed by GDF5, M1673 and 
W417F. The addition of W417R did not induce osteogenesis in murine MSCs. Therefore, it could be 
demonstrated that the GDF5 mutants exhibit a lower osteogenicity compared to GDF5 and BMP2.  
In combination with the results from the chondrogenic induction in murine MSCs, it was shown that a 
sufficient binding towards BMPR1a is necessary for both chondrogenesis and osteogenesis. Indeed, 
W417R which has the lowest affinity for BMPR1a had no effect on both chondrogenic and osteogenic 
differentiation. Given that the BMPR1a signaling is sufficient, the ratio of BMPR1a/BMPR1b signaling 
seems to drive chondrogenic and hypertrophic differentiation and not the single binding for BMPR1a or 
BMPR1b as originally hypothesized. Regarding osteogenesis, a correlation could be also found between 
the osteogenic stimulation and the BMPR1a/BMPR1b ratio indicating that compounds with a higher 
BMPR1a/BMPR1b ratio delay osteogenic differentiation.  
As a conclusion compounds with a lower BMPR1a/BMPR1b ratio will be more osteogenic, as BMP2, and 
compounds with a higher BMPR1a/BMPR1b ratio and a sufficient BMPR1a affinity, as M1673, will be 
more chondrogenic, less hypertrophic and will tend to prevent osteogenesis. 
 
5.3.3 Effect of GDF5 mutants on chondrogenesis and osteogenesis in human MSCs 
To confirm the results obtained with the murine mesenchymal stem cell line, chondrogenesis and 
osteogenesis were also evaluated in human MSCs. As a first step, the expression of BMPRs in human 
MSC was evaluated at the gene expression and protein level by qRT-PCR and western blot analysis. The 
BMPR1a and BMPR2 expression levels were comparable, whereas the gene expression of BMPR1b was 
significantly lower compared to that of BMPR1a and BMPR2 (Figure 40 A). The same was observed at 
the protein level. BMPR1a and BMPR1b were detectable by western blot analysis, but in accordance to 
  
the gene expression analysis the protein level of BMPR1b appeared lower compared to BMPR1a (Figure 
40 B).  
 
Figure 40  BMPR analysis in human MSCs at the gene expression and protein level. 
±
 
In summary, the presence of the different BMPRs were confirmed in human MSCs. Next, the GDF5 
mutants were tested for their chondrogenic/hypertrophic and osteogenic properties in human MSCs and 
compared to GDF5 and BMP2. 
 
5.3.3.1 Ability of GDF5 mutants to stimulate chondrogenesis and hypertrophy in human MSCs 
To induce chondrogenesis, a pellet culture system with one million cells/pellet was used. The cells were 
cultured in chondrogenic medium and were stimulated with 300 ng/ml BMP2, GDF5 and GDF5 mutants 
or remained unstimulated over 28 days as described before for the murine MSCs. However, no 
chondrogenic differentiation of human MSCs was observed (data not shown). To enhance 
chondrogenesis in human MSCs, the same experiment was repeated, but in the presence of 10 ng/ml 
TGFȾ3. On a weekly basis, cell and medium samples were analyzed for several differentiation markers: 
Type 2 collagen and aggrecan expression, Safranin O staining and type 2 collagen immunohistochemistry 
as chondrogenic differentiation markers and type 10 collagen expression, ALP concentration and type 
10 collagen immunohistochemistry as hypertrophic differentiation markers. 
The expression of type 2 collagen and aggrecan was significantly enhanced in the presence of 10 ng/ml 
TGFȾ3 compared to unstimulated cells in chondrogenic medium. Unfortunately, the combination of      
10 ng/ml TGFȾ3 with 300 ng/ml GDF5, GDF5 mutants or BMP2 resulted in type 2 collagen expression 
levels, which were comparable to that detected in the presence of 10 ng/ml TGFȾ3 (Figure 41 A). 
Similarly, the type 2 collagen staining was negative in control cells indicating that these cells did not 
undergo chondrogenesis while it was positive with TGFȾ3 alone or in combination with BMP2, GDF5 or 
GDF5 mutants but comparable to each other (Figure 41 D). Regarding the expression of aggrecan 
  
significant differences were detected with TGFȾ3, GDF5+TGFȾ3, M1673+TGFȾ3 and W417F+TGFȾ3 
compared to BMP2+TGFȾ3 at day 28 (Figure 41 B). However, the Safranin O staining was similar after 
the stimulation with TGFȾ3 alone or in combination with BMP2, GDF5 or GDF5 mutants (Figure 41 C).  
Thus, it could be demonstrated that TGFȾ3 strongly induced chondrogenesis in human MSCs but no 
additional induction could be observed with BMP2, GDF5 or the GDF5 mutants under the chosen 
concentration of TGFȾ3. It was hypothesized that the effects of the compounds were shielded by TGFȾ3. 
Consequently, the influence of BMP2, GDF5 and GDF5 mutants on chondrogenesis in human MSCs could 
not be analyzed. 
 
 
Figure 41  Analysis of chondrogenic markers in human MSCs cultured in chondrogenic medium in the absence or presence 
of TGFβ3 or in the presence of TGFβ3 with BMP2, GDF5 or GDF5 mutants over 28 days.
β
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The hypertrophic capacity of BMP2, GDF5 and GDF5 mutants combined with TGFȾ3 was analyzed, too. 
The expression of type 10 collagen was significantly enhanced by adding 10 ng/ml TGFȾ3 to the 
chondrogenic medium compared to unstimulated cells in chondrogenic medium. As observed before for 
the expression of chondrogenic markers, the type 10 collagen expression was similar for TGFȾ3 alone 
and in combination with BMP2, GDF5 and GDF5 mutants (Figure 42 A). However, the immuno-
histochemistry showed that the stimulation of human MSCs with BMP2 in combination with TGFȾ3 and 
to a lesser extent with GDF5 in combination with TGFȾ3 resulted in a positive type 10 collagen staining 
at day 28. On the contrary unstimulated cells, cells stimulated with TGFȾ3 alone or in combination with 
GDF5 mutants showed no type 10 collagen staining at day 28 (Figure 42 C). Accordingly, the ALP 
  
concentration in medium was increased more strongly with BMP2 and GDF5 in combination with TGFȾ3 
than with GDF5 mutants in combination with TGFȾ3 or with TGFȾ3 alone at day 21 and day 28 (Figure 
42 B). These results confirm that a higher BMPR1a/BMPR1b ratio reduces hypertrophy as observed on 
the murine MSCs. 
 
 
Figure 42  Analysis of hypertrophic markers in human MSCs cultured in chondrogenic medium in the absence or presence 
of TGFβ3 or in the presence of TGFβ3 with BMP2, GDF5 or GDF5 mutants over 28 days.
β
±  
 
Overall, the influence of the GDF5 mutants on chondrogenesis in human MSCs could not be evaluated. 
Nevertheless, an induction of hypertrophic differentiation was observable with BMP2 and GDF5, but not 
with M1673, W417F and W417R in combination with TGFȾ3 confirming that a higher BMPR1a/BMPR1b 
ratio prevent hypertrophy in human MSCs. 
 
5.3.3.2 Ability of GDF5 mutants to stimulate osteogenesis in human MSCs 
In addition to the chondrogenic and hypertrophic capacities of the GDF5 mutants, their abilities to 
stimulate osteogenesis in human MSCs were evaluated and compared to GDF5 and BMP2. Osteogenesis 
of human MSCs was performed in monolayer cultures. After reaching confluence, the cells were cultured 
in standard cultivation medium and treated with 300 ng/ml BMP2, GDF5 and GDF5 mutants or 
remained untreated over 28 days as described previously for murine MSCs. On a weekly basis, cell and 
medium samples were analyzed for the presence of osteogenic markers. The concentration of ALP and 
the expression of osteopontin were used as early osteogenic markers, whereas the expression of 
  
osteocalcin was used as a late-stage osteogenic marker. In addition, alizarin red staining of the cells was 
analyzed as a marker for calcium deposition occurring at later stages of osteogenesis. 
On the contrary to in the murine MSCs, the expression of early and late osteogenic markers was not 
enhanced after compound stimulation of human MSCs cultured in standard medium. Neither the 
expression of osteopontin, nor the expression of osteocalcin was changed by the stimulation with any of 
the compounds (Figure 43 A+B). Similarly, no ALP concentration (data not shown) and no alizarin red 
staining was detected at any time (Figure 43 C).  
Overall, in human MSCs the addition of osteogenic inductors to the cultivation medium seems to be 
necessary to induce osteogenesis. 
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Figure 43  Analysis of osteogenic markers in human MSCs cultured in standard culture medium in the absence or presence 
of BMP2, GDF5 and GDF5 mutant over 28 days.
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To confirm the influence of GDF5 mutants compared to GDF5 and BMP2 on osteogenesis in human 
MSCs, the cells were cultured in an osteogenic medium containing several essential substances for 
osteogenic induction of MSCs in vitro (see methods, chapter 4.2.3). As in the previous experiment, on a 
weekly basis, cell and medium samples were analyzed for the presence of osteogenic markers.  
Osteogenesis of human MSCs cultured in osteogenic medium was the strongest after BMP2 treatment 
(Figure 44). The expression of osteopontin was strongly upregulated in the presence of BMP2 in 
comparison to untreated cells, but not with GDF5 and GDF5 mutants (Figure 44 A). Similarly, the 
  
expression of osteocalcin was only upregulated in cells stimulated with BMP2 in comparison to untreated 
cells, but not with GDF5 and GDF5 mutants (Figure 44 B). In addition, the ALP concentration in medium 
was only detectable after BMP2, but not after GDF5 and GDF5 mutant stimulation (Figure 44 C). 
Furthermore, the alizarin red staining became positive after 14 days in presence of BMP2, after 21 days 
in the presence of GDF5 and after 28 days with M1673 and W417F. No staining could be seen in presence 
of W417R and in unstimulated cells (Figure 44 D). 
 
*
*
*
*
*
*
*
*
Osteopontin expression
time [days]
re
la
tiv
e 
m
RN
A 
co
n
te
n
t
0 7 142128 0 7 142128 0 7 142128 0 7 142128 0 7 142128 0 7 142128
0.0
0.1
0.2
0.3
0.4
CTL
GDF5
M1673
W417F
W417R
BMP2
*
*
*
*
n
s
n
s
n
s
n
s
n
s
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Osteocalcin expression
time [days]
re
la
tiv
e 
m
RN
A 
co
n
te
n
t
0 7 142128 0 7 142128 0 7 142128 0 7 142128 0 7 142128 0 7 142128
0.000
0.002
0.004
0.006
0.008
0.010 CTL
GDF5
M1673
W417F
W417R
BMP2
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
n
s
n
s
n
s
n
s
n
s
n
s n
s
n
s
n
s
n
s
 
CT
L
G
D
F5
M
16
73
W
41
7F
W
41
7R
B
M
P2
day 14
day 21
day 28
A
B
C
D
ALP concentration in medium
time [days]
AL
P 
[µ
g/
m
l]
7 14 21 28 7 14 21 28 7 14 21 28 7 14 21 28 7 14 21 28 7 14 21 28
0
5
10
15
be
lo
w
 
de
te
ct
io
n
 
ra
n
ge
be
lo
w
 
de
te
ct
io
n
 
ra
n
ge
be
lo
w
 
de
te
ct
io
n
 
ra
n
ge
be
lo
w
 
de
te
ct
io
n
 
ra
n
ge
be
lo
w
 
de
te
ct
io
n
 
ra
n
ge
be
lo
w
 
de
te
ct
io
n
 
ra
n
ge
be
lo
w
 
de
te
ct
io
n
 
ra
n
ge
be
lo
w
 
de
te
ct
io
n
 
ra
n
ge
be
lo
w
 
de
te
ct
io
n
 
ra
n
ge
be
lo
w
 
de
te
ct
io
n
 
ra
n
ge
be
lo
w
 
de
te
ct
io
n
 
ra
n
ge
be
lo
w
 
de
te
ct
io
n
 
ra
n
ge
be
lo
w
 
de
te
ct
io
n
 
ra
n
ge
be
lo
w
 
de
te
ct
io
n
 
ra
n
ge
be
lo
w
 
de
te
ct
io
n
 
ra
n
ge
be
lo
w
 
de
te
ct
io
n
 
ra
n
ge
be
lo
w
 
de
te
ct
io
n
 
ra
n
ge
be
lo
w
 
de
te
ct
io
n
 
ra
n
ge
be
lo
w
 
de
te
ct
io
n
 
ra
n
ge
be
lo
w
 
de
te
ct
io
n
 
ra
n
ge
be
lo
w
 
de
te
ct
io
n
 
ra
n
ge
BMP2
Alizarin red staining
 
Figure 44  Analysis of osteogenic markers in human MSCs cultured in osteogenic medium in the absence or presence of 
BMP2, GDF5 and GDF5 mutants over 28 days.
± 
To summarize, osteogenesis of human MSCs could only be induced in the presence of osteogenic 
stimulators within the culture medium and was strongest with BMP2. BMP2 was the only compound, 
which upregulated all analyzed osteogenic markers. Alizarin red staining of human MSCs showed a 
delayed mineralization with GDF5, followed by M1673 and W417F compared to BMP2. The delayed 
  
induction of mineralization corresponds with a higher KD or EC50 ratio for BMPR1a/BMPR1b: 
BMP2<GDF5<M1673<W417F<W417R.  
Overall, an evaluation of the GDF5 mutants on chondrogenic induction was not feasible in human MSCs. 
Nevertheless, it could be confirmed in human MSCs that the GDF5 mutants with a higher KD or EC50 
ratio for BMPR1a/BMPR1b exhibit a reduced hypertrophic and osteogenic capacity compared to GDF5 
and BMP2. 
 
Taken together the results from the MSC experiments showed that M1673 exhibits the highest 
chondrogenic capacity among the GDF5 mutants and a lower hypertrophic/osteogenic capacity 
compared to GDF5. It is hypothesized that M1673 displays an affinity to BMPR1a that enable 
chondrogenesis of MSCs. Simultaneously, M1673 has a BMPR1a/BMPR1b ratio that is high enough to 
prevent that MSCs undergo hypertrophy and to reduce osteogenic differentiation of MSCs in comparison 
to GDF5. 
  
6 Discussion 
 
Currently osteoarthritis (OA) is an incurable disease with only limited and mainly palliative treatment 
options. Therefore, it exists an unmet medical need for disease modifying OA drugs (DMOADs), which 
can deliver structural improvements by preventing OA progression or regenerating the damaged 
cartilage. The growth and differentiation factor 5 (GDF5) is a key regulator for cartilage formation 
during skeletal development and for its maintenance during adulthood and therefore could be a 
potentially useful growth factor for cartilage regeneration. Compared to other TGFȾ superfamily 
members like BMP2 or BMP7, the potential of GDF5 has been less investigated in the context of OA. 
Nevertheless, a few studies were performed to evaluate the therapeutic potential of GDF5. It was shown 
that GDF5 stimulates ECM production in chondrocytes [1, 4, 135], induces chondrogenesis of mesenchymal 
stem cells [2, 5, 128] and promotes cartilage repair in an OA rat model [3]. Moreover, there is some evidence 
for additional anti-catabolic capacities of GDF5 [4]. Finally, single nucleotide polymorphisms (SNPs) 
within the GDF5 gene leading to a reduced expression of GDF5 was found to be strongly associated with 
OA in a genome-wide association study [3]. Thus, GDF5 is an interesting target candidate for the 
regeneration of damaged OA cartilage. However, GDF5 was also shown to have undesirable hypertrophic 
and osteogenic activities in vitro and in vivo [3, 5]. To design an improved GDF5 with reduced 
hypertrophic and osteogenic features, different single point mutations in the type 1 receptor binding site 
of GDF5 were performed previously to this work. For the present work three of these GDF5 mutants 
(M1673, W417F and W417R) were evaluated for their ability to stimulate cartilage ECM production in 
chondrocytes and for their chondrogenic and osteogenic potentials in mesenchymal stem cells. Both cell 
types can produce cartilage and are consequently important target cells of a potential DMOAD. 
 
6.1 Anabolic effect of GDF5 mutants in primary chondrocytes 
 
Among the three GDF5 mutants, M1673 was previously shown to induce strongest the cartilage ECM 
production in bovine and porcine chondrocytes (see supplementary, S7+8). The present work aimed to 
confirm this anabolic effect of M1673 in human OA chondrocytes (hOAC).  
For this purpose, the anabolic effect of M1673 was investigated in hOAC cultured in monolayer over 7 
or 28 days and was compared to that of GDF5. Twelve monolayer cultures were realized with hOAC 
isolated from twelve different donors. These cultures showed only a weak and inconsistent effect of 
GDF5 and M1673 on the ECM production. Consequently, the anabolic effect of M1673 previously seen 
in porcine and bovine chondrocytes could not be confirmed in hOAC with this experimental setting 
(Table 6 + Figure 12). Contrary to these results, Bobacz and co-workers, showed a stimulatory effect of 
GDF5 on proteoglycan synthesis in hOAC cultured in monolayer over 7 days [153]. However, in the same 
study the synthesis of type 2 collagen was not affected by GDF5 indicating that not all ECM production 
  
markers were upregulated by the GDF5 stimulation. This study also differs from the present work as 
they used a serum-free culture medium [153]. Another previous study by Ratnayake and colleagues is in 
accordance to the results obtained in the present work. They could not demonstrate a robust anabolic 
effect of GDF5 on hOAC in a similar monolayer system used in the present work. They showed that the 
response of hOAC to exogenous GDF5 was detectable, but in a very inconsistent manner among the 
hOAC from different OA donors, whereas the addition of TGFȾ1 led to a reproducible anabolic response 
in the same cells [154]. The reason for this inconsistency of the GDF5 response could be that the 
chondrocytes from each OA patient have a different inflammatory status or correspond to various stage 
of disease progression, and therefore display different phenotypes. In addition, the poor responsiveness 
of hOAC to GDF5 and M1673 could be explained by the monolayer system itself. In the present work it 
was shown that the expression of BMPR1a and BMPR1b decreased significantly after culturing the hOAC 
for 6 days in monolayer compared to freshly isolated chondrocytes (Figure 20+23). Indeed, BMPR1a 
and BMPR1b are the main receptors for GDF5 and M1673 [113, 115]. This phenomenon might be inherent 
to the known chondrocyte dedifferentiation occurring in monolayer which is characterized by 
morphological changes and a shift from type 2 collagen expression to type 1 collagen expression [18, 46]. 
That phenotype loss was confirmed in hOAC monolayer cultures over 6 days compared to freshly isolated 
chondrocytes (Figure 18+21).  
 
An approach to overcome chondrocyte dedifferentiation is the culture of hOAC in 3D, which is known 
to better preserve the chondrocytes phenotype in comparison to monolayer cultures [18]. Consequently, 
it was hypothesized that culturing hOAC in 3D culture could improve the responsiveness of hOAC to 
GDF5 and M1673. This hypothesis was tested in two different 3D culture systems. In the first system, 
hOAC were allowed to aggregate and form cartilage-tissue analogs (CTAs), whereas for the second 
system hOAC were encapsulated in alginate beads. Both culture models are described to enable the cells 
to respond to growth factors [155-156]. Unfortunately, no significant effect on GAG accumulation was 
detectable after GDF5 or M1673 treatment neither in the CTAs nor in alginate beads with hOAC (Figure 
13). These results differ from previous results showing a strong anabolic effect of GDF5 and M1673 in 
porcine and bovine chondrocytes cultured as CTAs (see supplementary, S7+8). However, animal 
chondrocytes were isolated from young healthy pigs or cows, whereas hOAC were isolated from end-
stage OA cartilage of patients who underwent a total joint replacement surgery. These chondrocytes are 
older, diseased and inflamed. This could lead to an altered BMP receptor expression profile, which in 
turn could result in a decreased GDF5 response. It was also already described that many cell types 
become unresponsive to growth factors with age, disease and inflammation [157-158]. For example, it was 
shown that the responsiveness of human chondrocytes to the growth factors IGF1 and BMP7 declined 
with the increasing age of the donors from 24 to 81 years [158]. It was also demonstrated that increasing 
age lead to an enhancement of oxidative stress and lastly to a disruption in signal transmission within 
  
the chondrocytes [158]. In the present work, the only source for human chondrocytes was material from 
total joint replacement with a donor age of in average 71 years suffering from painful late-stage OA. 
These cells are probably less responsive to anabolic factors than healthy chondrocytes could be. 
Consequently, it was hypothesized that culturing the end-stage diseased hOAC in conditions 
corresponding to the environment of (almost) healthy articular cartilage could improve their condition 
by making them less diseased and restore their responsiveness to GDF5 and M1673.  
 
One condition of choice to mimic a ‘healthier’ cartilage environment was the culture of hOAC in hypoxia. 
Healthy articular cartilage is an avascular tissue, which is supplied with oxygen by diffusion from the 
synovial fluid resulting in an oxygen gradient within the articular cartilage from 10% in the superficial 
zone to 1% in the deep zone [31-32]. During OA, the cartilage becomes fibrillated and vascularized 
resulting in an increased oxygen tension within the OA cartilage [159]. It was hypothesized that lowering 
the oxygen tension in culture could help hOAC to recover partly a healthy phenotype. That was tested 
in the present work by the culture of hOAC in monolayer over 7 days or as CTAs over 28 days at a low 
oxygen tension (1%) and at a standard oxygen tension (21%). However, reducing the oxygen tension to 
1% had none or even a negative effect on the GAG concentration of hOAC cultured in monolayer (Figure 
14) or as CTAs (Figure 15) compared to the culture at 21% oxygen. Consequently, the culture of hOAC 
at a low oxygen tension of 1% was not favorable and was not further investigated. In contrast to the 
present work, it was shown by different research groups that lowering the oxygen tension to 1, 2, or 5% 
positively influenced the chondrocytes phenotype in 2D or 3D cultures. It enhanced the cartilage ECM 
production, promoted redifferentiation and even reduced the expression of hypertrophic markers and 
the production of ECM-degrading enzymes in chondrocytes [33-35]. A reason why hypoxia showed no 
beneficial effect on hOAC in the present work could be due to the disease status of the cells leading to a 
different response to hypoxia. It could be possible that the used oxygen tension of 1% was too low for 
hOAC. hOAC have already a decreased metabolism in comparison to healthy chondrocytes and low 
oxygen might reduce their metabolic activity even more. In addition, regarding the CTA constructs, the 
low oxygen tension of 1% may not be able to completely diffuse into the high cell density constructs 
resulting in an insufficient oxygen tension within the CTAs. 
 
A second way to mimic a ‘healthier’ cartilage environment and possibly make the hOAC more responsive 
to GDF5 and M1673 was the culture of hOAC in the presence of heparin additionally to GDF5 or M1673. 
Indeed, it is well known that heparin can potentiate the activity of some TGFȾ superfamily members by 
prolonging its bioavailability/activity and the presence of a heparin/heparan sulfate binding site was 
confirmed for the GDF5 molecule [2]. Healthy chondrocytes produce a considerable amount of cartilage 
ECM, which contains heparan sulfates, whereas OA chondrocytes produce less ECM resulting in a lack 
of heparan sulfates, which could be possibly the reason for a reduced responsiveness of hOAC to GDF5 
  
or M1673. Additionally anti-inflammatory properties are described for heparin [120], which could improve 
the hOAC condition. However, in the present work the addition of heparin had no beneficial or even an 
inhibitory effect on the hOAC responsiveness to GDF5 or M1673 (Figure 17). In contrast, for BMP2 it 
was shown that the binding of heparin resulted in a prolonged and enhanced biological activity by 
protecting BMP2 from degradation and by blocking BMP2 antagonists and inhibitory SMADs. This was 
shown in vitro by using an osteoblastic cell line and was also shown in vivo [120, 160-162]. However, the 
present work is in accordance to recently published data from Ayerst and colleagues, who demonstrated 
that the addition of heparin inhibited dose-dependently the GDF5 activity in MSCs [2]. The reason why 
heparin exerts a negative effect on the activity of GDF5, but not on BMP2 is unclear. It is known that 
interaction with heparin or heparan sulfate is not necessary for GDF5-receptor binding but prolongs the 
GDF5 bioavailability/activity. However, a high affinity of heparin for GDF5 may prevent the interactions 
of GDF5 with its receptors and reduce its effect. 
 
A last tested parameter to mimic a ‘healthier’ chondrocyte environment was an increased medium 
osmolarity. Healthy chondrocytes produce an abundant cartilage ECM containing osmotically active 
proteoglycans responsible for the maintenance of a high negative fixed-charge density and thus for a 
high osmolarity within healthy articular cartilage, which ranges from 350 to 480 mOsm [43]. During OA 
progression, the cartilage ECM and thus also the proteoglycans are degraded resulting in a reduction of 
osmolarity within the OA cartilage down to 270 mOsm at end-stage OA [40]. Consequently, the severity 
of OA is directly connected to a decrease of osmolarity within articular cartilage. It was suggested that 
culturing the end-stage hOAC at osmolarities that rather correspond to healthy articular cartilage could 
improve their condition and possibly restore their responsiveness to GDF5 and M1673. As a first step, it 
was shown that culturing hOAC for 7 days in monolayer at a medium osmolarity of 380 mOsm -what 
rather corresponds to osmolarities within healthy articular cartilage- increased significantly the GAG 
production compared to the culture at the standard medium osmolarity of 340 mOsm -what rather 
corresponds to osmolarities within OA cartilage (Figure 14). Therefore, it was suggested that increasing 
the medium osmolarity is beneficial for hOAC. It was then tested if the response to GDF5 and M1673 
was increased under these culture condition by comparing two different 3D culture systems. Culturing 
the hOAC as CTAs over 28 days at an increased medium osmolarity of 380 mOsm did not improve the 
response of hOAC to GDF5 and M1673 compared to untreated cells (Figure 16 A+B). On the contrary, 
culturing hOAC in alginate beads at 380 mOsm improved significantly the GAG accumulation after GDF5 
or M1673 stimulation compared to untreated cells (Figure 16 C+D). The reason why hOAC were 
responsive in alginate but not in CTAs is unclear. It is known that chondrocytes are anchorage dependent 
cells and will die without an appropriate support to adhere to. In 3D culture it was shown that 
chondrocytes build cell-matrix interactions and bind directly to their surrounding matrix [163]. In alginate, 
the cells are trapped in the gel and probably rapidly accumulate matrix in their direct vicinity allowing 
  
rapidly cell-matrix interactions. On the contrary, in CTAs matrix molecules can diffuse away and it might 
take longer for the cells to get surrounded by a matrix they can interact with. Because hOAC produce 
less cartilage ECM than healthy chondrocytes, this effect might be exacerbated in hOAC, which do not 
accumulate fast enough sufficient cartilage ECM to allow cell-matrix interactions and cell survival. 
Indeed, at the end of the CTA culture, the cell content was reduced in comparison to the initial seeding 
density. As a consequence, it would be possible that the remaining cells in the CTAs are too few to detect 
differences between GDF5 or M1673 stimulated cells compared to unstimulated cells. In summary, hOAC 
are responsive to GDF5 and M1673 in alginate culture at a ‘healthier’ medium osmolarity of 380 mOsm 
and this condition is therefore the most promising of all tested culture conditions.  
 
However, it was still unclear why hOAC become more responsive under higher osmolarity and whether 
380 mOsm is adequate to analyze the effects of GDF5 and M1673 in hOAC. Therefore, the osmolarity 
effect and its physiological relevance on hOAC was further characterized. For this purpose, monolayer 
cultures were performed with freshly isolated hOAC. The monolayer cultures were performed over 6 
days at the unchanged medium osmolarity of 340 mOsm and at increased medium osmolarities of 380, 
420 and 460 mOsm what covers the range of osmolarities reported for healthy cartilage. Afterwards the 
osmolarity effect was evaluated with hOAC encapsulated in alginate beads.  
It was shown that increasing the medium osmolarity reduced the cell concentration of the hOAC in 
monolayer and in alginate beads in an osmolarity-dependent way, but only significantly at 420 and 460 
mOsm compared to 340 mOsm and without falling below the seeding concentration and without a loss 
in cell viability (Figure 18+21+25). Thus, it could be concluded that the reduced cell concentration at 
increased osmolarities was not due to cell death but rather due to a reduced proliferation capacity of 
hOAC. Furthermore, increasing the medium osmolarity had a positive impact on the cartilage ECM 
molecules production and the phenotype of hOAC cultured in monolayer or encapsulated in alginate 
beads (Figure 18+21+25). In detail, the GAG production, type 2 collagen and aggrecan expression were 
enhanced from 380 to 460 mOsm compared to 340 mOsm (Figure 18+21+25). In monolayer cultures 
a better phenotype maintenance was observed, because the cell dedifferentiation (characterized by an 
enhanced type 1 collagen and decreased type 2 collagen expression) was prevented by increasing the 
medium osmolarity from 380 to 460 mOsm compared to 340 mOsm (Figure 18+21). In contrast to the 
monolayer culture, in alginate culture it could be observed that the chondrocytes phenotype was favored 
even without modulating the medium osmolarity. Indeed, at the end of the culture the expression of 
type 1 collagen was lower and the expression of type 2 collagen was higher than in freshly isolated 
chondrocytes. This effect on type 1 and type 2 collagen expressions were also found to be further 
enhanced by raising the medium osmolarity from 380 to 460 mOsm (Figure 25). When comparing these 
results to the literature, most of the findings are in accordance with observations form others. For 
instance, Windt and co-workers showed that culturing hOAC at an increased medium osmolarity of 480 
  
mOsm reduced the cell proliferation, whereas a moderately elevated medium osmolarity of 380 mOsm 
did not reduce cell proliferation in comparison to the unchanged medium osmolarity of 280 mOsm. On 
the contrary to the present work, they also observed a diminished cell viability already after 2 days of 
hOAC culture at 480 mOsm, but not at 380 or 280 mOsm [37, 46]. However, another study using healthy 
bovine chondrocytes encapsulated for 6 days in alginate beads demonstrated an unchanged viability 
after culturing them at enhanced medium osmolarities up to 570 mOsm [37, 39]. Regarding ECM 
production, it was already demonstrated that type 2 collagen, aggrecan and sox9 expression was 
enhanced, whereas type 1 collagen expression was decreased after culturing hOAC in monolayer at 380 
mOsm compared to 280 mOsm [41, 46]. In addition, the enhanced ECM molecule production at 380 mOsm 
compared to 280 mOsm was not only observable in unexpanded hOAC, but also in hOAC passaged up 
to 3 times [46] suggesting that the results of the present work would be also valid for expanded hOAC 
cultured in monolayer. The same research group showed that the positive influence of an enhanced 
medium osmolarity was mediated through the tonicity enhancer binding protein (TonEBP) [46]. TonEBP 
is a key transcription factor, which is known to be activated in response to hyperosmotic stress [45, 48] and 
mediate the response of chondrocytes to increased osmolarities. 
To further characterize the beneficial effect of an enhanced medium osmolarity on hOAC, the production 
of matrix-degrading enzymes and inflammatory cytokines was analyzed. It could be demonstrated that 
enhancing the medium osmolarity from 380 to 460 mOsm decreased significantly the MMP13 expression 
of hOAC cultured in monolayer or alginate beads, whereas the expression of ADAMTS5 was barely 
influenced (Figure 19+22+26). In addition, the production of MMP3 was shown to be significantly 
reduced from 380 to 460 mOsm in hOAC monolayer cultures, whereas the production of MMP1 and 
MMP9 was less or not affected (Figure 21+24). Regarding inflammatory cytokines, the highest 
production was observed for Il6, followed by TNFȽ and by Il1Ⱦ in both, monolayer and alginate bead 
cultures of hOAC (Figure 19+22+26). Enhancing the medium osmolarity from 380 to 460 decreased 
significantly and dose-dependently the production of Il6, TNFȽ and Il1Ⱦ in monolayer cultures as well 
as in alginate bead culture of hOAC (Figure 19+22+26). In accordance to the present work, it was 
already shown that ADAMTS4 and ADAMTS5 expression levels are not affected by an enhanced medium 
osmolarity in hOAC cultured in monolayer [41]. In contrast to the results of the present work, the same 
group showed an upregulation of MMP1, 3, 8 and 13 expression levels at 380 mOsm compared to 280 
mOsm [41]. These different observations might reside in the difference of the experimental setting; for 
example, they compared 280 and 380 mOsm while in the present work 340 mOsm was compared with 
380, 420 and 460 mOsm. In the present work, the downregulation of MMP13 expression was confirmed 
with a total of five monolayer experiments with hOAC isolated from five different donors and was also 
confirmed in a 3D culture system. Therefore, this effect was robustly reproducible. Moreover, it is 
described that ECM-degrading enzymes like MMP13 are induced by inflammatory cytokines [164] which 
were also shown to be reduced by increasing the medium osmolarity (Figure 19+22+26). To the best 
  
of our knowledge, the present work is the first analyzing the influence of an enhanced medium 
osmolarity on the cytokine production of hOAC. Tsuchida and co-workers showed that healthy and OA 
chondrocytes in culture produce more Il6 than TNFα while Il1β production was the lowest [164]. This 
order in the cytokine production levels is in accordance to that observed in the present work. 
Furthermore, it was shown by Tsuchida and co-workers that isolated healthy or OA chondrocytes 
produce more cytokines than chondrocytes in cartilage [164] indicating that in culture the level of 
cytokines is artificially elevated. The mechanism is not known but it can be postulated that the dramatic 
change of the cellular environment upon chondrocyte isolation elicits a stress response resulting in the 
production of inflammatory cytokines and proteases. It could be further postulated that increasing the 
culture medium osmolarity makes this environment change less dramatic and reduces this stress 
response in chondrocytes.  
To better understand the increased responsiveness to GDF5 and M1673, the effect of osmolarity on the 
expression of the BMP receptors was also analyzed. It could be demonstrated that an increased medium 
osmolarity led in trend to an enhanced expression of BMPR1a, BMPR1b and BMPR2 compared to 340 
mOsm (Figure 20+23). Moreover, a connection could be demonstrated between the presence of 
inflammatory cytokines and the BMP receptors expression (Figure 24) indicating that the reduced 
cytokine production at higher osmolarities would enable a higher BMPR expression level. However, a 
direct effect of the osmolarity on BMPR expression could not be excluded. Importantly, these results 
show that at increased osmolarities, the expression of BMPRs were higher what possibly explain the 
better responsiveness of the chondrocytes to GDF5 and M1673 in these culture conditions. 
In a first instance all these results were obtained by increasing the medium osmolarity with NaCl, which 
is routinely used for this purpose [37, 46, 48, 165]. The use of NaCl to modulate the medium osmolarity was 
compared to the use of sucrose with similar outcomes on all analyzed parameters (Figure 18-23). It 
indicates that the observed effects were not specific effects of sodium or chloride, but rather ‘real’ 
osmolarity effects. This is in accordance with a previous study which compared the use of NaCl and 
sucrose to adjust the medium osmolarity with the conclusion that no significant differences in gene 
expression patterns were detectable [41].  
 
Overall, an increased osmolarity was found to be an easy way to facilitate investigations with hOAC in 
vitro and increase their responsiveness to growth factors like GDF5. However, the question of the 
relevance of such culture conditions remained. The target cells of M1673 are middle-stage OA 
chondrocytes. Yet, in the present work late-OA chondrocytes which were additionally stressed by cell 
isolation were used. With an osmolarity of 380 mOsm instead of 340 mOsm the inflammatory status 
could be reduced to a level that might rather correspond to middle-stage OA chondrocytes in cartilage. 
To validate this culture system, it was decided to first evaluate the GAG accumulation in chondrocytes 
from seven different hOAC donors. Culturing the cells in alginate beads at 380 mOsm resulted in an 
  
enhanced and more robust GAG accumulation compared to the culture at 340 mOsm (Figure 29). 
Consequently, an in vitro model was established, which enable to characterize the anabolic effect of 
GDF5 and M1673 in hOAC. It consists in an alginate bead culture system combined with a medium 
osmolarity of 380 mOsm.  
 
Afterwards, the effect of M1673 was evaluated in hOAC cultured in alginate beads at 380 mOsm by 
analyzing many different cartilage ECM production markers. Because M1673 was already shown to exert 
the strongest anabolic effect among the GDF5 mutants, only M1673 was investigated in hOAC and 
compared to GDF5 (see supplementary, S7+8). An anabolic effect of GDF5 as well as M1673 was 
demonstrated in hOAC. Indeed, an increased GAG accumulation and aggrecan expression in alginate 
beads indicating proteoglycan synthesis was observed. Furthermore, GDF5 and M1673 also lead to an 
increased hydroxyproline, pro-peptide of collagen 2 accumulation and type 2 collagen expression in 
alginate beads indicating an increase of the global collagen synthesis (hydroxyproline) and of type 2 
collagen synthesis (Figure 30). In addition, the expression of MMP13 and ADAMTS5 was significantly 
downregulated after GDF5 and M1673 treatment compared to untreated cells indicating additional anti-
catabolic properties of the compounds (Figure 31 A+B). The anabolic and anti-catabolic properties of 
M1673 were less pronounced than that of GDF5, but they were nevertheless significant over control. 
Moreover, data of the present work showed some indications for a reduced hypertrophic and 
dedifferentiation capacity of M1673 compared to GDF5 (Figure 31 C+D). The anabolic effect of GDF5 
in 3D culture was previously described by some research groups, but all of them focused on healthy 
chondrocytes [1, 4, 134-135]. GDF5 was shown to exerts an anabolic effect on proteoglycan synthesis in 
bovine chondrocytes cultured as pellets for 21 days. The same research group also showed an increased 
pellet size as well as an enhanced Safranin O staining indicating proteoglycan synthesis after 21 days of 
GDF5 treatment in human nasal chondrocytes compared to untreated cells. However, no upregulation 
of type 2 collagen synthesis could be detected after GDF5 treatment neither in bovine nor human nasal 
chondrocytes compared to untreated cells [1]. Similarly, GDF5 was shown to exhibit anabolic effects on 
proteoglycan synthesis in healthy, human articular chondrocytes cultured in alginate beads over 9 days 
[135], in aggregate culture over 7 days [134] or in a pellet culture over 21 days [4]. Again, an anabolic effect 
of GDF5 on collagen synthesis in healthy, human articular chondrocytes was not detectable [4, 134-135]. 
The above-mentioned experiments with healthy, human articular chondrocytes in pellet culture showed 
not only anabolic, but also anti-catabolic and anti-hypertrophic effects of GDF5. In detail, they showed 
a downregulation of MMP13 and ADAMTS4 expression (catabolic markers) and of the type 10 collagen 
expression (hypertrophic marker) after GDF5 treatment [4]. An anti-catabolic effect of GDF5 was also 
observed in the present work. However, the present work led to the suggestion that GDF5 is hypertrophic 
instead of anti-hypertrophic. The different observations could be due to different experimental settings. 
  
For instance, the present work was performed with osteoarthritic instead of healthy chondrocytes and 
in medium without chondrogenic inductors. 
To the best of our knowledge the present work is the first showing anabolic and anti-catabolic effects of 
GDF5 and M1673 on diseased hOAC in 3D culture. Additionally, the present work is the first, which 
showed an anabolic effect of GDF5 not only by enhancing the proteoglycan, but also the type 2 collagen 
synthesis in chondrocytes. In comparison to GDF5, M1673 showed an equal or slightly reduced anabolic 
and anti-catabolic effect, but seems to be also less hypertrophic. Based on the results of the present work, 
it can be concluded that M1673 has the potential to promote cartilage repair and prevent further 
cartilage degeneration and has therefore the potential to become a DMOAD. 
 
6.2 Differentiation capacities of GDF5 mutants in mesenchymal stem cells 
 
Asides from chondrocytes, mesenchymal stem cells (MSCs) can also produce cartilage. During 
development, MSCs are able to differentiate into several tissue types including cartilage and bone [32]. 
Recently various MSC niches within the adult joint including subchondral bone, synovium, infrapatellar 
fad pad or synovial fluid were discovered [51]. This led to the suggestion that MSCs not only induce the 
tissue development, but may also contribute to articular cartilage maintenance and repair even during 
adulthood. Growth factors like members of the TGFȾ superfamily regulate embryonic cartilage 
development and are known to stimulate MSC migration, proliferation and differentiation [110, 166]. For 
instance, GDF5 was shown to stimulate not only matrix production in chondrocytes, but also to promote 
chondrogenesis in MSCs and to induce cartilage formation in an OA rat model [1-3]. Therefore, it was 
hypothesized in the present work that articular application of GDF5 could support the differentiation of 
the joint resident MSCs into chondrocytes and promote cartilage repair. However, GDF5 was also shown 
to have some undesired hypertrophic and osteogenic capacities in vitro and in vivo [3, 5] what can lead to 
osteophytes formation or mineralization and hardening of the cartilage matrix, two unwanted 
phenomenons. Thus, previously to the present work, different GDF5 mutants were designed by single 
point mutations in the type 1 receptor binding site of GDF5 to generate improved GDF5 versions with 
reduced hypertrophic and osteogenic properties. BMPs like GDF5 mediate their signals primarily by 
binding to the BMP receptors (BMPR), BMPR1a or BMPR1b in combination with BMPR2. Both receptor 
complexes, BMPR1a with BMPR2 or BMPR1b with BMPR2, are responsible for intracellular signal 
transmission and influence the fate of MSCs toward chondrogenesis or osteogenesis. However, the 
distinct roles of BMPR1a and BMPR1b are poorly understood until now and opinions about their 
different roles are contradictory. From the body of literature, it was hypothesized that BMPs inducing 
BMPR1a activation, promote osteogenesis and hypertrophy, while BMPs inducing BMPR1b activation, 
promote chondrogenesis. On this basis, the three GDF5 mutants M1673, W417F, and W417R were 
selected, all having a reduced BMPR1a affinity and a similar BMPR1b affinity compared to GDF5. It was 
  
hypothesized that these GDF5 mutants have a reduce osteogenic/hypertrophic capacity and a 
maintained chondrogenic capacity compared to GDF5. To verify this hypothesis, the GDF5 mutants were 
evaluated for their chondrogenic and osteogenic differentiation potentials in MSCs and compared to 
those of GDF5. BMP2 was used as a control for osteogenesis and chondrocyte hypertrophy. In addition, 
it was aimed to better understand the respective roles of BMPR1a and BMPR1b. 
 
As a first step, the binding affinities to BMPR1a, BMPR1b and BMPR2 of all GDF5 mutants as well as 
GDF5 and BMP2 were confirmed by SPR. In addition, they were characterized regarding their receptor 
dimerization potential in a cell assay that better represents the complexity of receptor interactions.  
BMP2 showed the highest binding affinity to BMPR1a of all tested compounds. For the GDF5 mutants a 
reduced BMPR1a affinity in comparison to GDF5 was confirmed. M1673 showed a reduced BMPR1a 
affinity compared to GDF5, which was further reduced for W417F. For W417R no binding to BMPR1a 
could be detected with the conditions used (Table 7). However, this does not exclude per se that W417R 
is unable to bind to BMPR1a. Indeed, W417R stimulated the dimerization of BMPR1a with BMPR2 in 
the in vitro assay (Figure 32+Table 8) indicating that W417R is still able to interact with BMPR1a. In 
contrast to the large BMPR1a affinity differences (factor 720 between the highest and lowest affinity), 
the affinities towards BMPR1b vary less among the compounds (factor 6 between the highest and lowest 
affinity). The ratio KD BMPR1a/KD BMPR1b were calculated and it was 1.7 for BMP2 and increased 
strongly for GDF5, followed by the GDF5 mutants (Table 7). Other studies also reported a similar affinity 
of BMP2 for BMPR1b and BMPR1a and a higher affinity of GDF5 for BMPR1b compared to BMPR1a [131, 
154].  
The compounds were also tested for their receptor dimerization potential in cell assays. The single 
affinities for BMPR1a or BMPR1b are not always in line with the potencies of the respective compounds 
to dimerize BMPR2 with BMPR1a or BMPR1b (Table 7+8). This discrepancy can be explained by the 
differences between the assay systems. The affinity measurements evaluate the binding of the respective 
BMPs to one single receptor. They do not take in account that the oligomerization of type 1 and type 2 
BMP receptors is required for the signal transmission of BMPs. Most of the receptors are present on the 
cell surface as single receptor subtypes. BMPs bind to one receptor subtype and induce the recruitment 
of the second receptor subtype resulting in a BMP-induced signal complexes (BISC) [126]. It was shown 
that BMP2 and GDF5 bind BMP receptor type 1 (BMPR1a or BMPR1b) with a higher affinity than BMP 
receptor type 2 (BMPR2). The resulting BMP/BMP receptor type 1 complex showed an increased affinity 
for the BMP receptor type 2 than BMPs alone. In addition, a minor receptor subset of about 10% is 
present on the cell surface as preformed receptor complexes (PFCs) containing both receptor subtypes. 
BMPs bind to these PFCs with higher affinities than to the single receptor subtypes [167]. In this regard, 
the affinity measurements represent only the first binding step of BMPs to one receptor subtype and does 
not capture the complexity of the receptors/ligand interactions. On the contrary, the in vitro dimerization 
  
assays probably take in account the multiple possibilities for the formation of the receptors/ligand 
complexes and consequently better represent the complexity of receptor interactions. 
Despite the discrepancies regarding single affinities and dimerization potencies, the ratio of the potencies 
obtained in the BMPR1a/BMPR2 and BMPR1b/BMPR2 assay showed the same ranking as the ratios 
obtained for the binding affinities (Table 7+8). In summary, it was evaluated that all GDF5 mutants 
were able to bind to their receptors and initiate receptor dimerization. The performed mutations within 
the GDF5 molecule successfully decreased the binding selectivity towards BMPR1a and shifted it towards 
BMPR1b. Thus, according to the initial hypothesis, W417R having the lowest BMPR1a affinity of all 
tested compounds and a BMPR1b binding selectivity similar to GDF5 should show the most reduced 
osteogenic/hypertrophic properties and still exhibit a similar chondrogenic potential compared to GDF5. 
 
To verify this hypothesis, the GDF5 mutants, GDF5 and BMP2 were tested for their chondrogenic and 
osteogenic potential in the murine stem cell line C3H10T1/2, which was established from mouse 
embryos in 1973 [168]. The advantages of the stem cell line over primary MSCs is that the C3H10T1/2 
cell line represents a homogenous cell population, which do not undergo spontaneous differentiation 
under standard culture conditions. Consequently, the addition of exogenous factors like BMPs are 
necessary to induce differentiation of C3H10T1/2 cells [169-170]. These cells were shown to have 
comparable osteogenic and chondrogenic differentiation potentials to that of primary murine bone-
marrow derived MSCs [170] and are consequently a valid tool to study differentiation processes. 
Nevertheless, human bone-marrow-derived MSCs were used to confirm the results obtained with 
C3H10T1/2 cells.  
 
Firstly, it was shown that all BMPRs including BMPR1a, BMPR1b and BMPR2 are present in C3H10T1/2 
cells with BMPR1b showing the lowest level of expression compared to BMPR1a and BMPR2 (Figure 
33). In contrast, previous studies could not show any expression of BMPR1b in C3H10T1/2 cells with 
the conclusion that these cells do not express BMPR1b [130, 171-172]. However, on the contrary to the 
present work the authors used a RT-PCR method that is not quantitative and has a lower sensitivity in 
comparison to quantitative RT-PCR. This could explain why they could not detect BMPR1b expression. 
The lower expression of BMPR1b compared to BMPR1a and BMPR2 was also shown for human MSCs 
(Figure 40) and it is also described by literature [128, 154].  
 
Chondrogenesis of C3H10T1/2 cells was performed in a pellet culture over 28 days in chondrogenic 
medium. The stimulation with GDF5, M1673 and BMP2 induced chondrogenesis, while only BMP2 
strongly induced hypertrophy in murine MSCs. GDF5 showed a less pronounced hypertrophic capacity 
compared to BMP2, which was even more reduced with M1673. W417F induced chondrogenesis only 
moderately compared to BMP2, GDF5 and M1673 and showed no effect on hypertrophy. W417R showed 
  
neither a chondrogenic nor a hypertrophic induction potential (Figure 34+35). Chondrocytes terminal 
differentiation or hypertrophy results in mineralization of the ECM and hardening of the cartilage [2] 
what is an unwanted effect. Consequently, the therapeutic potential of a potential DMOAD depends not 
only on its chondrogenic, but also on a low or an absence of hypertrophic differentiation potential. The 
chondrogenic and hypertrophic capacity of BMP2 in the murine stem cell line C3H10T1/2 was 
demonstrated several times [130, 169, 173-174] , whereas GDF5 was less intensively studied in these cells. To 
the best of our knowledge only Kaps and co-workers demonstrated a lower hypertrophic induction but 
also a lower chondrogenic induction potential of GDF5 compared to BMP2 in C3H10T1/2 cells [130].  
 
Additionally, it was aimed to better understand the respective roles of BMPR1a and BMPR1b in these 
differentiation processes. Our initial hypothesis postulated that BMPs, with a higher binding selectivity 
towards BMPR1b induce chondrogenesis, while BMPs with a higher binding selectivity to BMPR1a 
promote hypertrophy/osteogenesis. In the light of the chondrogenesis and hypertrophy results obtained 
in the C3H10T1/2 cells, this hypothesis had to be refined. The chondrogenic induction potential rather 
seems to depend on the binding selectivity of the compounds towards BMPR1a. Compounds with a 
strongly reduced BMPR1a affinity, like W417F and W417R, showed a reduced or even an absence of 
chondrogenic capacity in murine MSCs. Thus, a sufficient BMPR1a binding of the compounds seems to 
be necessary to induce chondrogenesis in murine MSCs. Furthermore, a higher BMPR1a affinity of the 
compounds, like BMP2 and GDF5, promoted hypertrophic differentiation of murine MSCs. By looking at 
the EC50 values, M1673 with its greater potency for BMPR1a/BMPR2 dimerization compared to GDF5 
should show a higher hypertrophic capacity than GDF5. On the contrary, it showed a lower hypertrophic 
capacity compared to GDF5. As M1673 had simultaneously the highest EC50 value for BMPR1b/BMPR2 
this led to the suggestion that BMPR1b might also play an important role in hypertrophic differentiation 
possibly by preventing it. Thus, it seems that it is not the single binding selectivity towards BMPR1a or 
BMPR1b, but rather the ratio between BMPR1a and BMPR1b which determine the cell fate. The 
literature concerning the distinct roles of BMPR1a and BMPR1b during chondrogenesis and hypertrophy 
is controversial. Several previous studies are in accordance with the observation of the present work, 
that BMPR1a is necessary for chondrogenesis [113, 129-130]. Moreover, some studies showed, in accordance 
to the results obtained in the present work, that BMPR1a also mediates hypertrophy and that BMPR1b 
rather prevent hypertrophy [112, 124, 131]. Kaps and co-workers concluded that BMPR1a initiate 
chondrogenesis, whereas the role for BMPR1b remained unclear [130]. In contrast two other studies 
demonstrated that BMPR1b mediates the chondrogenic properties of GDF5 [175] and that BMPR1b is 
crucial for chondrogenesis of MSCs [176]. 
In summary, BMP2 with a very low BMPR1a/BMPR1b ratio has a strong hypertrophic, but only a 
moderate chondrogenic capacity compared to GDF5 and M1673. Provided that a sufficient BMPR1a 
binding is given, a higher BMPR1a/BMPR1b ratio of the GDF5 mutants seems to prevent hypertrophic 
  
and enhance chondrogenic differentiation. It could be demonstrated in the present work, that the 
compound combining the best chondrogenic and anti-hypertrophic induction potential is the GDF5 
mutant M1673 having a BMPR1a affinity high enough for stimulating chondrogenesis and a 
BMPR1a/BMPR1b ratio high enough to already prevent hypertrophic induction (Figure 36). 
 
It was then evaluated if these results could be confirmed in human mesenchymal stem cells (human 
MSCs). Unfortunately, the chondrogenic capacity of the various compounds could not be analyzed in 
human MSCs. As a first step, the same experimental layout used for murine MSCs was applied. Indeed, 
in the murine stem cell line chondrogenesis was induced by the tested compounds in absence of TGFȾ 
and it was consequently decided to use similar culture conditions with the human MSC. However, in 
absence of TGFȾ, no chondrogenesis could observed with human MSCs, even not in the presence of 
BMP2, GDF5 or the GDF5 mutants (data not shown). TGFȾ1/3 are well-known chondrogenic 
stimulators, which are routinely used to induce chondrogenesis in human MSCs [2]. TGFȾ3 was also 
described to have a higher chondrogenic capacity compared to TGFȾ1 [177]. Consequently, a second 
chondrogenesis experiment was then performed with human MSCs in presence of TGFȾ3. 
Chondrogenesis of hMSCs was shown to be enhanced by stimulation with TGFȾ3, but no effect of the 
compounds could be detected anymore (Figure 41). It can be suggested that TGFȾ3 covered the effect 
of the tested compounds. In contrast, several previous studies demonstrated that the usage of TGFȾ1/3 
enhanced chondrogenesis of human MSCs but GDF5 could exert an additional effect [2, 5, 134, 178]. This 
additional chondrogenic effect of GDF5 over TGFȾ was mainly demonstrated at the gene expression level 
[2, 5, 134, 178]. One research group showed additionally an enhanced Safranin O staining after treatment 
with GDF5+TGFȾ3 compared to TGFȾ3 alone. However, they could not confirm an enhanced staining 
of type 2 collagen by immunohistochemistry [5]. Similarly, another research group demonstrated an 
enhanced gene expression of type 2 collagen and aggrecan after GDF5+TGFȾ1 stimulation compared to 
solely TGFȾ1, but detected a comparable type 2 collagen and Safranin O staining [134]. To optimize the 
system used in the present work to induce chondrogenesis, it could be beneficial to use a lower TGFȾ3 
concentration or higher concentrations of BMP2, GDF5 and GDF5 mutants to prevent that TGFȾ3 shields 
the effect of the tested compounds. However, other working groups demonstrated an additional effect 
of GDF5 over TGFȾ by using the same [2, 178] or even lower GDF5 concentrations [5, 128, 134] and the same 
TGFȾ concentration than the concentration used in the present work [2, 5, 128, 134, 178]. However, the 
experimental setting used in the present work might be slightly different and it remains a possibility that 
adapting the concentrations of the tested compounds and TGFȾ3 could enable to evaluate the 
chondrogenic effects of the GDF5 mutants. Another optimization strategy to enhance chondrogenesis in 
human MSCs could be the culture of the cells in a scaffold-free transwell culture system. This system 
enables the cells to form shallow flat cartilage discs on a porous membrane, which allows an uniform 
nutrient supply to all cells. In addition, this system was shown to be more efficient for inducing 
  
chondrogenesis of human MSCs than the routinely used pellet culture system [179]. It was shown by 
Ratnayake and colleagues that the stimulation of the cartilage discs with a combination of GDF5 and 
TGFȾ3 resulted in an increased chondrogenesis already after 7 days of culture compared to unstimulated 
cells [128]. Unfortunately, they did not compare the effect of GDF5+TGFȾ3 to the effect of TGFȾ3 alone. 
Nevertheless, it would be possible that this system could enable chondrogenesis of human MSCs after 
GDF5 stimulation, even in the absence of TGFȾ3. 
 
Despite the fact that an effect of the tested compounds on chondrogenesis could not be confirmed in 
human MSCs, the hypertrophic capacities of BMP2, GDF5 and GDF5 mutants were evaluated in 
combination with TGFȾ3 in the same system. A reduced hypertrophic induction potential for the GDF5 
mutants compared to GDF5 and BMP2 was observed: Indeed, GDF5 and BMP2 showed the strongest 
ALP activity. In addition, the type 10 collagen staining was positive only in presence of BMP2 or GDF5 
(Figure 42). Regarding type 10 collagen in human MSCs, all culture conditions containing TGFȾ3 
showed the same gene expression profile (Figure 42) while only the cells treated with TGFȾ3 together 
with BMP2 or GDF5 showed a positive immunostaining. The reason for this is unclear. Although, the 
mRNA level can give a suggestion that the protein is produced, it is known that sometimes mRNA levels 
and their corresponding protein levels are only weakly correlated [180-182] due to post transcriptional 
regulations [182-183]. Overall, a reduced hypertrophic induction potential for the GDF5 mutants having a 
higher binding selectivity towards BMPR1b compared to BMPR1a could be confirmed in human MSCs 
(Figure 42). Regarding the hypertrophic differentiation in human MSCs in presence of GDF5, our results 
are in accordance with the literature. Coleman and co-workers for example reported an increased ALP 
and type 10 collagen production (analyzed by western blot) in presence of GDF5 + TGFȾ3 in comparison 
to TGFȾ3 alone. Similarly, Murphy and colleagues showed an increased type 10 collagen expression with 
GDF5+TGFȾ1 and BMP2+TGFȾ1 in comparison to TGFȾ1 alone but no positive staining for type 10 
collagen. However, they used an aggregate culture over 7 days only [134] which might be too short to 
observe any type 10 collagen accumulation. 
 
To further characterize the therapeutic potential of the GDF5 mutants, their osteogenic capacities were 
analyzed and compared to GDF5 and BMP2. Osteogenesis of the murine stem cell line C3H10T1/2 was 
performed in monolayer cultures. The cells were treated with the GDF5 mutants, GDF5 or BMP2 over 
28 days in a standard culture medium. Osteocalcin expression and ALP activity were upregulated only 
in the presence of BMP2, but not in the presence of GDF5 and GDF5 mutants for up to 28 days. An 
alizarin red staining indicating matrix mineralization was not detectable with any of the tested 
compounds over 28 days (Figure 37). To enhance osteogenesis of C3H10T1/2 cells, an osteogenic 
medium was used which contains the typical supplements dexamethasone, ascorbate-2-phosphate and 
β-glycerolphosphate. These supplements are well-known for imitating the actions of several substances 
  
which are present in vivo and supporting osteogenic differentiation of MSCs [184]. ALP activity of the 
C3H10T1/2 cells was only detectable in the presence of BMP2, but not in the presence of GDF5 or GDF5 
mutants. The expression of osteocalcin was the strongest in the presence of BMP2, less pronounced with 
GDF5 and not detectable with the GDF5 mutants. In addition, matrix mineralization of C3H10T1/2 cells 
appeared in the presence of BMP2 at day 14, followed by GDF5 at day 21 and the GDF5 mutants M1673 
and W417F at day 28. No matrix mineralization was observed in the presence of W417R and in 
unstimulated cells cultured in osteogenic medium (Figure 38). These results indicate that BMP2 is more 
osteogenic than GDF5 and confirmed a reduced osteogenicity of the GDF5 mutants compared to GDF5. 
The reduced osteogenicity corresponds with a higher BMPR1a/BMPR1b ratio of the compounds. In 
accordance to these results, Date and co-workers demonstrated an enhanced osteocalcin expression and 
ALP activity after cultivation of the murine stem cell line in a standard culture medium containing BMP2 
[173]. The osteogenic effect of BMP2 was also confirmed by two other research groups. Both demonstrated 
that GDF5 did not influence the osteocalcin expression and ALP activity of the murine stem cell line 
cultured in standard culture medium [185-186]. Lastly and in accordance to the data of the present work, 
Kaps and colleagues demonstrated a reduced osteogenicity of GDF5 compared to BMP2 in C3H10T1/2 
cells cultured in osteogenic medium. They showed a less pronounced ALP staining and osteocalcin 
expression in the presence of GDF5 compared to BMP2 [130]. Others also demonstrated that BMP2 is 
more osteogenic than GDF5 in C3H10T1/2 cells [185, 187]. 
 
These new findings were confirmed in human mesenchymal stem cells. Osteogenesis of the human MSCs 
was performed in monolayer cultures. The cells were treated with GDF5 mutants, GDF5 or BMP2 over 
28 days in a standard culture medium. In contrast to the murine stem cell line, neither the ALP activity, 
nor the osteopontin or osteocalcin expression was enhanced, not even with BMP2. In accordance to the 
murine results, an alizarin staining was not detected with any compound over 28 days (Figure 43). Next, 
the human MSCs were cultured as described above, but in osteogenic medium. The ALP activity as well 
as the expression of osteopontin and osteocalcin was upregulated in the presence of BMP2, but not in 
the presence of GDF5 or the GDF5 mutants for up to 28 days. In addition, the earliest alizarin red staining 
was observed in the presence of BMP2 at day 14, followed by GDF5 at day 21, followed by M1673 and 
W417F at day 28. No alizarin red staining was detectable in the presence of W417R and in unstimulated 
cells cultured in osteogenic medium (Figure 44). These results confirmed that BMP2 is more osteogenic 
than GDF5 and that GDF5 is more osteogenic than the GDF5 mutants. It was also observed that the 
reduced osteogenicity of the GDF5 mutants compared to GDF5 and BMP2 corresponds to a higher 
BMPR1a/BMPR1b ratio. In contrast to the results of the presented work, Kleinschmidt and co-workers 
detected an alizarin red staining and an ALP activity in human MSCs already by culturing them in 
osteogenic medium for 21 days, in absence of BMP stimulation [188]. They showed that the stimulation 
with BMP2 or GDF5 did not result in a significantly higher osteogenic differentiation in addition of the 
  
induction observed with osteogenic medium alone [188]. An explanation could be that in comparison to 
the present work a 10-fold higher concentration of dexamethasone was used, which is known to be 
necessary to stimulate osteogenesis in in vitro cultures of human MSCs [184]. This elevated 
dexamethasone concentration might have shielded the effect of GDF5 and BMP2. In accordance to the 
results of the present work, Marupanthorn and colleagues demonstrated an enhanced osteogenic 
differentiation of human MSCs after stimulation with BMP2 compared to that in osteogenic medium 
alone [189]. The effects of GDF5 and BMP2 were hardly compared in human MSCs. To the best of our 
knowledge, only Kwon and colleagues compared their effects. However, they showed an enhanced 
osteogenic differentiation with GDF5 compared to BMP2 stimulation [190]. 
 
In summary, M1673 was the GDF5 mutant with the strongest chondrogenic induction potential. 
Chondrogenesis was lower with M1673 compared to GDF5, but M1673 showed advantages over GDF5. 
Indeed, M1673 showed a reduced hypertrophic and osteogenic capacity compared to GDF5.  
Regarding the role of BMPR1a and BMPR1b in osteogenesis and chondrogenesis, it was shown that the 
ability of BMPs to stimulate cartilage or bone formation is not regulated by their single binding for 
BMPR1a or BMPR1b per se, but rather by their BMPR1a/BMPR1b ratio. Provided that a sufficient 
BMPR1a binding is given, compounds having a higher BMPR1a/BMPR1b ratio showed stronger 
chondrogenic and reduced hypertrophic and osteogenic capacities. As the results from the present work 
showed a critical role of BMPR1a not only for osteogenesis, but also for chondrogenesis, BMPR1a and 
BMPR1b could have respective supporting functions rather than controlling distinct pathways. 
Additional indications for this suggestion is given by the fact that BMPR1a and BMPR1b transmit their 
signals by activation of the same downstream pathways. It would be possible that BMPR1a promote 
differentiation processes including chondrogenesis, hypertrophy and osteogenesis, whereas BMPR1b 
would initiate fine-tuning mechanisms to control these differentiation processes.  
 
6.3 M1673 as a possible DMOAD candidate 
 
M1673 was shown to stimulate the ECM production of mature chondrocytes including bovine, porcine 
and human OA chondrocytes. In addition, M1673 strongly activated mesenchymal stem cells to 
differentiate into chondrocytes and simultaneously prevented them to undergo hypertrophic 
differentiation. In addition, osteogenesis of mesenchymal stem cells was delayed with M1673 compared 
to GDF5. 
 
  
 
Figure 45  An intra-articular injection of M1673 might have a therapeutic potential as a possible DMOAD. 
 
Taken together, M1673 was evaluated in the present work to be the GDF5 mutant with the greatest 
therapeutic potential to induce regeneration of OA cartilage and could therefore considered as a possible 
DMOAD candidate. From the results of the present work, it can be suggested that the intra-articular 
injection of M1673 could have two positive aspects. First, it will stimulate the OA chondrocytes within 
the cartilage to produce ECM resulting in a regeneration of the damaged cartilage. Second, it will activate 
MSCs from several joint niches to migrate to the damaged cartilage and will induce their chondrogenesis 
which will contribute to the regeneration of the OA cartilage. This regenerated cartilage will be hyaline 
cartilage as M1673 prevents hypertrophy of MSCs and consequently mineralization and hardening of 
the regenerated cartilage. Moreover, M1673 will prevent osteogenesis of the MSCs suggesting that there 
would be no unwanted osteophyte formation in vivo in contrary to what was previously demonstrated 
for GDF5 [3]. 
  
7 Future perspectives 
 
The aim of the work presented herein was to evaluate the therapeutic potential of three GDF5 mutants 
M1673, W417F and W417R in vitro and to compare them to GDF5. The results of this work 
demonstrated that M1673 has a greater therapeutic potential as a DMOAD than the two other GDF5 
mutants but also than GDF5 itself. Indeed, M1673 has similar anabolic and chondrogenic properties but 
a reduced hypertrophy and osteogenicity compared to GDF5 and therefore might have a higher potential 
for cartilage regeneration. 
  
For future investigations, it would be interesting to further investigate the mode of action of M1673. 
Two signal pathways are described for BMPs, the SMAD-dependent pathway and the non-SMAD 
pathway through MAPKs [110]. Both pathways are probably necessary for inducing chondrogenesis or 
osteogenesis. However, most of the literature concerning downstream pathways of BMPs focus on the 
SMAD-dependent pathway, whereas the non-SMAD pathway remains not fully understood. A crosstalk 
between the SMAD-dependent and the non-SMAD pathways also probably exists. Moreover, the distinct 
mode of receptor oligomerization seems to determine which of the both pathways are activated. The 
binding of BMPs to preformed receptor complexes (PFC) induces the SMAD-dependent pathway. In 
contrast, the formation of a BMP induced receptor complex (BISC) activates mainly the MAPK pathway, 
but is also able to activate the SMAD-dependent pathway [126, 167].  
Both, GDF5 and BMP2, are described to activate the phosphorylation of SMAD1/5/8 [131, 154, 157]. A 10-
fold higher concentration of GDF5 was needed to induce a SMAD phosphorylation level, which was 
comparable to that induced by BMP2. Furthermore, GDF5 and BMP2 are described to activate the 
phosphorylation of the MAPKs, p38 [191-192] and ERK [192-193] at similar levels [131, 191]. The MAPKs, p38 
and ERK, modulate the SMAD-dependent pathway probably by mediating the proteasomal degradation 
of SMAD1/5/8 [126, 194-195]. The MAPK JNK was shown to be neither phosphorylated by GDF5 nor by 
BMP2 [191].  
During the present work, the investigation of the activation of signaling pathways by GDF5, GDF5 
mutants and BMP2 was already started. The goal was to evaluate whether the compounds with different 
BMPR1a/BMPR1b binding profiles activate differently the SMAD or the MAPK pathways and what is the 
role of these two signaling pathways in chondrogenesis or osteogenesis. Human chondrocytes would 
have been the material of choice for this study but because of the high donor variability and the lack of 
responsiveness of the hOAC in monolayer, this option was excluded. Another possibility would have 
been to differentiate MSCs into cartilage and bone cells and subsequently analyze signaling pathway 
activations. However, there is also a high donor variability and it is difficult to determine a time point 
for these analyses - it would be possible that several time points are necessary. Finally, it was decided to 
use a human chondrogenic and a human osteogenic cell line. 
  
It was first tested which cell lines show an expression of all BMP receptors, especially of the weakly 
expressed BMPR1b. On this basis, the osteoblast-like cell line Saos-2 and the chondrocyte cell line 
HCS2/8 were selected for signaling pathway analyses. The osteoblast-like cell line Saos-2 was derived 
from an osteosarcoma, it is known to react to anabolic factors and to preserve a typical osteoblastic 
phenotype closely related to that of primary human osteoblasts [196-197]. However, this osteoblast-like cell 
line has to be stimulated with an osteogenic medium containing ascorbic acid and β-glycerolphosphate 
to induce terminal differentiation and mineralization of the cells [198-199]. Unfortunately, the assay 
validation was not successful and the focus was subsequently placed on the chondrogenic cell line. The 
HCS2/8 cell line was derived from a human chondrosarcoma, it was shown to react to anabolic factors 
and it is known to preserve a chondrocyte phenotype closely related to that of primary human 
chondrocytes [200-201]. During the present work, it was shown that HCS2/8 cells are responsive to GDF5, 
GDF5 mutants and BMP2. The expected signaling pathways (SMAD1/5/8, p38 and ERK) were activated, 
while JNK was not activated by the compounds. However, a robust and reproducible differential 
activation by the different compounds was only detectable for the SMAD1/5/8 activation. A stronger 
phosphorylation of SMAD1/5/8 was detectable for the compounds having a higher BMPR1a affinity 
(data not shown). That observation is in accordance with a previous study by Klammert and colleagues 
[131]. For future investigations, it would be interesting to demonstrate robust different activation patterns 
of the tested compounds for p38 and ERK and also to analyze the downstream pathways in a suitable 
osteogenic cell line. That could enable to better understand the different roles of BMPR1a and BMPR1b 
on downstream activation and the role of these pathways in chondrogenesis and osteogenesis. 
 
On the other hand, the present work focused on in vitro assays to evaluate the therapeutic potential of 
the GDF5 mutants compared to GDF5. It is a crucial question whether M1673 will also show promising 
results in vivo.  
Before analyzing the efficacy of M1673 on the disease by using an OA animal model, an ectopic mouse 
model would offer a possibility to confirm the in vitro data of the present work regarding mutant 
selection. An ectopic mouse model offers advantageous over an OA animal model by being faster and 
outcomes are easier to measure. In addition, fewer animals are needed and a larger number of 
compounds can be analyzed compared to an OA animal model. That could enable to show the superiority 
of M1673 over the other GDF5 mutants and GDF5 also in vivo with the aim to start an OA animal model 
only with one compound – M1673. 
Commonly used are immune-deficient mice like SCID mice, which permit a xenogene implantation of 
human derived cells or tissues [202-203]. For the above-mentioned purpose, two different cell types could 
be used for subcutaneous implantation in the dorsum of SCID mice. Firstly, human OA chondrocytes 
(hOAC) could be implanted to confirm that the treatment with M1673 led to a better phenotype 
maintenance of hyaline cartilage compared to the treatment with GDF5. Secondly, human mesenchymal 
  
stem cells (human MSCs) could be implanted to confirm in addition that M1673 is less osteogenic 
compared to GDF5. Both approaches are suitable to compare the chondrogenic potential of M1673 with 
the other GDF5 mutants and GDF5.  
In more details, hOAC as well as human MSCs could be pre-inducted with the compounds in in vitro 
pellet cultures for two to six weeks, followed by a subcutaneous implantation time for four to eight 
weeks. For human MSCs, it is described that this kind of model rather lead to a calcification of the 
implants than to maintain a stable cartilage structure [204] allowing to investigate the osteogenic potential 
of the compounds. One option to reach a stable ectopic chondrogenesis of human MSCs was described 
to be a longer in vitro pre-differentiation of 12 weeks, which allows a nearly complete pronounced 
chondrogenic differentiation stage in vivo [205]. The pre-induction with the compounds in vitro results in 
the production of extracellular cartilage matrix, which varies between the different compound 
stimulations. Thus, the in vitro pre-induction method allows to analyze what happens with the pre-
formed pellets in vivo. 
An alternative could be to analyze the effects of the compounds directly in vivo without previous in vitro 
pre-induction. Therefore, both cell types should be polymerized in a fibrin/thrombin mixture, which is 
supplemented with the compounds respectively to ensure a permanent compound supply after 
implantation. Moreover, it would be possible to encapsulate these constructs in alginate, which imitate 
the chondrogenic environment and was shown to enhance chondrogenesis in vivo compared to non-
encapsulated pellets [202]. In addition, the encapsulation prevents inter alia the degradation of the 
compounds by immune cells of the mice [202]. Indeed, SCID mice are deficient for B- and T-lymphocytes, 
but they still contain macrophages, granulocytes and NK-cells.  
The explanted constructs should be analyzed for chondrogenic markers like Safranin O staining or type 
2 collagen immunohistochemistry as well as for hypertrophic and osteogenic markers like alizarin red 
staining or immunohistochemistry of type 1 and 10 collagens.  
Based on that it would be possible to demonstrate the beneficial effects of M1673 over the other GDF5 
mutants as well as over GDF5 also in vivo. Moreover, the above described approaches using human 
MSCs could be also interesting for cartilage tissue engineering analyses for example for the treatment of 
cartilage injuries. 
 
OA animal models are indispensable to provide proof of concept data before starting human clinical 
trials [206]. They should be used to analyze the efficacy of M1673 on osteoarthritis. OA animal models 
can be divided into spontaneous and induced ones. Spontaneous models display the slow development 
of OA closely related to the human situation, but they require a long time and are expensive. Induced 
OA models rather mimicking the post-traumatic OA development, can be performed chemically or 
surgically and are much shorter compared to spontaneous models [207]. Chemically induced OA models 
are performed by intra-articular application of a toxin or inflammatory compound into the joint and are 
  
primary used to evaluate the symptomatic effect of drugs [207]. In contrast, surgically induced OA models 
are performed by a surgery leading to joint destabilization/changes and enable to analyze structural and 
symptomatic effects of drugs.  
As a first step, the efficacy of M1673 could be evaluated in small animals like mice, rats, rabbits or guinea 
pigs. Recently it was demonstrated by Parrish and colleagues that the intra-articular application of GDF5 
reversed OA progression and stimulated cartilage repair in a surgically induced OA rat model using 
medial meniscus transection [3]. Based on this, it would be recommended to use the same rat model to 
evaluate the therapeutic potential of M1673 on OA in vivo. After the therapeutic effect of M1673 has 
been demonstrated in small animals, larger animal OA models using dogs, sheep’s, goats or horses should 
be performed. This could confirm the efficacy of M1673 in animals having joints, which are closer related 
to human joints and thus better mimic the human scenario [206-207] and to set up better predictions of the 
drug dosing in humans. 
 
Before starting clinical trials, it would be interesting to propose a strategy to classify patient subgroups, 
which could potentially show a higher benefit from a potential M1673 treatment. That classification 
could for example be performed based on the patient’s genotype. GDF5 was shown to be a susceptibility 
gene for OA. Single nucleotide polymorphisms (SNPs), rs143383 and rs143384, were identified within 
the promoter sequence of the human GDF5 gene. Both SNPs lead to a C/T transition substitution. The 
risk allele thymine was shown to reduce the expression of GDF5 within the whole joint [208], which in 
turn is associated with a 1.3- to 1.8-fold higher risk for developing OA [136]. It can be suggested that 
hOAC from donors bearing the thymine allele will have a reduced GDF5 expression and could show a 
higher response to the application of exogenous GDF5 or M1673. It would be interesting to correlate the 
SNPs of hOAC isolated from different patients with their responsiveness to GDF5 and M1673 in vitro. If 
a positive correlation is seen, it could be proposed to perform a similar analysis in the clinical setting to 
possibly identify high responders. For the present work, hOAC from ten donors were analyzed for their 
SNPs and correlated to their responsiveness to GDF5 and M1673. Unfortunately, the weak and 
inconsistent response to the compounds in monolayer culture did not enable to establish a correlation. 
Moreover, ten different hOAC cultured in alginate beads were also analyzed for their SNPs, but a better 
responsiveness to GDF5 or M1673 of hOAC having the risk allele thymine was not observable (data not 
shown). However, these correlation experiments in vitro should be performed with a much larger sample 
size to reach a sufficient statistical power. 
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9 Appendix 
 
9.1 Supporting information 
 
S 1 Fresh unprocessed human bone marrow from Lonza.
 
Certificate of analysis: 
 
 
Processing of human bone marrow: 
The fresh unprocessed human bone marrow was divided in two tubes and each fraction was mixed with 
50 mL PBS and centrifuged. The pellet was thoroughly resuspended in 20 mL of red cell lysis buffer 
(Sigma, Cat.N°87157), let on ice 3 min and centrifuged. This step was repeated 2 additional times. The 
two cell pellets were then combined and washed two times with PBS, the cells were counted and 
inoculated at 10x106 cells/cm2 in DMEM-hg supplemented with 10% FBS, 2 mM Glutamine, 8 ng/mL 
bFGF on gelatin-coated tissue culture flasks. When 60-80% confluency was achieved, cells were 
harvested with TrypLE express (Gibco, Cat. N°126403) and passaged until passage 2. Passage 2 was 
realized in a gelatin-coated 10-tray cell factory system with 1500 cells/cm2 and 2 l of the same medium. 
Cells were then frozen at 5 million cells/ml in Cryostor (Stem Cell Technologies Cat. N°07930), and kept 
in liquid nitrogen until use. 
  
Charaterization of human MSCs:  
Additionally, the colleagues from MilliPoreSigma characterized the cells harvested from passage 2 by 
FACS analysis. Cells were resuspended at 50 000 cells/mL in DMEM + 2% (W/v) BSA and incubated 
with the respective antibodies 20 min in the dark. Cells were then washed once in PBS and analyzed 
with a Guava flow cytometer. According to the International Society for Cell Therapy [209], the following 
markers were investigated: CD105 (Abcam, Cat.N°53318), CD90 (Millipore, Cat.N°FCMAB211F), CD73 
(Abcam, Cat. N°106697), CD11b (Millipore, Cat.N°FCMAB178P), CD79a (Millipore, Cat.N° 
FCMAB208P), CD14 (Millipore, Cat. N°FCMAB181F), CD45 (Millipore FCMAB118P), CD34 (Millipore 
Cat.N°CBL555F), CD19 (Millipore, Cat.N°FCMAB184F) and HLA-DR (Millipore, Cat.N°FCMAB184F). 
The MSCs were CD105+, CD90+, CD73+, CD11b-, CD79a-, CD14-, CD45-, CD34- , CD19 -and HLA-
DR+, the latter being due to the expansion in presence of bFGF [210].  
 
S 2 ECM production and phenotype analysis of hOAC in monolayer cultures at different osmolarities adjusted with NaCl. 
 
GAG production  Cell concentration Cell viability 
 
380 
mOsm 
420 
mOsm 
460 
mOsm 
380 
mOsm 
420 
mOsm 
460 
mOsm 
380 
mOsm 
420 
mOsm 
460 
mOsm 
Donor 1 1.07 2.18 2.47 1.10 0.71 0.65 1.03 0.98 1.01 
Donor 2 1.19 1.81 2.01 0.89 0.80 0.85 1.02 1.04 1.04 
Donor 3 1.23 1.50 1.87 0.91 0.86 0.77 1.00 1.00 0.99 
Donor 4 1.67 2.52 2.77 0.92 0.75 0.70 1.00 0.96 0.98 
Donor 5 1.23 1.31 1.44 0.74 0.55 0.48 1.00 0.94 0.95 
          
 
Collagen 1 expression Collagen 2 expression Aggrecan expression 
 
380 
mOsm 
420 
mOsm 
460 
mOsm 
380 
mOsm 
420 
mOsm 
460 
mOsm 
380 
mOsm 
420 
mOsm 
460 
mOsm 
Donor 1 0.94 1.38 0.92 1.62 3.37 4.59 1.59 3.91 7.12 
Donor 2 0.82 0.60 0.48 1.71 2.22 2.78 1.52 1.69 3.47 
Donor 3 0.77 0.71 0.65 1.26 1.08 4.38 3.95 4.09 29.19 
Donor 4 0.86 0.93 0.45 2.19 3.10 2.64 1.52 2.80 4.46 
Donor 5 0.86 0.54 0.37 3.49 4.81 5.91 3.76 4.25 8.96 
 
 
 
 
 
 
 
  
  
S 3 Proteases and cytokines production of hOAC in monolayer cultures at different osmolarities adjusted with NaClȾ Ƚ
 
 
MMP13 expression ADAMTS5 expression    
 
380 
mOsm 
420 
mOsm 
460 
mOsm 
380 
mOsm 
420 
mOsm 
460 
mOsm    
Donor 1 0.73 0.46 0.50 0.88 0.70 0.69    
Donor 2 0.95 0.96 0.77 0.89 0.97 0.83    
Donor 3 0.59 0.58 0.30 0.84 0.78 0.55    
Donor 4 0.70 0.51 0.43 0.94 1.06 0.81    
Donor 5 1.06 0.58 0.29 1.01 0.69 0.50    
          
 
Il1β production TNFα production Il6 production 
 
380 
mOsm 
420 
mOsm 
460 
mOsm 
380 
mOsm 
420 
mOsm 
460 
mOsm 
380 
mOsm 
420 
mOsm 
460 
mOsm 
Donor 1 0.82 0.81 0.56 0.79 0.72 0.48 0.79 0.72 0.48 
Donor 2 1.25 1.57 1.41 1.19 1.47 1.35 1.19 1.47 1.35 
Donor 3 0.99 0.48 0.23 0.95 0.60 0.41 0.95 0.60 0.41 
Donor 4 0.97 0.95 0.63 1.07 1.05 0.74 0.79 0.79 0.76 
Donor 5 0.89 0.87 0.33 0.94 0.94 0.46 0.74 0.68 0.47 
 
 
S 4 BMPR expression analysis of hOAC in monolayer culture at different osmolarities adjusted with sucrose.
 
          
 
BMPR1a expression BMPR1b expression BMPR2 expression 
 
380 
mOsm 
420 
mOsm 
460 
mOsm 
380 
mOsm 
420 
mOsm 
460 
mOsm 
380 
mOsm 
420 
mOsm 
460 
mOsm 
Donor 1 1.17 1.30 1.26 0.95 0.81 2.96 1.16 1.37 1.91 
Donor 2 1.08 1.62 1.54 1.08 1.18 2.21 1.07 1.35 1.32 
Donor 3 1.36 1.56 2.87 1.52 1.76 2.48 1.03 1.18 2.92 
Donor 4 0.92 1.16 1.66 1.36 1.81 2.33 1.16 1.32 1.41 
Donor 5 1.16 1.18 1.25       1.03 0.99 1.01 
 
 
 
 
 
 
  
  
S 5  Expression of BMP receptors in hOAC cultured in monolayer after stimulation with TNFȽ, Il1Ⱦ or Il6. Ƚ Ⱦ
BMPR1a 
 
Il1β TNFα Il6 
Donor 1 1.39 0.64 0.15 
Donor 2 0.72 0.03 0.09 
Donor 3 0.92 0.27 0.08 
Donor 4 2.75 0.81 0.18 
 ↑↑ ↓↓↓↓ ↓↓↓↓ 
BMPR1b 
 
Il1β TNFα Il6 
Donor 1 1.43 0.02 0.01 
Donor 2 1.91 0.03 0.02 
Donor 3 0.91 0.02 0.004 
Donor 4 5.31 0.21 0.03 
 ↑↑↑ ↓↓↓ ↓↓↓ 
BMPR2 
 
Il1β TNFα Il6 
Donor 1 1.97 0.66 0.14 
Donor 2 3.78 1.03 0.03 
Donor 3 1.02 0.32 0.07 
Donor 4 3.29 1.36 0.18 
 ↑↑↑ ↓↑ ↓↓↓ 
 
 
 
 
 
 
 
 
  
  
 
S 6 Anabolic effect of GDF5 and GDF5 mutants on ECM synthesis in porcine chondrocytes.
GAG concentration/ CTA
G
AG
 in
 
µg
/C
TA
CTL GDF5 M1673 W417F W417R
0
2000
4000
6000
8000
10000
12000
***
***
***
*
Aggrecan expression
re
la
tiv
e 
m
R
NA
 
co
n
te
n
t
CTL GDF5 M1673 W417F W417R
0.0
0.1
0.2
0.3
0.4
**
*
Hydroxyproline concentration/CTA
H
Pr
o
 
µg
/C
TA
CTL GDF5 M1673 W417F W417R
0
200
400
600
800
1000
***
***
***
***
Collagen 2 expression
re
la
tiv
e 
m
R
NA
 
co
n
te
n
t
CTL GDF5 M1673 W417F W417R
0.0
0.2
0.4
0.6
***
***
A
C
B
D
 
 
 
 
 
 
  
  
 
S 7 Anabolic effect of GDF5 and GDF5 mutants on ECM synthesis in bovine chondrocytes.
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S 8  Anabolic effect of GDF5 and M1673 on proteoglycan synthesis in hOAC at 380 mOsm.
 
 
GAG concentration in beads Aggrecan expression 
 Fold increase at 380  Fold increase at 380 
 GDF5 M1673 GDF5 M1673 
Donor 1 1.71 1.41 3.96 2.64 
Donor 2 2.23 2.20 4.37 2.27 
Donor 3 2.72 2.10 2.11 1.29 
Donor 4 2.25 1.70 5.11 2.89 
Donor 5 1.98 1.49 3.65 2.74 
Donor 6 2.07 1.83 2.50 1.26 
Donor 7 1.59 1.37 1.49 1.51 
Donor 8 1.83 1.62   
Donor 9 1.93 1.59   
Donor 10 3.76 1.98   
Donor 11 2.46 1.92   
Donor 12 3.84 2.15   
Donor 13 2.04 1.71   
Donor 14 1.90 1.64   
Donor 15 2.50 1.81   
 
 
 
S 9  Anabolic effect of GDF5 and M1673 on collagen synthesis in hOAC at 380 mOsm.
 
Collagen 2 expression HPro concentration in beads  ProC2 concentration in beads 
 Fold increase at 380 Fold increase at 380 Fold increase at 380 
 GDF5 M1673 GDF5 M1673 GDF5 M1673 
Donor 1 13.31 6.33 1.22 1.17 3.17 1.72 
Donor 2 9.82 4.72 1.05 0.98 1.17 1.05 
Donor 3 5.38 4.62 1.38 1.19 2.08 1.88 
Donor 4 9.15 5.21     
Donor 5 2.99 3.09     
Donor 6 5.67 2.98     
Donor 7 2.54 2.57     
  
S 10  Anti-catabolic effect of GDF5 and M1673 on MMP13 expression in hOAC at 380 mOsm.
 
 
MMP13 expression 
 Fold increase at 380 
 GDF5 M1673 
Donor 1 0.31 0.82 
Donor 2 0.28 0.48 
Donor 3 0.12 0.24 
Donor 4 0.05 0.15 
Donor 5 0.33 0.82 
Donor 6 0.28 0.52 
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